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The neurotoxic effects of Manganese and the novel protective role of Drp1 in 
the autophagy pathway 
Carolina Sportelli 
The precise pathological mechanism of Manganese (Mn) is not yet known however prior 
evidence suggests a prominent role of mitochondrial dysfunction. Relevant to Parkinson’s 
disease, Mn is known to bind to α-synuclein and increase its aggregation. Autophagy is also 
implicated in neurodegeneration however little is known about the effects of Mn on this 
pathway. The aim of this thesis was to investigate the effects of Mn on autophagy, α-synuclein 
aggregation and mitochondrial function in multiple paradigms. The effects of inhibiting the 
mitochondrial fission protein Drp1 were also assessed in these cellular contexts following Mn 
exposure. 
Acute exposure to sub-lethal Mn concentrations, in vitro and in vivo, caused an inhibition of 
autophagy flux in the absence of mitochondrial dysfunction. Despite this, Drp1 inhibition 
improved Mn-induced autophagy impairment and reduced cell death. In a cellular model of α-
synuclein overexpression, in addition to the effect on autophagy, Mn also potentiated α-
synuclein aggregation; rescued by Drp1 inhibition. This was observed at a later timepoint, 
suggesting that α-synuclein aggregation could be a consequence of impaired autophagy. 
The effects of chronic Mn accumulation on neurodegenerative pathology were assessed in six 
month old transgenic SLC39A14 knockout mice. Accumulated levels of the autophagy 
markers, LC3 and p62, were identified in both DAergic and GABAergic neurons, indicative of 
impaired autophagy. These neurons exhibited normal mitochondrial morphology, 
corroborating results from previous chapters. No alterations in striatal TH density or microglial 
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activation within the substantia nigra were observed at this timepoint, however increased 
astrocyte activation was identified. 
This study is the first to examine the effects of Mn exposure on mitochondrial function, 
autophagy flux and α-synuclein aggregation concurrently. Results demonstrate that the 
autophagy pathway is primarily affected, followed by α-synuclein aggregation whereas 
mitochondrial function remains unaffected. Despite this, the inhibition of Drp1 ameliorated the 
effects of Mn on these pathways. The discovery that the pathogenic and protective mechanisms 
of Mn and Drp1 inhibition, respectively, intersect at the autophagic pathway is novel and 
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1.1 Introduction to Parkinson’s disease 
1.1.1 History and epidemiology  
Known as the second most prevalent neurodegenerative disorder after Alzheimer’s disease 
(AD), Parkinson’s disease (PD) is an age-related disorder that impacts about 6.2 million people 
worldwide, a figure that is estimated to rise and strike roughly 14.2 million individuals by 2040 
(Dorsey and Bloem, 2018). PD was first described by James Parkinson, in 1817, as a 
neurological syndrome termed ‘shaking palsy’ (Parkinson, 2002). PD pathology is mainly 
characterised by a selective degeneration of dopaminergic (DAergic) neurons in the substantia 
nigra pars compacta (SNpc) and the presence of fibrillar aggregates referred to as Lewy bodies 
(LBs), which manifest in clinical phenotypes such as resting tremor, bradykinesia, rigidity, and 
postural instability (Schapira, 2009). Although the aetiology of PD is not fully understood, 
several risk factors and genetic mutations have been discovered and suggested to play a crucial 
role in the development and progression of the disease.  
The incidence of PD increases with age and is estimated to affect roughly 1% of the population 
over 60 at any time during their life (Tysnes and Storstein, 2017). PD is 1.5 times more 
prevalent in men than in women (Taylor et al., 2007). This difference could be related to more 
frequent occupational exposures in men and neuroprotection from oestrogens in women and 
X-linked genetic factors (Gatto et al., 2014, Cerri et al., 2019). 
 
1.1.2 Clinical features  
The cardinal motor features of PD start to develop once the DAergic cells (more than 50% in 
comparison to a young adult) in the nigrostriatal system are lost (Reeve et al., 2014, Chung et 
al., 2001). The disease is usually diagnosed according to the presence of motor symptoms first 
described by Hughes et al. (1992).  
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Non-motor symptoms are also a common feature of PD and they may appear in the early pre-
symptomatic stage as well as throughout the disease course, negatively influencing the patient's 
health-related quality of life.  
Age is the greatest risk factor for developing PD. Evidence shows that incidence rates increase 
strongly at the age of 60, peak at 85-89 years and then decline after 90 years of age (Driver et 
al., 2009).  
 
1.1.3 Pathological features 
The pathological hallmarks of PD are the loss of the nigrostriatal DAergic neurons and the 
presence of eosinophilic protein deposits, named Lewy bodies (LBs) (Figure 1.1), located in 
the SNpc of the remaining DAergic neurons (Przedborski, 2017). They usually are observed 
within the cell soma, but also reside in neurites or free in the extracellular space (Gibb et al., 
1991). Although the pathophysiologic significance of these inclusion bodies still remains 
largely unknown, the main biochemical components of LBs are α-synuclein (Spillantini et al., 
1997, Spillantini et al., 1998), .ubiquitin (Kuzuhara et al., 1988) and more recently lipids, 
mitochondria and other organelles (Shahmoradian et al., 2019).   
The cell bodies of the nigrostriatal neurons that reside in the SNpc project their axons to the 
striatum (comprised of the caudate nucleus and the putamen) and those in the ventral tegmental 
area (VTA) project to the cortical and limbic areas (Bjorklund and Dunnett, 2007, Hegarty et 
al., 2013). The ultimate functional output of the striatum involves the coordination of 
movement. Loss of DAergic neurons, rich in neuromelanin (Marsden, 1983), results in the 
gross depigmentation of the SNpc, along with the depletion of dopamine (DA) in the putamen 
(Bernheimer et al., 1973) (Figure 1.1). The mesolimbic DAergic neurons, the cell bodies of 
which are located in the VTA, are much less affected in PD (Uhl et al., 1985) and this leads to 
a significantly less depletion of DA in the caudate (Price et al., 1978). PD is commonly thought 
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to be characterised solely by DAergic neuron loss, however the neurodegeneration extends well 
beyond DAergic neurons. Other catecholaminergic cell groups are targeted and they include 
the locus coeruleus, some cells of the sympathoadrenal system and the serotoninergic neurons 
of the raphe nuclei. Loss of cholinergic neurons of the nucleus basalis of Meynert is also 
observed, and this may be responsible, at least in part, for dementia (Whitehouse et al., 1983, 





Figure 1.1 Neuropathology of PD. (A) 
Schematic representation of the nigrostriatal 
pathway (in red) consisting of projections 
from DAergic neurons in the SNpc to the 
striatum (i.e., caudate nucleus and putamen). 
(B) Schematic representation of the 
degenerated nigrostriatal pathway (in red). 
The loss of DAergic input to the putamen 
(dashed red line) is more severe compared to 
that projected to the caudate (red solid line). 
(C) Immunostaining with an antibody against 
α-synuclein reveals a Lewy body (brown 
reaction product in cell indicated by black 
arrow) with an intensely immunoreactive 
central zone surrounded by a faintly 
immunoreactive peripheral zone (left image). 
Conversely, immunostaining with an 
antibody against ubiquitin yields more 
diffuse immunoreactivity within the Lewy 




1.1.4 Aetiology of Parkinson’s disease 
The relative contributions of genetic versus environmental factors, regarding the development 
and progression of PD, have been hotly debated. Genetic studies have been the predominant 
driving force in PD research over the last few decades, although currently only less than 10% 
of PD cases can be directly linked to monogenic mutations (Klein and Westenberger, 2012). 
The remaining cases have been attributed to environmental exposures and gene-environment 
interactions, making PD a multifactorial disorder with a complex aetiology. Despite many 
years of focused research, the causes of PD remain to be elucidated. Understanding the causes 
of this disease is pivotal as that knowledge could lead to directed research that will develop 
new and potential therapies.  
 
1.1.5 Genetic mutations in Parkinson’s disease 
Since the discovery of the first missense substitution in SNCA, the gene encoding α-synuclein 
(Polymeropoulos et al., 1997), the understanding of the genetic contribution to PD has 
progressed rapidly. Genome-wide association studies (GWAS) and Genome-wide complex 
trait analysis (GCTA, which estimates phenotypic variance explained by all genome-wide 
single-nucleotide polymorphisms for complex traits) have led to important genetic discoveries 
associated with an increased risk of developing PD. Currently, over 20 known genes are linked 
to different forms of PD (PARK loci) and the underlying gene mutation has been identified in 
11 of them (Hernandez et al., 2016, Blauwendraat et al., 2020). Several associated risk-
conferring loci, that do not have the PARK designation, have also been identified to have 
modest influence on lifetime risk of developing PD (Simón-Sánchez et al., 2009, Satake et al., 
2009, Nalls et al., 2014, Nalls et al., 2019). Recently, the most comprehensive understanding 
of the genetic architecture of PD was carried out in a GWAS. The authors revealed 90 
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independent risk-associated variants, providing a biological context for these risk factors, and 
demonstrated that a considerable genetic component of PD still remains unidentified (Nalls et 
al., 2019, Blauwendraat et al., 2020). The major monogenic mutations and associated risk genes 
in PD are summarised in Table 1.1. 
A comprehensive description of genetic factors involved in PD pathogenesis is beyond the 
scope of this introduction and the following section will focus on SNCA, PINK1 and Parkin; 





















































































































































































The SNCA unequivocally associated with familial parkinsonism, is key to the pathophysiology 
of both familial and sporadic PD. It is well known for encoding α-synuclein and although 
mutations in this gene are overall rare, the SNCA locus can be described as the most powerful 
variant factor for PD development (Lill et al., 2012, Nalls et al., 2019). The first point mutation, 
A53T, was discovered more than 20 years ago on chromosome 4q22.1 (Polymeropoulos et al., 
1997). Since then, additional pathogenic missense mutations (A30P, E46K, G51D, and H50Q), 
as well as gene duplications and triplications, have been identified in familial PD (Kruger et 
al., 1998, Singleton et al., 2003, Zarranz et al., 2004, Appel-Cresswell et al., 2013, Lesage et 
al., 2013). Of note, a-synuclein overexpression and mutations are disease causing, however 
additional not-fully penetrant polymorphisms/variants, associated with a risk of developing 
PD, have also been discovered (Nalls et al., 2019). Shortly after the first genetic finding 
(Polymeropoulos et al., 1997), a-synuclein was described as a key factor of sporadic PD as the 
main component of LBs (Spillantini et al., 1997). Since then, research has largely centred 
around the role of a-synuclein-associated mechanisms to further understand PD pathogenesis.  
a-synuclein is a small protein (140 amino acids) highly expressed in the brain, mainly in 
presynaptic axon terminals and is comprised of three domains: residues 1–60 as N-terminal 
region, residues 61–95 as central region and residues 96–140 as C-terminus region. The central 
region, identified as the hydrophobic non amyloid β-component (NAC) domain, is critical for 
fibril formation (El-Agnaf et al., 1998). The C-terminal acidic tail domain is the major site for 
post translational modifications (PTMs), protein truncation (Li et al., 2005) and interaction 
with modulators of a-synuclein aggregation including metal cations (Binolfi et al., 2006). The 
overall a-synuclein protein is formed of seven imperfect 11 residues repeats with a conserved 
KTKEGV sequence: four resides in the amphipathic N-terminal region and three in the NAC 
core (George et al., 1995). 
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α-synuclein is a multifunctional protein involved in a range of cellular functions and has been 
reported to interact with and affect a variety of proteins, in particular at the presynaptic terminal 
(Figure 1.2). There is evidence on the ability of α-synuclein to bind to the SNARE-protein 
synaptobrevin-2 and chaperone SNARE-complex assembly and subsequently promote 
neurotransmitter release (Burre et al., 2010, Burre et al., 2012), regulate membrane interaction 
of the G-protein Rab3 (Chen et al., 2013), bind and modulate synapsin III (Zaltieri et al., 2015), 
bind to VMAT2 (Guo et al., 2008), stimulate and modulate dopamine and serotonin 
transporters (Wersinger et al., 2006, Swant et al., 2011, Butler et al., 2015) and regulate tyrosine 
hydroxylase (Perez et al., 2002, Baptista et al., 2003, Yu et al., 2004). In addition to interacting 
with various proteins at the presynaptic level, α-synuclein has also been reported to interact 
with mitochondria (Nakamura et al., 2008, Li et al., 2007, Di Maio et al., 2016), the 
endoplasmic reticulum (Cooper et al., 2006, Thayanidhi et al., 2010) and nuclei (Kontopoulos 
et al., 2006). α-synuclein has also been shown to modulate lipid synthesis (Ruipérez et al., 
2010) and prevent oxidation of unsaturated lipids in vesicles by acting as an antioxidant 
(Hashimoto et al., 2002, Zhu et al., 2006).  
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α-synuclein is known to interact with mitochondria via its N-terminal domain (Nakamura et 
al., 2008, Rostovtseva et al., 2015, Di Maio et al., 2016). However, it has also been argued that 
α-synuclein does not localise to mitochondria but to the mitochondria-associated endoplasmic 
reticulum membrane (MAM), where it regulates mitochondrial morphology. This function can 
be impaired by pathogenic mutations in α-synuclein (Guardia-Laguarta et al., 2014). Although 
Figure 1.2 Cellular membranes, targets and pathways potentially involved in the normal, 
physiological functions of α-synuclein. α-synuclein is a highly soluble, cytoplasmic protein, that 
binds to a variety of cellular membranes of different properties and compositions. These interactions 
are considered critical for at least some normal functions of α-synuclein and may well play critical 
roles in both the aggregation of the protein and its mechanisms of toxicity. In physiological 
conditions, α-synuclein adopts an unfolded conformation, however it can also form a multimeric 
structure when bound to synaptic vesicles  (Davidson et al., 1998, Weinreb et al., 1996, Ahn et al., 
2002, Burre et al., 2010, Fauvet et al., 2012, Theillet et al., 2016). This suggests that the dynamic 
regulation of α-synuclein function depends on the local cellular environment. Others have suggested 
that native α-synuclein is a tetramer that co-exists, in a dynamic equilibrium, with the unfolded 
monomer. Any perturbation of this dynamic equilibrium promotes the incrementation of the 
monomer form, which is associated with aggregation and pathology (Bartels et al., 2011, Wang et 




the interaction between mitochondria and α-synuclein is still poorly understood, α-synuclein 
preferentially binds to highly negative charged membranes, facilitated by the presence of 
cardiolipin. Cardiolipin is a scaffold protein for the components of the electron transport chain 
(ETC) and its interaction with α-synuclein is sought to potentially stabilise ETC proteins 
(Chicco and Sparagna, 2007, Guardia-Laguarta et al., 2015). 
α-synuclein possesses an interesting characteristic that both overexpression of wild-type (WT) 
and mutant forms of the protein can cause pathology. This is mainly due to α-synuclein 
tendency to aggregate, gradually evolving from small soluble oligomers to larger insoluble 
fibrils, ultimately generating LBs. It is still unclear what α-synuclein conformations have 
disease-modifying effects on DAergic neurons and whether LBs represent compensatory 
storage forms of the toxic aggregates or whether LBs themselves lead to neuronal cell death 
(Olanow et al., 2004, Wakabayashi et al., 2007).  
Although the genetic variants of α-synuclein represent only a small percentage of PD cases, 
these findings have strengthened the argument for the central role of this protein in PD 
pathogenesis. In addition, since α-synuclein is the major component of LBs, present in the 
majority of PD patients, it is likely that α-synuclein plays a pivotal role in the multiple cellular 
mechanisms involved in PD pathophysiology; these will be discussed in the following relevant 
sections.  
 
1.1.5.2 PINK1 and Parkin 
Loss of function mutations in PINK1 and Parkin represent the most common cause of 
autosomal recessive early-onset familial PD, with or without the presence of LB pathology 
(Kitada et al., 1998, Sasaki et al., 2004, Valente et al., 2004, Samaranch et al., 2010). Firstly 
described in 1997 in 13 Japanese families (Matsumine et al., 1997), Parkin mutations are 
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considered to be the most prevalent autosomal recessive PD mutations accounting for 77% of 
familial cases (with an age of onset < 30 years) and 10–20% of early-onset PD in general (Klein 
and Lohmann-Hedrich, 2007, Kilarski et al., 2012, Klein and Westenberger, 2012). Parkin is 
comprised of 12 exons that encode the 465 amino acid protein, Parkin (Kitada et al., 1998). 
Parkin is an E3 ubiquitin ligase with an amino-terminal ubiquitin-like (Ubl) domain and a 
carboxyl-terminal ubiquitin ligase domain (Shimura et al., 2000, Hristova et al., 2009). In 2001, 
the second gene causing early PD onset was identified in an Italian family (Valente et al., 2001), 
PINK1, responsible for 9% of cases (Klein and Westenberger, 2012). The 8 exon PINK1 gene 
encodes the 581 amino acid protein phosphatase and tensin homolog (PTEN)-induced kinase1 
(PINK1) (Valente et al., 2004). The protein consists of a C-terminal kinase domain and a 
mitochondrial targeting sequence in the N terminus, consistent with its mitochondrial 
localisation in cells (Valente et al., 2004, Zhou et al., 2008).  
PINK1 and Parkin are mainly involved in a signalling pathway that activates mitochondrial 
quality control pathways in response to mitochondrial damage and are tightly associated with 
mitochondrial dysfunction in PD. Under basal conditions, PINK1 binds to the outer 
mitochondrial membrane (OMM) and is then transferred to the inner mitochondrial membrane 
(IMM) via the translocase of the outer mitochondrial (TOM) complex and the and translocase 
of the inner membrane 23 (TIM23). Here, full length PINK1 is cleaved by IMM-bound 
proteases and degraded by the proteasome, leading to low levels of PINK1 in healthy 
mitochondria (Meissner et al., 2011, Yamano and Youle, 2013). Upon mitochondrial damage 
and loss of membrane potential, PINK1 import to the IMM is impaired, causing it to 
accumulate at the OMM (Jin et al., 2010, Lazarou et al., 2012, Okatsu et al., 2013). This 
accumulation leads to PINK1 homodimerisation and subsequent autophosphorylation, which 
induces kinase activation and phosphorylation of both ubiquitin and the Ubl domain of Parkin 
at residue Ser65. This phosphorylation stimulates Parkin activity and its recruitment from the 
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cytosol to the mitochondria (Kondapalli et al., 2012, Shiba-Fukushima et al., 2012). The 
concerted action between PINK1 and Parkin causes the polyubiquitination of multiple OMM 
substrates and subsequent targeting to the autophagic machinery for lysosomal degradation. 
In addition, PINK1 and Parkin are involved in the regulation of mitochondrial dynamics, 
through mechanisms involving the turnover of fission and fusion associated proteins (Deng et 
al., 2008, Poole et al., 2008, Gegg et al., 2010, Buhlman et al., 2014, Pryde et al., 2016), and 
in mitochondrial biogenesis by an indirect interaction with Peroxisome proliferator-activated 





1.2 Toxicants and environmental factors in Parkinson’s disease 
The discovery of genetic mutations and their functional characterisation in cellular and animal 
models have yielded crucial understanding of the pathogenesis of PD. However, prior to the 
discovery of the first genetic mutation linked to PD, research was mainly focused on 
environmental factors and their implication in the progression of the disease. This dominant 
environmental theory started with the discovery of 1‐methyl‐4‐phenyl‐1,2,3,6‐
tetrahydropyridine (MPTP), a contaminant of a synthetic opiate, which caused irreversible 
parkinsonism (Langston et al., 1983). This discovery led to a number of epidemiological 
studies and meta-analyses, which identified various environmental factors, including pesticides 
and heavy metals, that increased the risk of developing PD (Tanner et al., 2011, Wang et al., 
2011a, Caudle et al., 2012, Kamel, 2013). Pesticides and heavy metals are perhaps the most 
widely studied environmental toxicants involved in PD pathogenesis, and the ability of some 
to persist in the environment long after their application increases the possibility of human 
exposure to these contaminants. 
 
1.2.1 Pesticides 
The link between occupational exposure of two pesticides, rotenone and paraquat, and PD was 
first reported in individuals who made use of either pesticide and developed the disease 2-2.5 
times more often than nonusers (Tanner et al., 2011). Results from this case–control 
study confirmed the association of PD with the use of pesticides classified as complex I 
inhibitors or oxidative stressors. This study provided a link between basic research and human 
populations and yielded new insights into the pathogenesis of PD. Since then, tremendous 
progress has been made into understanding, in more depth, the mechanisms of action of these 
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pesticides and their effects in relation to PD. More in depth description of the association 
between pesticides and PD can be found in section 7.1.1 and 7.1.2. 
 
1.2.2 Heavy metals 
Several studies have reported changes in metal levels in the brain of deceased PD patients 
compared to non-PD controls of similar age, and suggested that high exposure to metals could 
be associated with an increased risk of developing PD (Rybicki et al., 1993, Forte et al., 2005, 
Willis et al., 2010, Ogunrin et al., 2013). Several epidemiological studies have reported a 
substantial association between PD and long-term exposure to heavy metals (Tanner et al., 
1987, Winkel et al., 1995, Gorell et al., 1997, Gorell et al., 1999, Miller et al., 2003). In 
particular, in the occupational setting, the exposure to specific heavy metals, including 
manganese (Mn), were found to double the risk of developing PD (Coon et al., 2006, Racette 
et al., 2017). Despite their requirements in many physiological activities, excessive metal levels 
can produce detrimental effects to mitochondrial function by generating oxidative stress 
(Martinez-Finley et al., 2013, Kumudini et al., 2014, Park et al., 2015a). Furthermore, metal 
overexpression can cause DNA damage, protein misfolding, ER stress, autophagy 
dysregulation, activation of apoptosis and interaction with proteins involved in the 
development of neurodegeneration, such as α-synuclein and β-amyloid, and alter their 
structures (Malecki, 2001, Cervantes-Cervantes et al., 2005, Ha et al., 2007, Gunter et al., 2010, 
Salvador et al., 2010, Seo et al., 2013, Stephenson et al., 2013, Zhang et al., 2013, Angeli et 
al., 2014, Chen et al., 2016).  





1.3 Manganese neurotoxicity and Parkinson’s disease 
1.3.1 Manganese properties and uses 
Manganese (Mn) is an essential trace metal required for normal development and function 
(Sadler, 1982, Horning et al., 2015). The primary route of human Mn intake is through the diet 
and it has been established that the daily uptake of Mn should be 2.3 mg for men and 1.8 mg 
for women (Greger, 1998). This daily requirement is reflected in the role of Mn as a cofactor 
for a variety of metalloproteins, including Mn-superoxide dismutase (MnSOD), arginase and 
pyruvate carboxylase. Mn is also essential for the function of a variety of enzymes, including 
glutamine synthetase and hydrolases (Wedler et al., 1982, Borgstahl et al., 1992, Kanyo et al., 
1996, Reddi et al., 2009). Mn has 11 oxidation states, with Mn2+ and Mn3+ being the most 
common in biological systems, and its metabolism is associated with iron due to their similar 
redox behaviour (Claus Henn et al., 2011, Kim et al., 2013, Kwakye et al., 2015). Mn redox 
state influences its kinetics and toxicity (Reaney et al., 2002, Reaney et al., 2006). Mn valence 
states can vary within the body and in vitro results suggest that Mn3+ species are more cytotoxic 
than Mn2+ (Chen et al., 2001). 
 
1.3.2 Manganese transport  
As Mn is key to various cellular events but becomes toxic at high levels, the intracellular Mn 
concentration needs to be kept under strict control (Peres et al., 2016b). Mn enters the human 
body through ingestion, inhalation, dermal permeation, or administered via intravenous 
injection (Chen et al., 2018b). The principal route of Mn intake is via food consumption. In 
adults, only 3-5% of ingested Mn is absorbed through the intestinal epithelium, distributed to 
various tissues and then excreted via bile (Davidsson et al., 1989a) (Figure 1.3).  
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Mn can enter the brain via three routes: the blood-brain barrier (BBB), the blood-cerebrospinal 
fluid (CSF) barrier and the olfactory tract. BBB and the blood CSF barrier represent the main 
interfaces that regulate brain Mn homeostasis. The BBB consists of capillary endothelial cells 
and acts as a separator between blood and brain interstitial fluid (Abbott and Friedman, 2012). 
The blood-CSF barrier separates blood from the CSF and consists of epithelial cells of the 
choroid plexus (Strazielle and Ghersi-Egea, 2000). Mn can cross both barriers, utilising several 
different transport mechanisms (Crossgrove et al., 2003, Yokel, 2009, Bornhorst et al., 2012), 
however an in vitro study assessing Mn transfer to the brain, whilst monitoring its effect on the 
barrier properties, uncovered a stronger Mn sensitivity to the blood-CSF barrier compared with 
BBB (Bornhorst et al., 2012), suggesting it might represent the main route for Mn to reach the 
brain.  
The olfactory route is an alternative pathway for Mn transport to the brain. The majority of 
clinical reported cases caused by Mn intoxication derive from occupational exposure. In 
particular, the adult population with the highest risk for Mn intoxication is represented by 
industrial workers, including miners (Rodier, 1955), smelters (Cook et al., 1974) and welders 
(Bowler et al., 2011), who inhale a significant amount of Mn-containing fume and dust. Mn is 
then absorbed in the lungs and enters the blood circulation. This led studies to investigate the 
nose and olfactory system as a possible route of direct entry to the CNS and recognised the 
olfactory pathway as a key contributor to Mn accumulation in the brain (Henriksson and Tjalve, 
2000, Dorman et al., 2006a, Elder et al., 2006). In particular Elder et al. (2006) showed that 
Mn can be transported along the olfactory nerve directly into the olfactory bulb and further into 
the CNS, bypassing the protective blood brain barrier (BBB). Following 12 days of intranasal 
Mn exposure, Mn concentrations increased in the olfactory bulb, striatum, frontal cortex and 
cerebellum and caused neuroinflammatory changes, indicating that the olfactory neuronal 
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pathway represents an efficient way for transporting inhaled Mn into the CNS (Elder et al., 
2006).  
Intravenous administration of agents containing high levels of Mn represent an additional route 
of Mn exposure. In contrast to others, this exposure route bypasses the regulation at the 
gastrointestinal tract resulting in 100% absorption of the metal (Aschner and Aschner, 2005), 
which is quickly distributed to different tissues. 
Mn transport has been mainly studied in mammalian systems and studies have largely focused 
on cellular influx mechanisms. Depending on its oxidative state, Mn can be imported in the 
central nervous system (CNS) via multiple membrane importers (Davidsson et al., 1989b). 
Mn2+ is the main form of Mn that exists in the blood and is normally complexed with different 
molecules, including α2-macroglobulin, albumin and citrate (Harris and Chen, 1994, 
Crossgrove et al., 2003, Nischwitz et al., 2008); Mn2+ is then secreted in the bile, and some can 
be oxidised to Mn3+ by ceruloplasmin (Jursa and Smith, 2009). The plasma carrier protein for 
Mn3+ is transferrin, which is synthesised in the liver and secreted in the plasma (Gunter et al., 
2013). Mn3+ enters the brain via TfR-mediated mechanisms, whereas Mn2+ uptake occurs 
mainly as free ion species or by carrier-mediated processes (Aschner and Gannon, 1994, 
Crossgrove et al., 2003, Yokel, 2009). Mn can access neurons and glia via the divalent metal 
transporter 1 (DMT1), transferrin receptor (TfR), calcium (Ca) channels, zinc transporters 
(ZIP8 and ZIP14), members of the organic anion transporter polypeptide (OATP) or ATP-
binding cassette (ABC) superfamilies (when bound to citrate) and diffusion (Crossgrove et al., 
2003, Crossgrove and Yokel, 2004, Huang et al., 2004, Crossgrove and Yokel, 2005, Gunter 
et al., 2013). It is important to note that these transporters, in addition to Mn, also transport 
other metals, such as iron (Fe), copper (Cu), zinc (Zn), and calcium (Ca). Studies performed in 
yeast and C. elegans have reported a homeostatic regulation of influx transporters to regulate 
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Mn cellular levels depending on Mn deficiency and/or toxicity (Au et al., 2009, Jensen et al., 
2009).  
Efflux transporters represent an essential process that regulates Mn cellular levels. To date, not 
many transporters have been found to mediate Mn efflux. Four separate transporters/pumps 
have been found to be involved in Mn efflux: the solute carriers, ferroportin and SLC30A10, 
the secretory pathway Ca2+-ATPase 1 (SPCA1) and ATPase 13A2 (ATP13A2) (Yin et al., 
2010, Leitch et al., 2011, Mukhopadhyay and Linstedt, 2011, Madejczyk and Ballatori, 2012, 
Leyva-Illades et al., 2014). Although results have demonstrated that both ferroportin and 
SPCA1 are implicated in Mn efflux and detoxification in cell culture (Yin et al., 2010, Leitch 
et al., 2011, Mukhopadhyay and Linstedt, 2011, Madejczyk and Ballatori, 2012), their roles in 
mediating Mn detoxification at the whole organism level still remain to be investigated. On the 
contrary, SLC30A10 appears to have a crucial role in maintaining cellular Mn levels and 
protecting against Mn-induced toxicity (Leyva-Illades et al., 2014). ATP13A2 (PARK9)  is a 
multifunctional protein highly expressed in the brain, especially in the SNpc, and mutations in 
ATP13A2 have been discovered in early onset parkinsonism (Di Fonzo et al., 2007), thus 
suggesting a link with PD. Its substrate specificity and physiological function are not fully 
understood, however studies suggest ATP13A2 is involved in lysosomal degradation of 
proteins, Mn homeostasis, and most recently Zn transport (Ramirez et al., 2006, Gitler et al., 
2009, Ramonet et al., 2011, Chesi et al., 2012). Various studies revealed an interaction between 
ATP13A2 and Mn. Loss of function of ATP13A2 enhanced Mn toxicity, promotes α-synuclein 
accumulation and cause mitochondrial dysfunction. Expression of ATP13A2 was shown to 
exert a protective role against Mn- and α-synuclein-induced toxicity. In addition, ATP13A2 
was upregulated in response to Mn treatment (Gitler et al., 2009, Tan et al., 2011, Kong et al., 
2014). These results suggest that ATP13A2 can transport Mn from the cytosol to the lumen of 
lysosomes, and thus, act as a Mn efflux transporter. Ultimately, they reveal a connection 
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between PD genetics (α-synuclein and PARK9) and an environmental risk factor (PARK9 and 
Mn).  
Figure 1.3 Overview of Mn metabolism and mechanisms of transport. Only 3–5% of ingested 
Mn is absorbed through the intestinal epithelium and the majority is excreted via bile. The image 
shows that in plasma, Mn is either conjugated with transferrin (Tf) or citrate and can then be 
distributed to various tissues. Mn can cross the BBB and access neurons and glia. Several proteins 
are implicated in Mn transport across the plasma membrane. When conjugated with Tf and 
recognized by the transferrin receptor (TfR), Mn is endocytosed and can enter the cytoplasm 
through DMT-1. When conjugated to citrate Mn may be carried by members of the organic anion 
transporter polypeptide (Oatp) or ATP- binding cassette (ABC) superfamilies. Mn can also cross 
the plasma membrane via diffusion or through the dopamine transporter (DAT). Given their 
similarities (valence), Mn can cross Ca2+ channels in mitochondria. SLC30A10 and ferroportin and 
ATP13A2 are three of the known Mn efflux transporters known to export Mn in the extracellular 





1.3.3 Manganese toxicity 
Despite its essentiality, excessive and prolonged exposure to Mn can lead to its accumulation 
in the basal ganglia, triggering a disease referred to as Manganism. This is characterised by 
motor impairments, behavioural changes and cognitive alterations (Couper, 1837). A 
population-based case-control study assessed the occupational exposures to several heavy 
metals including Mn and suggested that chronic occupational exposure to Mn (>1 mg/m3) is a 
risk factor for PD (Gorell et al., 1999).  Hypermagnesemia can also occur in individuals with 
chronic liver failure (Hauser et al., 1994, Krieger et al., 1995) or patients receiving total 
parenteral nutrition (Fitzgerald et al., 1999, Bertinet et al., 2000). Further, studies have shown 
an association in patients undergoing hemodialysis and elevated serum Mn levels, 
accompanied with changes in the basal ganglia (da Silva et al., 2007). Interestingly, studies 
revealed that both humans and rats with chronic Fe deficiency could accumulate Mn at high 
levels in the basal ganglia (Herrero Hernandez et al., 2002, Kim et al., 2005, Fitsanakis et al., 
2008, Fitsanakis et al., 2011). These results indicate that changes in Fe dietary, whether 
increased or decreased, could contribute to Mn deposition in the brain and this could be due to 
the competition of Fe and Mn for shared metal transporters. Furthermore, individuals that 
consume well water containing high levels of the metal (Kawamura et al., 1941, Wasserman et 
al., 2006) or soy-based infant formulas (Krachler and Rossipal, 2000) are at higher risk for Mn 
intoxication. In addition to environmental exposure, genetic mutations have also been 
implicated in Mn neurotoxicity (discussed in section 1.3.4).  
Various studies have reported that Mn accumulates mainly in the liver, brain and bone (Rahil-
Khazen et al., 2002, Krebs et al., 2014, Liu et al., 2014), however the brain is the most 
susceptible organ to Mn intoxication as most of the patients with Mn poisoning show symptoms 
of neurological dysfunction. Neurons are more vulnerable to Mn intoxication possibly due to 
their long lifespan and high energy demand. In particular, the ability of Mn to induce reactive 
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oxygen species (ROS) and alter ATP production (Martinez-Finley et al., 2013), may render 
neurons more suspectable the metal. Given its paramagnetic property, brain Mn can be detected 
using T1-weighted magnetic resonance imaging. Brain MRI results from welders and smelters 
exposed to Mn have shown that it primarily accumulates in the striatum, globus pallidus (GP) 
and SN (Yamada et al., 1986, Jiang et al., 2007, Dydak et al., 2011). 
Clinical effects of Mn toxicity also include psychiatric disturbances and cognitive deficits as 
evidenced by a study performed in welders (Josephs et al., 2005). Several studies in non-human 
primates were carried out to assess the behavioural, neuroimaging and neuropathological 
consequences of chronic Mn exposure. They reported that animals developed subtle deficits in 
spatial working memory, reduced spontaneous activity and manual dexterity, in addition to an 
increase in compulsive-like behaviours (Schneider et al., 2006, Schneider et al., 2009, 
Schneider et al., 2015). 
In addition to neuronal loss and behavioural changes caused by Mn exposure, numerous studies 
have described pathologic changes in the GP, a region that is rich in γ-aminobutyric 
acid (GABA) projections (Macdonald and Olsen, 1994). GABA is known as the most 
abundant inhibitory neurotransmitter in the adult brain, located in medium spiny neurons of the 
striatum, where it mediates DAergic activity (Ade et al., 2008). Yamada et al. (1986) reported 
a loss of GABAergic cells, reduction of myelinated fibres and moderate astrocytic 
proliferation following chronic Mn poisoning. Studies performed in Mn-treated non-human 
primates, further confirmed that GABAergic neurons were affected in the GP (Eriksson et al., 
1987). Interestingly the effects of Mn toxicity on GABAergic neurotransmission are 
controversial. Some studies associate exposure to Mn with significantly elevated striatal 
GABA levels (Gwiazda et al., 2002, Garcia et al., 2006, Reaney et al., 2006, Anderson et al., 
2008, Fordahl et al., 2010), while others report reduced GABA levels (Erikson et al., 2002, 
Takeda et al., 2002, Struve et al., 2007, Stanwood et al., 2009). Despite the inconsistency of 
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studies examining the effects of Mn on the GABA system, it is clear that the GABAergic 
system is affected by Mn exposure. More studies are needed to establish whether GABAergic 
cells are directly impaired by Mn accumulation or whether GABA variations are the result of 
any other changes in basal ganglia circuitry. 
Another crucial neurotransmitter in the brain that plays a key role in movement coordination 
and cognition is dopamine (DA), synthesised in DAergic terminals by the tyrosine hydroxylase 
(TH) enzyme. The majority of the studies assessing Mn‐induced neuro-chemical and 
pathological changes have focused on the DAergic system due to its association with 
movement control. Although yet to be fully understood, there is increasing evidence of Mn 
accumulation in DA‐rich brain regions, causing a reduction in DA levels in the striatum (Seth 
and Chandra, 1984, Tran et al., 2002). As DAT has been hypothesised to mediate Mn transport, 
Erikson et al. (2005) assessed changes in Mn accumulation in dopamine transporter knockout 
(DAT-KO) mice compared to WT. Their results clearly displayed reduced Mn in the striatum 
of exposed DAT-KO mice compared to WT, suggesting DAT involvement in facilitating 
striatal Mn accumulation. Other studies have shown that subcutaneous injection in mice or 
intravenous injection of Mn in non‐human primates caused a decrease in striatal DA release 
(Olanow et al., 1996, Guilarte et al., 2006a, Khalid et al., 2011). Additionally, following acute 
intraperitoneal Mn injections, disruption in multiple neurotransmitter systems, including 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were observed in the rat 
brain. These deficits could be responsible, in part, for the described locomotor deficits (O'Neal 
et al., 2014). 
Evidence suggesting Mn can cause neuronal loss in the SNpc and induce neurodegeneration, 
derive from rodents either injected with Mn directly into the SNpc or the striatum (Diaz-Veliz 
et al., 2004, Zhao et al., 2009, Fernandes et al., 2010, Mo et al., 2016), intraperitoneally 
(Stanwood et al., 2009, Robison et al., 2015), via inhalation (Ordonez-Librado et al., 2010) or 
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by oral gavage (Langley et al., 2018). Several studies have investigated the correlation between 
Mn neurotoxicity on the expression of DA receptors (D1 and D2) and DAT, however results 
are controversial. Oral administration of MnCl2 in neonate rats caused a reduction in 
D1 receptors and DAT levels in the nucleus accumbens and the dorsal striatum and an increase 
in D2 receptor expression in the prefrontal cortex (Kern et al., 2010). Nam and Kim (2008),  
showed that intraperitoneal injections of MnCl2 caused a dose-dependent increase of striatal 
D2 receptor expression at both mRNA and protein levels. However Seth and Chandra (1984) 
reported a significant reduction in striatal D2 receptor levels in developing rats following Mn 
poisoning. These differences could be caused by various factors, such as duration of exposure, 
routes of administration, age of the experimental animals and Mn redox state (Bouabid et al., 
2016). 
 
1.3.4 Genetic disorders of manganese metabolism 
 
Multiple metal transporters have been implicated in causing excess Mn accumulation and 
neurological disorders (Horning et al., 2015). The DMT-1, TFR and FPN1, mainly considered 
Fe transporters are also involved in Mn metabolic pathways, as evidenced by changes in Mn 
transport in mice harbouring deficits in Fe metabolism (Kim et al., 2013, Seo and Wessling-
Resnick, 2015). Recently, transporters known for carrying Zn have also been implicated in Mn 
metabolism. The SLC30 (ZnT, zinc transporter) and SLC39 (ZIP, Zinc-Iron Permease) 
transporters maintain cellular Zn homeostasis in the body by operating in opposing directions 
(Huang and Tepaamorndech, 2013). ZnT proteins have dual roles and can function as cation 
diffusion proteins and reduce intracellular Zn concentrations either by transporting (efflux) the 
metal to the extracellular space or by sequestrating it into intracellular compartments (Huang 
and Tepaamorndech, 2013, Kambe et al., 2014). In contrast, ZIP proteins increase cytoplasmic 
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Zn concentrations when depleted, through influx at the plasma membrane or from endosomes, 
mitochondrial and lysosomes (Lichten and Cousins, 2009, Jeong and Eide, 2013).  
Recent studies have shown that alterations in function/localization of ZnT10 (SLC30A10) 
cause parkinsonism and dystonia with hypermagnesemia (Quadri et al., 2012, Tuschl et al., 
2012). Affected patients were born to consanguineous parents and harboured homozygous 
SLC30A10 mutations (missense or frameshift mutations). SLC30A10 was found to be widely 
expressed in the basal ganglia and serum Mn appeared to be increased by10-fold compared to 
normal levels. These patients had no history of exposure to high Mn levels, indicating that loss-
of-function mutations in SLC30A10 are associated with Mn retention (Quadri et al., 2012, 
Tuschl et al., 2012). To further investigate the function of the SLC30A10 protein and 
understand why mutations in this gene caused parkinsonism, Leyva-Illades et al. (2014) 
performed a combination of mechanistic and functional studies in vitro using HeLa cells and 
primary midbrain neurons and in vivo using C. elegans. Their results demonstrated that 
SLC30A10 is a cell surface-localized Mn efflux transporter that protects against Mn-induced 
toxicity by reducing its intracellular levels (Leyva-Illades et al., 2014). SLC30A10 mutations 
block the transporter ability to execute its efflux activity, promoting Mn accumulation. Using 
imaging tools, Carmona et al. (2019) confirmed the role of SLC30A10 in HeLa cells expressing 
either SLC30A10 WT or the disease-causing 105–107 mutant (SLC30A10-Δ105-107). They 
further identified the Golgi apparatus as the main compartment of Mn accumulation in 
SLC30A10 mutants, inferring possible interactions with the vesicular trafficking complex as 
disease causative (Carmona et al., 2019). Collectively, these results describe the cellular 
function of SLC30A10 and mechanisms by which mutations in this protein affect Mn 
homeostasis and contribute to the progression of a familial parkinsonian syndrome. 
The liver has a key role in maintaining Mn homeostasis in the body as it represents the major 
route for its elimination, by secreting excess Mn into the bile (Papavasiliou et al., 1966, Roth, 
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2006). Patients with mutations in the hepatic metal ion transporter SLC39A8 have been linked, 
contrarily to SLC30A10, to reduced blood Mn levels (Boycott et al., 2015). Mn deficiency 
causes reduced activity of Mn-dependent enzymes including the β-1,4-galactosyltransferase 
and MnSOD. This leads to a congenital glycosylation disorder, as well as mitochondrial 
deficiency (Park et al., 2015b, Riley et al., 2017). Lin et al. (2017) showed that both SLC39A8 
global- and liver specific-knockout mice developed markedly decreased Mn levels in multiple 
organs. In addition, SLC39A8 was shown to localise to apical canalicular membrane of 
hepatocytes and promote Mn absorption from the bile to the hepatocytes, thereby reducing 
biliary Mn excretion (Lin et al., 2017). While the efflux transporter SLC30A10 and the influx 
transporter SLC39A14 (discussed later) work together to reduce Mn overload, SLC39A8 has 
an opposing role in promoting Mn uptake into the organism. 
SLC39A14 was first discovered for its role in Zn uptake in the liver in response to acute 
inflammation. Studies performed by Liuzzi et al. (2005) showed that, amongst all the ZnT and 
ZIP transporter genes, ZIP14 (SLC39A14) was the most upregulated under inflammatory 
conditions (turpentine and LPS). Additionally, proinflammatory cytokines, such as IL-1β, 
stimulated the production of nitric oxide, which increased SLC39A14 transcriptional activity 
and enhanced Zn transport (Lichten et al., 2009). Despite the attention given to ZIP14 in 
relation to Zn transport, in vitro evidence suggested that this specific transporter also transports 
Mn (Fujishiro et al., 2014).  
Recently, mutations in SLC39A14 have indeed been shown to disrupt Mn homeostasis, 
resulting in its accumulation, particularly in the GP and the striatum and cause childhood-onset 
parkinsonism–dystonia (Tuschl et al., 2016). In addition, SLC39A14 was shown to function 
primarily as a Mn transporter, as homozygous SLC39A14 mutations impair Mn uptake, 
without affecting other metals. These results were corroborated in a zebrafish model carrying 
CRISPR-induced mutations in the SLC39A14 orthologue (Tuschl et al., 2016). MRI scans 
27 
 
from patients with both SLC39A14 and SLC30A10 mutations appear similar with both 
exhibiting cerebral Mn deposition, neuronal loss and spongiosis in the GP as well as myelin 
and axonal loss throughout various white matter regions (Lechpammer et al., 2014, Tuschl et 
al., 2016). Individuals with SLC39A14 deficiency or mutations, however, do not develop 
polycythaemia or liver disease and their Fe levels appear to be normal (Tuschl et al., 2016). 
Under physiological conditions, Tuschl et al. (2016) suggest that Mn is absorbed in the 
duodenum and then transported into the liver via the SLC39A14 transporter and excreted into 
the bile via SLC30A10. On the contrary, SLC39A14 deficiency impairs hepatic Mn uptake and 
biliary excretion, causing Mn accumulation in the blood and brain. To test this hypothesis, Xin 
et al. (2017) generated and characterised global and hepatocyte-specific SLC39A14-knockout 
mice. Global SLC39A14-knockout mice (SLC39A14−/−) displayed high Mn concentrations in 
the brain and other extrahepatic tissues, accompanied by motor deficits that were ameliorated 
by treatment with the metal chelator Na2CaEDTA. In contrast, hepatocyte-specific SLC39A14-
knockout mice did not develop Mn accumulation in the brain or other extrahepatic tissues and 
did not present motor deficits, except for significantly reduced hepatic Mn levels. These 
results suggest that selective hepatocytic loss of SLC39A14 expression is not sufficient to 
induce Mn accumulation. In addition, these mice exhibited normal Mn, Zn and Cu levels in all 
the studied tissues, except for the liver in which Mn levels were significantly reduced (Xin et 
al., 2017). Interestingly, hepatocyte-specific SLC39A14-knockout mice fed with a high Mn diet 
displayed increased Mn levels in the brain, but not in the liver, suggesting the brain of these 
mice is highly susceptible to Mn toxicity possibly caused by the inability to sequester Mn in 
the liver. Jenkitkasemwong et al. (2018) not only confirmed that SLC39A14 deficiency alters 
Mn homeostasis causing it to accumulate in the brain, but additionally showed that 
SLC39A14−/− mice also display impaired Mn excretion. Following Mn administration via tail 
vein injection, mice were housed individually in metabolic cages and feces/urine were 
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collected. The diminished excretion of Mn by SLC39A14−/− mice, six hours after Mn injection, 
appeared to be caused by impaired uptake of plasma Mn by the liver and pancreas compared 
to WT mice and therefore reduc Mn elimination in the bile (Jenkitkasemwong et al., 2018). 
Similarly to patients with loss-of-function mutations in SLC39A14, SLC39A14−/− mice display 
motor deficits, that cannot be corrected by a low-Mn diet.  
Overall, identification of new inherited Mn transporter defects caused by mutations in three 
solute carrier proteins, SLC30A10, SLC39A14, and SLC39A8 has furthered our understanding 
on Mn homeostasis and Mn-related disease changes. 
 
1.3.5 Differences between Manganism and Parkinson’s disease 
Regardless of the source, Mn overexposure can cause an irreversible, progressive condition 
that resembles PD. As stated previously, PD is known to be a motor disorder that results from 
selective loss of DAergic neurons in the SNpc. In contrast, Manganism is known to target 
GABAergic neurons in the GP and, relatively, spare the nigrostriatal DAergic system 
(Crossgrove and Zheng, 2004, Olanow et al., 1996) (Figure 1.4). Symptoms produced by Mn 
overexposure are characterised by dystonic movement of the extremities with tremor and a 
distinctive gait referred to as ‘cock-walk’ in which patients  walk  on  their  toes,  leaning 
forward (Barbeau, 1984). Despite the noticeable presence of bradykinesia and rigidity, tremor 
is not as evident in Mn-overexposed patients (Lucchini et al., 2009). Further, levodopa, the 
most commonly used and effective drug in PD is ineffective in alleviating Mn-induced motor 
symptoms (Koller et al., 2004, Cersosimo and Koller, 2006). Guilarte et al. (2006a) also 
reported that monkeys repeatedly exposed to Mn developed a deficit in DA release, with no 
changes in striatal DA concentrations or in DAT levels, suggesting a dysfunction rather than a 
degeneration of the DAergic system. Despite differences between these two disorders, Mn 
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could still be involved in PD pathogenesis by interacting with the genetic makeup of an 
individual and enhancing its susceptibility to develop or accelerate the progression of the 
disease. Epidemiological studies have investigated the relationship between PD and blood 
and/or urine levels of heavy metals and discovered an accumulation of Mn levels in PD patients 
(Fukushima et al., 2010, Fukushima et al., 2013). In addition, rodents exposed to Mn for four 
weeks displayed a significant accumulation of Mn in DAergic neurons as compared to controls 
(Robison et al., 2012, Robison et al., 2015). 
Similar to PD, however, Manganism is a progressive neurodegenerative disorder, with only 
partial recovery of certain symptoms following elimination of the source for an extended period 
of time (Bowler et al., 2011). 
  
Figure 1.4 T1-weighted MRI images of the same monkey brain at the level of the globus 
pallidus before (A) and after (B) 17 months of Mn administration. Mn administration produces 
bilateral hyperintensive signal throughout the brain compared to baseline images. Abbreviation: C/P, 
caudate/putamen; GP, globus pallidus; LHb, lateral habenula. From Guilarte and Gonzales (2015). 
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1.4 Mechanisms of pathophysiology in Parkinson’s disease 
The aetiology of PD is complex and multi-factorial, however multiple studies have provided 
important insight into mechanisms of neuronal dysfunction and degeneration. These non-
mutually exclusive mechanisms include mitochondrial dysfunction, accumulation of toxic 
misfolded proteins and impaired proteostasis and neuroinflammation. 
 
1.4.1 Mitochondrial dysfunction 
Mitochondria are well-defined cytoplasmic structures that have been long considered as vital 
organelles, primarily for their key role in ATP synthesis. They are also crucial for various other 
cellular processes including programmed cell death, innate immunity, autophagy, redox 
signalling, calcium homeostasis and stem cells reprogramming (Kamer and Mootha, 2015, 
Rambold and Pearce, 2018, Nikoletopoulou et al., 2013). By electron microscopy (EM) the 
mitochondrial ultrastructure is visible as a double membrane system, where the OMM faces 
the cytosol, and the IMM protrudes into the mitochondrial matrix, which contains 
mitochondrial DNA (mtDNA). The intermembrane space (IMS) is the compartment between 
the IMM and OMM. Over the last 30 years the concept of mitochondria as static and isolated 
structures has changed drastically. Indeed, mitochondria are extremely dynamic organelles that 
undergo constant morphological changes through fission/fusion processes (Figure 1.5). The 
balance between these two opposite processes is essential for regulating mitochondrial number, 
size and position within the cytoplasm and is referred to as ‘mitochondrial dynamics’ (Liesa et 
al., 2009). Neurons are highly active cells with a complex shape that require energy at distal 





In mammals, mitofusins (Mfn1 and Mfn2) and optic atrophy 1 (OPA1) represent the major 
regulators of mitochondrial fusion. During fusion the coordination of the OMM and the IMM 
are required to generate larger mitochondria. This event promotes an exchange of substrates 
and mtDNA between healthy and dysfunctional mitochondria (also known as functional 
complementation), along with an increase of ATP supply (Chen and Chan, 2010, Youle and 
Figure 1.5 Schematic representation of mitochondrial fission and fusion processes. 
Mitochondrial dynamics represent a continuous process whereby pre-existing mitochondria alter 
their morphologic profile thus adapting to the specific demands of the cell. Following biogenesis, 
mitochondria may be broken into smaller, more mobile organelles through fission and fused to form 
larger, more respiratory active structures through fusion. During fission Drp1 translocates from the 
cytosol to the mitochondrial outer membrane, oligomerises and subsequently produces small and 
motile mitochondria. MFF and Fis1, along with MiD49 and MiD51, represent outer mitochondrial-
anchored fission proteins required for Drp1 stabilization. Fusion is mediated by three mammalian 
proteins: Mfn1 and Mfn2 for outer membrane fusion, and OPA1 for inner membrane fusion. 




van der Bliek, 2012). Genetic deletion of mitofusin proteins culminate in the progressive 
abrogation of fusion and causes mitochondrial dysfunction in both culture and tissues (Chen et 
al., 2003, Chen et al., 2005, Chen et al., 2010). Mfn2, in particular, has been implicated in 
physiological processes such as transport, ER tethering and calcium uptake (de Brito and 
Scorrano, 2008, Misko et al., 2010, Filadi et al., 2015). Neurons lacking Mfn2 have been 
associated with increased ER stress, decreased anterograde transport of mitochondria along 
microtubules, lower axonal and synaptic densities of mitochondria, and organelle accumulation 
in the soma (Baloh et al., 2007, Chen et al., 2007a, Pham et al., 2012). Among different cell 
types, neurons are particularly sensitive to Mfn2 defects as they require functional 
mitochondria located at dendrites and synaptic termini, to support proper ATP production and 
Ca2+ buffering (Celsi et al., 2009). Mfn2 mutations have been linked to a neurological disorder, 
characterised by degeneration of long peripheral nerves, known as Charcot–Marie–Tooth 
disease type 2A (CMT2A) (Zuchner et al., 2004). This disorder is a subtype of a heterogeneous 
group of congenital neuromuscular diseases that target motor and sensory neurons, known as 
CMT disease (Cartoni and Martinou, 2009).  
On the other hand, fission requires the cytosolic dynamin related protein 1 (Drp1), a GTPase 
protein that uses energy released from GTP hydrolysis to promote division. The fission 
mechanism is still not fully understood, however, once recruited to the OMM by Mid49 and 
Mid51 (essential for the stabilisation of Drp1), by the mitochondrial fission factor (Mff) and 
fission-1 (Fis1), Drp1 assembles into a dimeric ring like structure and constricts the 
mitochondria until fission takes place (Ingerman et al., 2005). The resulting mitochondria are 
smaller and more motile and can therefore be transported to distal parts of the cell. Further, 
fission segregates mitochondria with healthy and damaged mtDNA, marks them for mitophagy 
and facilitates mitochondrial quality control (Scott and Youle, 2010, Youle and van der Bliek, 
2012, Archer, 2013). Mutations in Drp1 and Mff have been implicated with severe neurologic 
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phenotypes in humans (Waterham et al., 2007, Vanstone et al., 2015, Koch et al., 2016, Nasca 
et al., 2018). For example, Koch et al. (2016) established that Mff loss of function is associated 
with early-onset Leigh-like basal ganglia disease. Waterham et al. (2007) reported 
microcephaly, abnormal brain development, optic atrophy and hypoplasia in a new born with 
defects in both mitochondrial and peroxisomes’ fission, as well as a heterozygous, dominant-
negative mutation in Drp1 (coding-sequence mutation in the middle domain of Drp1). In 
addition, Drp1-null mice die by embryonic day 11.5 from developmental defects of the 
cerebellum (Wakabayashi et al., 2009). This lethality is not caused by the loss or reduction of 
ATP levels, but is due to swollen mitochondria in Purkinje cells and impaired apoptosis 
(Wakabayashi et al., 2009). Further, post-natal deletion of Drp1 in Purkinje cells have been 
shown to cause mitochondrial tubules to elongate due to excess fusion and form large 
mitochondria, oxidative stress, respiratory dysfunction, accumulation of ubiquitinated proteins 
and consequently neurodegeneration (Kageyama et al., 2012). Mitochondrial defects were, 
however, restored with antioxidants treatment (Kageyama et al., 2012). These results not only 
show that Drp1 is required for embryonic and brain development in mice, but also demonstrate 
how Drp1 may suppress oxidative damage and promotes neuronal survival. Therefore, a 
balance of mitochondrial dynamics is not only necessary for mitochondrial morphology but 
also for cell function and survival. 
The first evidences that implicated mitochondrial dysfunction in the development of PD 
derived from studies performed in the late 80’s. Results showed that the activity of the 
mitochondrial complex I, in the SN of PD patients, was significantly decreased (Bindoff et al., 
1989, Schapira et al., 1989). Mutations in the mtDNA have also been related to 
PD.  Mitochondrial oxidative phosphorylation requires both mitochondrial and nuclear DNA-
encoded proteins. mtDNA encodes 13 proteins that are all subunits of respiratory chain 
complexes, 22 tRNAs, and 2 rRNAs. Studies performed in DAergic neurons of the SNpc 
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revealed that these had high levels of mtDNA deletions. MtDNA mutations were somatic and 
associated with respiratory chain deficiency (Bender et al., 2006). In particular, the highest 
rates of mtDNA deletions (>60%) were observed in neurons with deficient cytochrome c 
oxidase (COX) activity (Kraytsberg et al., 2006). These results suggest that mtDNA deletions 
may be directly responsible for impairing cellular respiration. It is important to note that 
mtDNA mutations were specific to DAergic neurons and this could potentially increase their 
susceptibility to oxidative stress, which could then contribute to their selective loss in PD 
(Bender et al., 2006, Kraytsberg et al., 2006). This suggestion is supported by studies 
performed in MitoPark mice, which present a deletion of the mitochondrial transcription factor 
A (Tfam) gene, master regulator of mtDNA transcription, in DAergic neurons (Ekstrand et al., 
2007). Ekstrand et al. (2007) discovered that DAergic neurons of the SNpc had reduced 
mtDNA expression and respiratory chain impairments. Mitochondrial impairment led to a 
deterioration of motor function along with intraneural inclusions and loss of DAergic neurons. 
Impairment in the release of DA was also found in six-eight weeks old MitoPark mice 
suggesting that nigrostriatal dysfunction could proceed any behavioural deficits in this genetic 
PD model (Good et al., 2011). No strong evidence clearly shows that mtDNA mutations are a 
major primary cause of PD, however mtDNA mutations could accumulate with time as a 
consequence of cellular stress and mitochondrial replication errors. Once the mtDNA 
mutations are too severe, the resulting respiratory deficiency could contribute to neuronal 
degeneration and cell death. Of note, complex I is particularly vulnerable to mtDNA 
modifications, since seven of its subunits are encoded by mtDNA (Janssen et al., 2006). 
Mitochondrial dysfunction associated with PD pathogenesis can also result from impaired 
mitochondrial trafficking. Mitochondria move along axons relying on motor proteins and 
microtubules via retrograde (towards the cell body) and anterograde (towards the terminus) 
transport. Retrograde transport is controlled by dynein motors while anterograde movements 
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are driven by kinesin motors (Devine and Kittler, 2018). MPP+ was reported to affect 
mitochondrial motility and alter mitochondrial directionality, by reducing anterograde 
transport and increasing retrograde, thus impeding delivery of mitochondria to synapses (Kim-
Han et al., 2011). Additionally, Sterky et al. (2011) showed that DA neurons of MitoPark mice 
exhibited an impaired anterograde axonal transport of mitochondria along with respiratory 
chain deficiency and mitochondrial fragmentation. Of particular interest for PD pathogenesis 
is the axonal trafficking of α-synuclein and mitochondria. α-synuclein oligomers were shown 
to impair anterograde axonal transport of mitochondria by causing subcellular changes in 
adaptor motor proteins and energy deficits (Prots et al., 2018).  
Various epidemiological studies have also demonstrated that pesticides and other toxins 
involved in PD pathogenesis can directly target mitochondria and induce neurodegeneration. 
The first direct evidence that linked mitochondrial dysfunction and PD came from the 
discovery of MPTP, a neurotoxin that caused chronic parkinsonism in drug-abused patients 
(Langston et al., 1983). MPP+ the known metabolite of MPTP, is known for its ability to inhibit 
mainly complex I but also complex III and IV (Nicklas et al., 1985, Desai et al., 1996), decrease 
ATP production, generate ROS (Fabre et al., 1999), reduce mitochondrial gene expression 
(Piao et al., 2012), alter mitochondrial proteins such as chaperones, metabolic enzymes, 
oxidative phosphorylation-related proteins, inner and outer mitochondrial proteins (Burte et al., 
2011), induce changes in proteins involved in DA signalling, ubiquitin system, calcium 
signalling, oxidative stress response and apoptosis (Zhang et al., 2010). In addition, chronic 
and systematic exposure to rotenone was reported to inhibit complex I activity (Betarbet et al., 
2000). Paraquat causes extensive mitochondrial oxidative damage by accumulating in the 
mitochondrial matrix and generating free radicals (Cocheme and Murphy, 2008). Maneb was 
also shown to inhibit mitochondrial complex III (Zhang et al., 2003a).  
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Heavy metals are crucial for enzyme function and protein folding, but in excess they can lead 
to neurotoxic oxidative processes. As mitochondria are highly susceptible to oxidative stress 
caused by radicals produced during ATP synthesis, mitochondrial bio-metal homeostasis must 
be well regulated to safely control the redox potential of metal enzyme cofactors (Grubman et 
al., 2014). Cu, Zn, Fe and Mn are all localised to various compartments of the mitochondria 
and a range of cofactors, chaperones and ion pumps regulate their levels and function (Pierrel 
et al., 2007). Relevant to this work, mitochondria are known to be one of the major sites of Mn-
induced cellular dysfunction (Cotzias and Greenough, 1958). In fact, Mn can be rapidly 
transported into the mitochondrial matrix as Mn2+ via the calcium (Ca2+) uniporter channel. 
Slow export, however, occurs via the Na+-independent Ca2+ -channel. An overexposure of Mn, 
therefore, causes an increased accumulation of Mn within the mitochondria and subsequent 
inhibition of Na+-dependent and -independent Ca2+ -efflux; this results in elevated Ca2+ levels 
within the mitochondrial matrix (Gavin et al., 1990), which can promote ROS formation and 
inhibit the ETC (Kowaltowski et al., 1995, Kruman and Mattson, 1999). Generally, the 
superoxide radical (O2
−•) is the first ROS species that is formed. This can be converted into 
hydrogen peroxide (H2O2) by superoxide dismutase (MnSOD catalyses the reaction in the brain 
mitochondria). In the presence of Mn or other metals, H2O2 can be converted through the 
Fenton reaction, into the very reactive hydroxyl radical (OH•) (Goldstein et al., 1993). The 
ROS generated by increased mitochondrial Mn has been demonstrated to initiate a cascade of 
events including the opening of the permeability pore, loss of membrane potential, reduction 
in ATP synthesis and mitochondrial swelling, that will eventually lead to cellular apoptosis 
(Gavin et al., 1990, Gavin et al., 1992, Kowaltowski et al., 1998, Gavin et al., 1999, Barhoumi 
et al., 2004, Gunter et al., 2012, Martinez-Finley et al., 2013).  
In addition, studies have shown that Mn can be actively sequestered and accumulate in the 
mitochondria, resulting in increased formation of ROS and subsequent inhibition of OXPHOS 
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(Gavin et al., 1990, Gavin et al., 1992, Kruman and Mattson, 1999). Zhang et al. (2003b) 
reported that chronic injection of MnCl2 in both male and female rats for six weeks, directly 
inhibited complex I-IV of brain mitochondria. Mn toxicity was further associated with 
mitochondrial dysfunction and DNA fragmentation in rat primary neuron cultures (Malecki, 
2001). Astrocytic mitochondria have also been shown to be a direct target of Mn-induced 
toxicity, as reported by studies examining mitochondrial calcium responses in primary cortical 
astrocytes stimulated with ATP (Tjalkens et al., 2006). In addition, Mn reduces mitochondrial 
membrane potential and increases ROS in cultured astroglial cells (Barhoumi et al., 2004).  
The above studies described the effects of Mn on oxidative phosphorylation, however not much 
is known about the effects of Mn toxicity on mitochondrial dynamics. Alaimo et al. (2013) 
used human Gli36 cells to investigate possible mitochondrial dynamics changes in Mn-exposed 
human astrocytes. Results indicated that, in addition to triggering the mitochondrial apoptotic 
pathway Mn causes a deregulation in mitochondria-shaping proteins (Opa-1, Mfn-2 and Drp-
1) expression levels (Alaimo et al., 2013). In a subsequent study, Alaimo et al. (2014) 
demonstrated that, in addition to Δψm dissipation, high concentrations of Mn (750 µM MnCl2) 
generate an imbalance in fusion/fission equilibrium resulting in an increased mitochondrial 
fragmentation. The authors showed a reduced presence of Opa1 on mitochondria and an 
increased translocation of Drp1 to the mitochondria following Mn exposure, indicative of 
increased mitochondrial fission. These defects were restored by inhibiting Drp1 both 
genetically and pharmacologically (Alaimo et al., 2014). Sarkar et al. (2018) further examined 
the interrelationship between mitochondrial dysfunction and astrocytic inflammation in Mn 
neurotoxicity. Their results clearly indicated that Mn induces neuroinflammation in astrocytes 
through mitochondrial bioenergetics impairment. Treatment with mito-apocynin (a 
mitochondrial targeted antioxidant) attenuated these mitochondrial deficits (Sarkar et al., 
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2018). Collectively these studies imply that restoring mitochondrial health in various cell types 
could be neuroprotective against Mn-induced neurotoxicity.  
The role of mitochondrial dysfunction in PD has been further strengthened following the 
discovery and study of genes implicated in familial PD. Strong evidence in both human and 
animal PD models show disruptions in mitochondrial dynamics and transport, bioenergetics 
defects, complex I inhibition and increased ROS (Moon and Paek, 2015, Park et al., 2018).  
Many PD-associated PARK genes have been linked to mitochondrial dysfunction. In particular, 
the association between a-synuclein, PINK1, Parkin pathologies and mitochondrial 
dysfunction may play a crucial role in PD. Various studies have investigated the interplay 
between mitochondria and α-synuclein physiologically and in pathological conditions. α-
synuclein is now known to be a key physiological modulator of mitochondrial homeostasis by 
interacting with directly with MAM and regulating ATP synthase to improve the efficiency of 
ATP production (Nakamura et al., 2008, Guardia-Laguarta et al., 2014, Ludtmann et al., 2016). 
This interaction allows a-synuclein, when overexpressed or mutated, to cause structural 
changes in mitochondria, oxidative stress and/or bioenergetic defects (Hsu et al., 2000, Martin 
et al., 2006, Stichel et al., 2007, Devi et al., 2008, Parihar et al., 2008, Liu et al., 2009a, Chinta 
et al., 2010, Loeb et al., 2010, Nakamura et al., 2011). Accumulation of WT α-synuclein was 
shown to reduce complex I activity and promote ROS generation in DAergic neurons of PD 
patients (Devi et al., 2008).  Recent studies have established that mice overexpressing human 
WT α-synuclein under the Thy1 promoter exhibit mitochondrial dysfunction (between four and 
eight months of age) in DAergic neurons, long before the onset of striatal DA loss, which 
occurs at 14 months (Subramaniam et al., 2014). Further, A53T human α-
synuclein overexpressing transgenic mice displayed early-onset mitochondria abnormalities, 
which preceded DAergic degeneration (Chen et al., 2015a). Di Maio et al. (2016) discovered 
that certain post-translationally modified forms of α-synuclein (soluble oligomers, DA-
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modification, and S129E) can bind specifically to TOM20 preventing its interaction with the 
co-receptor, TOM22 and impair mitochondrial protein import. Interestingly, in both α-
synuclein overexpressing WT mice and post-mortem human tissue from PD 
brains, mitochondrial dysfunction was associated with TOM40 reduction, a specific 
component of the mitochondrial transport machinery. TOM40 deficits led to increased 
mitochondrial DNA deletions, oxidative DNA damage, decreased ATP production and altered 
levels of complex I proteins (Bender et al., 2013). Bender et al. (2013) also showed that 
overexpression of TOM40 rescued energy deficits and oxidative damage in these mice.  
Dynamic processes such as mitochondrial fusion/fission and axonal transport are also affected 
by α-synuclein. Severe mitochondrial fragmentation and reduced motility both in vitro and in 
vivo have been previously shown in overexpressing WT and mutated forms of α-synuclein 
(Kamp et al., 2010, Nakamura et al., 2011, Gui et al., 2012, Chen et al., 2015a, Bido et al., 
2017). In a zebrafish model of α-synuclein toxicity, sensory neurons displayed fragmented 
mitochondria, which could occasionally cause mitochondrial swelling within the 
axon (O'Donnell et al., 2014). A recent study investigated the detrimental effect of A53T 
mutation on primary neurons and found that mitochondrial motility was selectively impaired, 
as was mitochondrial membrane potential and respiratory capacity (Li et al., 2014a). α-
synuclein has also been shown to bind to the promoter region of PGC1α, under oxidative stress 
conditions and inhibit the expression of downstream genes, therefore impacting and reducing 
mitochondrial biogenesis (Siddiqui et al., 2012). Impairment of complex I function and 
increased production of reactive oxygen species ROS have been observed in α-synuclein 
overexpressing or A53T mutated cells (Devi et al., 2008, Loeb et al., 2010, Reeve et al., 2015). 
In addition, experiments in recombinant WT and mutant α-synuclein rats were shown to affect 
mitochondrial membrane potential and ATP production (Banerjee et al., 2010). In summary, 
α-synuclein can impair mitochondrial function at multiple levels: by impairing the electron 
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transport chain (ETC), causing an imbalance in mitochondrial dynamics and reducing 
mitochondrial biogenesis.  
Abnormalities in mitochondrial function and morphology have additionally been reported in 
multiple in vitro and in vivo models of PINK1 and Parkin. In particular, PINK1 deficient and 
PD-associated mutant models feature reduced mitochondrial membrane potential, ATP levels, 
decreased respiratory capacity, increased mitochondrial Ca levels and permeability transition 
pore opening, increased oxidative stress, protein aggregation and reduced proteosomal activity 
(Gautier et al., 2008, Piccoli et al., 2008, Gandhi et al., 2009, Gegg et al., 2009, Liu et al., 
2009b, Morais et al., 2009, Dagda et al., 2009, Cui et al., 2010, Heeman et al., 2011, Gautier 
et al., 2012, Morais et al., 2014). Additionally, PINK1-deficient mice display complex I deficits 
(Gautier et al., 2008, Morais et al., 2014) and reduced calcium buffering capacity (Akundi et 
al., 2011) in isolated brain mitochondria. Aged Parkin knock-out brains further exhibit deficits 
in the expression of multiple mitochondrial proteins, causing reduced respiratory capacity and 
increased oxidative damage (Palacino et al., 2004, Periquet et al., 2005, Stichel et al., 2007). 
It is evident that mitochondria are a common pathogenic target for both genes and 
environmental toxicants linked to PD. Given the extensive and key role of mitochondria, 
ranging from the classic “powerhouses” of the cell, to maintaining calcium homeostasis, 
controlling synaptic activity, initiating apoptosis and the spread of α-synuclein (discussed in 
1.4.2), it is not surprising that impaired mitochondrial function would negatively impact 




1.4.1.1 Drp1  
In vitro and in vivo studies have shown that DAergic neurotoxins MPP+, 6-OHDA and 
rotenone could induce Drp1 hyperactivity and mitochondrial fragmentation leading to DAergic 
cell death in neuronal cultures (Barsoum et al., 2006a, Meuer et al., 2007, Gomez-Lazaro et 
al., 2008). Inhibition of Drp1 or overexpression of Mfn1 could prevent this neurotoxin-induced 
mitochondrial fission and neuronal cell death. Several groups have and highlighted the 
importance of Drp1 function and its potential as a therapeutic target in neurodegenerative 
disorders. In particular, inhibition of the mitochondrial fission factor Drp1, both genetically 
and using small molecules, was reported to protect cells from neurodegeneration in different 
models of PD (Dagda et al., 2009, Lutz et al., 2009, Cui et al., 2010). Mitochondrial division 
inhibitor 1 (mdivi-1) is a small-molecule inhibitor of Drp1, first characterised by Cassidy-Stone 
et al (2008). By directly binding to Drp1, mdivi-1 blocks its assembly into oligomeric ring 
structures and its GTPase activity, therefore interfering with its physiological function 
(Cassidy-Stone et al., 2008). Mdivi-1 has been used in multiple disease studies, and data 
suggest efficacy in several models of neurodegeneration. Xie et al. (2013) showed that mdivi-
1 could exert neuroprotective effects against hippocampal neuron damage induced by seizures. 
Abnormal mitochondrial function and morphology induced by mutant PINK1L347P in N27 cells 
was prevented by exposing cells to 10 μM mdivi-1 (Cui et al., 2010). Recently, Bido et al. 
(2017) showed that mdivi-1 could reduce neurodegeneration, α-synuclein aggregation and 
mitochondrial fragmentation in a A53T-α-synuclein rat model of PD. In addition to mdivi-1, 
Qi et al. (2013) used a model of PD in neuronal cultures and demonstrated that the peptide 
P110 (selective Drp1 inhibitor) conferred neuroprotection against mitochondrial fragmentation 
and ROS production. Inhibition of mitochondrial fission also improved mitochondrial 
membrane potential and mitochondrial integrity by reducing apoptosis and restoring LC3-II 
puncta to control levels (Qi et al., 2013). Results indicating that P110 could provide 
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neuroprotective effects was further strengthened by Filichia et al. (2016) who reported that 
P110 could restore DAergic neuronal loss, DAergic nerve terminal damage and behavioural 
deficits caused by MPTP. 
Drp1 function has also been targeted using genetic approaches, such as viral vectors that 
harbour dominant negative Drp1 mutations. These mutations are non-functional and impair 
Drp1 oligomer formation, preventing excessive fission. Stereotactic injection of recombinant 
adeno-associated viral (rAAV) to deliver Drp1 dominant negative K38A to the SN has been 
shown to attenuate neurotoxicity and restore pre-existing striatal DA release deficits in 
PINK1−/− and MPTP pre-treated mice (Rappold et al., 2014). The A395D dominant negative 
Drp1 mutation, first discovered in a neonate with microcephaly (Waterham et al., 2007) 
promoted mitochondrial elongation in HeLa cells as a consequence of decreased fission (Chang 
et al., 2010). A recent study compared the cellular impact of a novel Drp1 mutation, R403C, to 
the previously described A395D variant (Fahrner et al., 2016). The group reported that the 
R403C mutation, acting as a dominant-negative of Drp1, reduced Drp1 recruitment to the 
mitochondria and oligomerization, impairing mitochondrial fission activity. In addition, 
R403C mutation appeared less severe and more tolerated at the phenotypic and cellular level 
compare to the previously reported A395D mutation (Chang et al., 2010, Fahrner et al., 2016). 
Fan et al. (2019) also reported that blocking Drp1, using multiple approaches (gene silencing 
overexpression of K38A and mdivi-1), improved mitochondrial function and autophagic flux 
in experimental models of α-synuclein.  





1.4.2 α-synuclein aggregation and spread 
Protein aggregation is a common theme underlying neurodegenerative diseases. Research in 
PD has largely focused on protein misfolding and aggregation given the association of α-
synuclein gene mutations with familial forms of the disease and the discovery of the protein as 
the main component of LBs. Despite the controversy regarding the native conformation of α-
synuclein and which conformation is more susceptible to aggregation, it is now clear that 
transition to an aggregated β-sheet conformation is necessary for insoluble inclusions or LBs 
(Miraglia et al., 2018). The aggregation process has been suggested to be a nucleation reaction 
that is sought to develop in a sequential way. Here, soluble species undergo a process that 
generates oligomeric species, which can then form protofilaments and eventually mature fibrils 
(Figure 1.6). 
  
Figure 1.6 Hypothetical model of α-synuclein toxicity and spread of pathology in PD. 
Schematic illustration of the stepwise process whereby normal, highly soluble a-synuclein misfolds 
and is converted into pathological oligomers and higher-order aggregates that fibrillise and deposit 
into LBs in affected neurons of the PD brain. α-synuclein can also be transmitted inter-cellularly. 
Several of the proposed toxic consequences of the accumulation and spread of α-synuclein are 




In vitro evidence suggests a precise time course, with an initial lag phase, in which α-synuclein 
monomers are converted into insoluble β-sheet rich structures (nucleation), a growth phase and 
a plateau state (reached when the monomer concentration is depleted) that terminates with the 
accumulation of protofibrils and amyloid fibrils (Lashuel et al., 2002, Vilar et al., 2008, 
Cremades et al., 2012, Tuttle et al., 2016). In vitro results have also demonstrated that α-
synuclein fibrils may have either a ribbon or a fibril structure (Bousset et al., 2013, Guo et al., 
2013). In addition to fibrils, stable toxic oligomers of α-synuclein have also been described to 
accumulate during this process (Cremades et al., 2012, Chen et al., 2015b). Oligomers are 
defined as low-molecular weight aggregates, soluble or insoluble, that do not have a fibrillary 
organisation. Similar to α-synuclein fibrils, various forms of oligomers have been described in 
vitro, differing in size and morphology (Lashuel et al., 2002). α-synuclein fibrils are believed 
to grow by adding monomers onto existing aggregates rather than oligomers (Buell et al., 
2014). Both oligomers and fibrils have toxic effects with different mechanisms of pathology.  
The pathogenic aggregation of α-synuclein is a critical event in PD pathogenesis and it can be 
caused by both endogenous and exogenous factors, including metals and pesticides, genetic 
mutations, PTMs and protein-protein interactions (Deleersnijder et al., 2013). The hypothesis 
that α-synuclein fibrillation could worsen PD pathology and promote its disease progression 
derives from the discovery of two α-synuclein mutants (A53T and E46K), linked to early-onset 
PD, which exhibited an increased fibrillation propensity in vitro (Conway et al., 1998, Narhi et 
al., 1999, Greenbaum et al., 2005). In addition, a novel pathogenic mutation of α-synuclein 
(H50Q) has also been shown to accelerate α-synuclein aggregation (Appel-Cresswell et al., 
2013, Proukakis et al., 2013, Ghosh et al., 2013). On the contrary, other α-synuclein mutations 
(G51D, and A53E) associated with familial forms of PD have been proven to decrease α-
synuclein fibrillation (Ghosh et al., 2014, Fares et al., 2014). Less agreement exists concerning 
the effects of the PD-associated A30P mutation, as this variant has been reported to either slow 
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(Lemkau et al., 2012) or accelerate α-synuclein aggregation (Narhi et al., 1999, Li et al., 2001, 
Lashuel et al., 2002, Li et al., 2002), or have no effect (Conway et al., 2000) compared to the 
WT protein. Overall, these studies suggest that α-synuclein fibrillation rate is not directly 
correlated to disease pathogenesis and that monitoring the effects of α-synuclein mutations on 
the oligomerisation rate could possibly resolve this complexity. Evaluation of α-synuclein 
oligomerisation kinetics may represent a promising approach since pre fibrillar α-synuclein 
oligomers have been suggested to be the most toxic entity responsible for DAergic loss in PD 
(Winner et al., 2011).  
Studies performed on human α-synuclein transgenic mice revealed that the accumulation of 
oligomers mainly occurred at synaptic sites causing synaptic and neuronal degeneration 
(Rockenstein et al., 2014). Consistent with these results, oligomers have been found to reduce 
neuronal excitability (Kaufmann et al., 2016) and affect synaptic function  by altering lipid raft 
composition and increasing N-methyl-D-aspartate (NMDA) receptor activation at postsynaptic 
membranes (Diogenes et al., 2012, Emanuele et al., 2016). These alterations can impact 
mitochondrial function (Sarafian et al., 2013), cytoskeletal architecture (Chen et al., 2007b, 
Prots et al., 2013), protein clearance pathways (Cuervo et al., 2004, Xilouri et al., 2009, 
Emmanouilidou et al., 2010) and enhance oxidative stress (Junn and Mouradian, 2002). 
In addition, α-synuclein is subject to extensive PTMs including phosphorylation, which is the 
most widely studied. PTMs have been shown to  impact α-synuclein aggregation 
and oligomerisation in different ways. Using specific antibodies, Fujiwara et al. (2002) 
discovered that a major constituent of LBs in PD brain tissue was α-synuclein phosphorylated 
at residue S129. Moreover, the soluble fraction (non-fibrillar) of tissue from PD patients, 
containing α-synuclein, was also found to be phosphorylated at S129 (Anderson et al., 
2006).  The exact effects of phosphorylation at S129 on α-synuclein have not been fully 
understood, however several studies have demonstrated that phosphorylation accelerated α-
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synuclein aggregation and toxicity in different cell models (Smith et al., 2005, Sugeno et al., 
2008). In addition, phosphorylation accelerated DAergic neuronal loss in transgenic mice 
overexpressing α-synuclein compared to those expressing WT or phosphorylation-deficient 
(S129A) forms (Chen and Feany, 2005, Wakamatsu et al., 2007, Rieker et al., 2011). These 
discoveries suggest that phosphorylation could alter α-synuclein tendency to aggregate or form 
oligomeric species and may therefore affect PD progression or initiation. 
Increasing evidence is indicating that α-synuclein may self-propagate and spread progressively 
between interconnected brain regions via cell-to-cell transmission mechanisms including non-
classical exocytosis, exosome release and nanotubes that directly connect the cytoplasm of two 
cells (Guo and Lee, 2014) (Figure 1.6). Additionally, α-synuclein aggregates have been 
identified in enteric neurons of patients with early-stage PD (Hilton et al., 2014). These results 
have strengthened the hypothesis that an unknown pathogen (virus or bacterium) in the gut 
could be responsible for PD pathology initiation (Braak et al., 2003b). This theory, known as 
the Braak’s hypothesis, suggests that PD may originate from the gastro-intestinal tract, where 
an as-of-yet unidentified triggering event initiates a pathological cascade, involving α-
synuclein, which slowly migrates to the brain, starting from the olfactory bulb and the gut 
(Braak et al., 2003a, Hawkes et al., 2007). Soon after Braak’s hypothesis, two groups 
independently reported that PD patients, transplanted with embryonic mesencephalic neurons 
into the striatum, developed LBs 11-16 years after grafting, suggesting that the disease could 
have propagated from the host to graft cells because these cells were relatively young 
(Kordower et al., 2008, Li et al., 2008). Following these findings, the terms “prion” and “prion-
like” started to be widely used to define the potential pathogenic mechanism of the α-synuclein 
protein. In vitro studies demonstrated that introduction of α-synuclein preformed fibrils (PFFs) 
could act as a seed and recruit endogenous α-synuclein into pathologic, insoluble inclusions 
that resembled LBs (Luk et al., 2009, Hansen et al., 2011, Volpicelli-Daley et al., 2011). The 
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formation of these α-synuclein aggregates in recipient cells led to synaptic dysfunction, which 
culminated in neuronal loss. Once demonstrated that α-synuclein could be transmitted between 
cells, the potential pathogenic effect of α-synuclein transmission was explored in vivo. Both 
synthetic and murine disease-associated forms of α-synuclein greatly accelerated the formation 
and propagation of pathological inclusions and triggered an early onset of characteristic motor 
clinical signs compared with that of uninoculated mice (Luk et al., 2012a, Luk et al., 2012b). 
More recently, Recasens et al. (2014) validated the ability of α-synuclein species, derived from 
LBs extracts, inoculated in both mice and monkeys, to initiate a PD-like pathological process. 
This included intracellular and presynaptic accumulations of pathological α-synuclein in 
different brain regions.  
Mitochondria have been repeatedly implicated in the proposed propagation of α-synuclein. For 
example, Baumuratov et al. (2016) discovered structural mitochondrial abnormalities in enteric 
neurons of post-mortem tissues from PD patients. Further, Braidy et al. (2014) showed that α-
synuclein could accumulate in primary human foetal enteric neurons from the gastrointestinal 
tract and spread between foetal enteric neurons. In addition, accumulation of α-synuclein led 
to impaired mitochondrial complex I activity, reduced mitochondrial function which 
culminated in cell death. Another study demonstrated that rotenone exposure in mice, triggered 
α-synuclein release from enteric neurons (Pan-Montojo et al., 2012). α-synuclein was then 
taken up by presynaptic sympathetic neurites, which retrogradely transported the protein to the 
soma, where it accumulated (Pan-Montojo et al., 2012). Additionally, rat ventral midbrain 
neurons exposed to exogenous PFFs displayed impaired mitochondria and selective DA 
neurodegeneration; combined exposure to PFFs and rotenone resulted in an additive toxicity 




Impaired lysosomal degradation has also been shown to promote α-synuclein release from 
cells, in multiple models (Lee et al., 2013, Braidy et al., 2014, Jiang et al., 2017). For example, 
Lee et al. (2013) showed that autophagy inhibition, both pharmacologically and genetically, 
caused increased exocytosis of α-synuclein, which promoted α-synuclein deposition and cell 
death in neighbouring neurons. Interestingly, a study showed that cells with endo-lysosomal 
membrane permeabilization were more vulnerable to the seeding effects of α-synuclein 
aggregates (Jiang et al., 2017). This study suggests that lysosomal impairment might play an 
important role in PD progression as it accelerates the seeding progression of α-synuclein. 
Collectively, these studies and others, demonstrate that α-synuclein spreads from one neuron 
to another and that mitochondria and autophagy are central to the resultant pathology. 
 
1.4.3 Autophagy dysfunction 
Oxidative stress, mitochondrial dysfunction and α-synuclein aggregation represent some of the 
main pathological features that contribute to PD pathology, however all these factors are linked 
to proteostasis mechanisms such as the ubiquitin-proteasome system (UPS) and selective 
autophagy. Autophagy, is required in normal and stress conditions and is a highly conserved 
metabolic process, responsible for degrading most long-lived proteins, unwanted aggregate-
prone proteins and dysfunctional organelles from accumulating to toxic levels (Button et al., 
2015). Cytosolic proteins are degraded through three distinct autophagy mechanisms, 
according to the different pathways by which the cargo is delivered to the lysosomes or 
vacuoles: chaperone-mediated autophagy (CMA), microautophagy, and macroautophagy.  
The first line of defence in degrading soluble misfolded proteins is the UPS, a selective 
proteolytic system in which recognised substrates are tagged with ubiquitin for processive 
degradation by the proteasome (Nandi et al., 2006). The UPS is responsible for degrading 80-
90% of short-lived, abnormal, denatured, or damaged proteins (Rock et al., 1994). Specific 
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misfolded proteins can be degraded by the CMA, a process based on the recognition of a 
specific KFERQ motif, found in roughly 30% of cytoplasmic proteins, including α-synuclein 
(Dice, 1990, Vogiatzi et al., 2008). This amino acid sequence can be recognised by the cytosolic 
chaperone heat shock cognate protein of 70 kDa (hsc70), which targets the substrates and 
translocates to the lysosomal membrane where it interacts with the lysosome-associated 
membrane protein type 2a (LAMP2A) (Chiang et al., 1989, Cuervo and Dice, 1996). 
Substrates are then translocated to the lumen and degraded into amino acids by lysosomal 
hydrolases. Some misfolded proteins that escape the surveillance of the UPS and CMA or tend 
to form aggregates are directed to macroautophagy. The focus of this chapter will be on 
macroautophagy (here referred to as “autophagy”), which is believed to be crucial for the 
timely removal of aggregated forms of pathogenic proteins in neurodegenerative diseases and 
is the most extensively studied (Mizushima et al., 2011). During autophagy the cytoplasmic 
cargo (comprised of many cellular constituents) is engulfed by double membranous structures 
named autophagosomes and delivered to lysosomes for degradation; complete autophagic 





Autophagy begins with the formation of an isolation membrane (also called a phagophore) and 
it involves the UNC-51–like kinase (ULK) complex, (including ULK1, Atg13, FIP200, and 
Atg101) and the class III phosphatidylinositol (PtdIns) 3-kinase or PI3K-III complex 
(including Beclin 1, Atg14L, Vps15, Vps34, and Ambra1). The presence of an activatory 
stimulus, such as deprivation of nutrients or growth factors or the presence of a dysfunctional 
Figure 1.7 Overview of the autophagy pathway. Schematic representation depicting the process of 
macroautophagy (referred to as autophagy). When autophagy is induced, cytoplasmic materials are 
sequestered by a double-membraned structure, called autophagosome. These autophagosomes fuse 
with late endosomes (termed amphisomes) or lysosomes to become autolysosomes, in which the 
sequestered cargos are degraded and recycled for the maintenance of cellular homeostasis. Autophagy 
can be divided into five steps: formation of the isolation membrane (nucleation), elongation of the 
isolation membrane (elongation), completion and transport of the autophagosome (maturation), 
docking and fusion between autophagosome and lysosome (fusion), lysosomal degradation of the 




organelle, is able to activate the AMP-activated protein kinase (AMPK) pathway and/or inhibit 
the mammalian target of rapamycin (mTOR). As a consequence, the ULK1 complex is 
activated by phosphorylation and then translocates to the ER. Activated ULK1 phosphorylates 
Beclin-1 on Ser14, promoting the activity of the ATG14L-containing VPS34 complexes 
(Russell et al., 2013). VPS34 then produces phosphatidylinositol 3,4,5-triphosphate (PI3P) 
(Matsunaga et al., 2010) at the site of phagophore nucleation and recruits proteins involved in 
the phagophore elongation. Multiple autophagy (ATG) proteins are required, for the elongation 
process that involves two steps. The first stage represents the development of the ATG-5-
ATG12-ATG16L complex to allow vesicle membrane formation, whilst the second involves 
the cleavage of LC3 by ATG4B to form LC3-I. This is followed by conjugation to 
phosphatidylethanolamine (PE), mediated by ATG7 and ATG3, to form LC3-II. The latter 
protein is necessary for the recruitment of membrane components allowing vesicle elongation 
as well as the recognition of autophagic cargoes and fusion of autophagosomes with lysosomes. 
As the phagophore expands and fuses, the ATG5-ATG12-ATG16L complex dissociates from 
the outer membrane while LC3-II remains integrated with the completed autophagosome. LC3-
II acts as docking site of adaptor proteins and cargo receptors. The substrates that need to be 
degraded are recognised and bound by receptor proteins, such as p62, allowing them to be 
engulfed upon vesicle fusion. The resulting autophagosomes are subsequently transported 
along microtubules to the microtubule organizing centre (MTOC), where the lysosomes are 
clustered. Here they will fuse with lysosomes to form autolysosomes. Due to the acidic 
environment within lysosomes and the presence of multiple proteases, the autophagy substrates 
will be degraded, and the resultant products are recycled by the cell (Klionsky and Schulman, 
2014).  
Cellular mechanisms related to autophagy initiation and autophagosome maturation have been 
relatively well characterised, whilst the process involving fusion of autophagosomes with 
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lysosomes is still largely unknown. The current knowledge of the proteins implicated in the 
fusion of autophagosome to lysosomes is based on the general understanding of intracellular 
membrane trafficking, particularly three sets of protein families: Ras-related protein in brain 
(Rab) GTPases, membrane-tethering complexes and soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors (SNAREs) (Nakamura and Yoshimori, 2017) More in depth 
description of the roles of Rabs, SNAREs and tethering factors can be found in section 7.1.3. 
Interestingly, Phosphoinositides (PIs) are involved in intracellular membrane trafficking. 
Recent studies have uncovered roles for PIs during the late stage of autophagy, including the 
transport of autophagosomes and the autophagosome-lysosome fusion (Nakamura and 
Yoshimori, 2017). 
The transcription factor EB (TFEB) is also known to be involved in regulating the expression 
of lysosomal genes. Once TFEB translocates to the nucleus, it upregulates autophagy and 
lysosomal genes enabling the activation of its target genes, autophagosome formation and 
autophagosome-lysosome fusion (Settembre et al., 2011, Martini-Stoica et al., 2016). Studies 
have also demonstrated that overexpression of TFEB improved degradation of complex 
molecules, such as the pathogenic protein huntingtin and glycosaminoglycans (Sardiello et al., 
2009, Tsunemi et al., 2012). 
For cells to be healthy and viable, a homeostatic balance between synthesis and degradation of 
cellular organelles is necessary, a process highly dependent upon an intact autophagy pathway. 
Although it has been shown that the number of autophagosomes present in neurons is low 
compared to other cell types, defective lysosomal clearance can still lead to accumulation of 
autophagosomes with toxic consequences (Boland et al., 2008). It has been shown that mice 
that have defective autophagy cannot survive and that knockouts of multiple ATG genes cause 
neurodegeneration along with aggregate formation (Kuma et al., 2004, Hara et al., 2006, 
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Komatsu et al., 2006). Deficiency in ATG7 or in the PD-associated protein ATP13A2 induces 
PD neurodegeneration (Komatsu et al., 2006, Ahmed et al., 2012, Dehay et al., 2012b, 
Friedman et al., 2012, Usenovic et al., 2012, Bento et al., 2016, Sato et al., 2018). Interestingly, 
studies indicate that constitutive neuronal autophagy may represent a crucial regulatory 
pathway for axonal homeostasis. The loss of basal autophagy either by deletion of ATG genes 
or lysosomal protease inhibition in neurons, led to disruption of axonal transport of specific 
cargoes, causing them to accumulate and cause axonal swelling (Hara et al., 2006, Komatsu et 
al., 2006, Yue, 2007, Lee et al., 2011). Autophagy affects many pathways and increasing 
evidence have linked reduced clearance of proteins to neurodegeneration. In regard to α-
synuclein, initial studies have proposed that the UPS represented the main proteolytic system 
responsible for α-synuclein degradation (Bennett et al., 1999), however more recent studies 
suggest that the lysosome may be the main route for its clearance (Webb et al., 2003, Cuervo 
et al., 2004, Lee et al., 2004). 
Several are the studies that have described α-synuclein involvement in autophagy dysfunction. 
Initial studies reported apoptosis and autophagic degeneration in the SN of PD patients 
(Anglade et al., 1997). Additionally, Yu et al (2009) revealed accumulated levels of LC3-II 
and Beclin proteins in brains of patients with Dementia with LBs and in the SN of mice 
overexpressing A53T mutant α-synuclein, compared to controls. Further, aged mutant mice 
displayed higher autophagy biomarker levels compared to younger animals, indicative of a less 
efficient autophagy pathway. RNA interference against Beclin or ATG5, or chemical inhibition 
by 3MA were used to block autophagy. This blockade promoted α-synuclein aggregation in 
vitro, confirming the interplay between autophagy and α-synuclein clearance (Yu et al., 2009). 
PC12 cells expressing A53T mutant human α-synuclein displayed an increased amount of 
autophagic–vesicular structures along with a disruption of lysosomal hydrolysis and 
proteasomal function (Stefanis et al., 2001). Tanik et al. (2013) showed that following 
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internalisation of PFFs in α-synuclein-expressing HEK293 cells or cultured primary neurons, 
α-synuclein inclusions were resistant to degradation despite their interaction with autophagy-
lysosomal pathway and UPS components. Interestingly, despite the reduction of α- synuclein 
expression, α-synuclein aggregates persisted, suggesting that once seeding occurs, these 
inclusions are refractory to clearance from cells. Following these results, the same group used 
ultrastructural analyses and live imaging to demonstrate that α-synuclein accumulations 
impaired axonal transport of signalling and degradative organelles by affecting the transport of 
Rab7 and TrkB receptor–containing endosomes (receptors known to undergo predominantly 
retrograde axonal transport in endosomes). They also reported abnormalities in autophagosome 
acidification, and autophagosome/lysosome fusion as evidenced by a reduced colocalization of 
LC3 with LAMP1 (Volpicelli-Daley et al., 2014). Overall, evidence from in vivo and in vitro 
models associate α-synuclein with autophagy impairment. Indeed, increase of α-synuclein 
aggregation and/or impairment in autophagy pathways promote higher α-synuclein levels 
and/or the inhibition of their degradation, creating a loop cycle of neurotoxicity. 
Another mechanism implicated in α-synuclein turnover is the CMA, a form of autophagy that 
is often up-regulated in response to cellular stress (Cuervo and Dice, 2000a, Cuervo and Dice, 
2000b). Cuervo et al. (2004) showed that unlike WT α-synuclein, which could be degraded by 
the CMA, mutant A30P and A53T could bind to LAMP-2A (with a high affinity) and act as 
uptake blockers, inhibiting their own degradation and preventing the binding of other 
substrates. Xilouri et al. (2009) showed that A53T mutant α-synuclein could cause CMA 
impairment, as observed in adenoviral transfected PC12 and SH-SY5Y cells and that this 
dysfunction promoted global lysosomal dysfunction. Interestingly, Martinez-Vicente et al. 
(2008) assessed the effects of α-synuclein PTMs on the CMA pathway. Their results showed 
that oxidation and nitration impaired α-synuclein degradation without affecting the clearance 
of other substrates. Phosphorylation and exposure to DA, on the other hand, completely 
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prevented protein removal through CMA pathway. In addition, post mortem brain samples 
from PD patients exhibited a decreased expression of both hsc70 and LAMP-2A in the SNpc 
and amygdala as compared to healthy controls (Alvarez-Erviti et al., 2010). Further, loss of 
LAMP-2A was correlated with an accumulation of α-synuclein and consequential nigral cell 
death (Xilouri et al., 2016). Most of these studies suggest that α-synuclein mutants or PTMs 
can impede substrate delivery into lysosomes by blocking LAMP-2A, thereby disrupting 
CMA. Recently, however, Mazzulli et al. (2016) reported that α-synuclein accumulation could 
reduce the enzymatic activity of multiple lysosomal hydrolases, causing lysosomal dysfunction 
that was not dependent on CMA. α-synuclein accumulation altered the ER-Golgi localisation 
of Rab1a, a key mediator of vesicular transport. Rab1a overexpression restored protein 
trafficking and lysosomal function, along with Golgi structure, and reduced pathological α-
synuclein in patient neurons (Mazzulli et al., 2016).  
Evidence supporting a role for dysfunctional autophagy as a causative factor in PD also derive 
from studies on mitophagy. Autosomal recessive forms of juvenile PD have been associated 
with mutations in genes encoding PINK1 (Valente et al., 2004) and the E3 ubiquitin ligase 
Parkin (Kitada et al., 1998). Studies have demonstrated that PINK1 and Parkin operate in the 
same pathway to promote autophagic clearance of mitochondria or mitophagy. PINK1 is 
stabilised on the outer membrane of impaired mitochondria, where it recruits and activates 
Parkin and ultimately leads to the sequestration of dysfunctional mitochondria into 
autophagosomes (Narendra et al., 2008, Matsuda et al., 2010). Since PINK1 and Parkin were 
shown to be implicated in coordinating the selective clearance of damaged mitochondria via 
the autophagy/lysosome pathway, this also provided a link between the two major cellular 
dysfunctions implicated in PD pathogenesis: mitochondrial and cellular degradation 
impairments (Springer and Kahle, 2011). Importantly, PD-associated mutations in either genes 
inhibited mitophagy at different steps and through distinct mechanisms, highlighting the 
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etiological importance of this pathway (Geisler et al., 2010a, Geisler et al., 2010b, Lee et al., 
2010, Fiesel et al., 2015). 
Mitochondrial dysfunction induced by LRRK2 also provides a strong link to the impaired 
autophagy. Several groups have demonstrated, both in vitro and in vivo, that LRRK2 mutation 
can cause an accumulation in autophagic and lysosomal structures (MacLeod et al., 2006, 
Plowey et al., 2008, Gómez-Suaga et al., 2012). PD patient-derived induced pluripotent stem 
cells (iPSCs) expressing LRRK2-G2019S also exhibited a block in autophagy flux (Sánchez-
Danés et al., 2012). Interestingly, by inhibiting Drp1, using the Drp1 peptide inhibitor P110, 
autophagy function was improved and the detrimental changes in cell morphology caused by 
the G2019S mutation were reduced in both PD patient fibroblasts and DAergic neurons derived 
from iPSCs (Su and Qi, 2013).  
Further insights into lysosomal dysfunction in PD come from studies investigating the 
lysosomal enzyme β‐glucocerebrosidase (GBA). The prevalence of GBA mutations varies in 
different PD populations but these mutations have been reported in more than 30% of PD 
patients with Ashkenazi Jewish ancestry (Sidransky and Lopez, 2012). This gene encodes 
glucocerebrosidase (GCase), a lysosomal hydrolase that converts the sphingolipid 
glucosylceramide to glucose and ceramide in the lysosomal membrane.  Homozygous GBA 
mutations cause Gaucher disease (Tsuji et al., 1987), a lysosomal storage disorder in which the 
substrate glucosylceramide accumulates, impairing the autophagy pathway.  Further, inhibition 
of GBA was shown to enhance intercellular transmission of α-synuclein species, therefore 
contributing to the spread of PD pathology (Bae et al., 2014). In brain regions of PD patients 
with increased α-synuclein expression, GBA activity was significantly reduced (Mazzulli et 
al., 2011, Gegg et al., 2012, Murphy et al., 2014). This further impaired α-synuclein clearance 
mediated by autophagy.  
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Perhaps the most direct evidence linking lysosomal dysfunction to PD is the demonstration that 
loss-of-function mutations in the ATP13A2 gene, cause a juvenile and early-onset form of 
parkinsonism (Ramirez et al., 2006). Despite its multifunctionality, ATP13A2 has been linked 
to endosome-lysosome dynamics (Dehay et al., 2012b, Usenovic et al., 2012), and mutations 
or genetic depletion of this gene caused decreased lysosomal acidification, impaired proteolytic 
processing of lysosomal proteases, reduced degradation of lysosomal substrates (e.g., SNCA) 
and diminished clearance and subsequent accumulation of autophagosomes. These alterations 
could lead to cell death and might contribute to the formation of LBs (Dehay et al., 2012a). 
Recent studies have shown that ATP13A2 depletion negatively regulates another PD-
associated gene, synaptotagmin 11 (SYT11) at both transcriptional and post-translational levels. 
Decreased SYT11 causes lysosomal dysfunction and impairs degradation of autophagosomes.  
Overexpression of SYT11 in ATP13A2 knockdown cells was able to rescue the autophagy 
blockade observed in these cells, indicating that ATP13A2-induced blockage of autophagy 
(under ATP13A2-depleting conditions) is triggered by decreased expression of SYT11. These 
results demonstrated that both ATP13A2 and SYT11 are crucial for the survival of cells under 
pathological conditions (Bento et al., 2016).  
The effects of parkinsonian toxins including MPTP, rotenone, PQ and 6-OHDA have also been 
assessed in relation to the autophagy pathway, where evidence suggests these neurotoxic agents 
promote the accumulation of autophagic vacuoles, indicative of autophagy induction (Chen et 
al., 2007c, Gonzalez-Polo et al., 2007, Zhu et al., 2007, Dagda et al., 2008, Yu et al., 2009), as 
a likely response to mitochondrial impairment and generation of oxidative stress. On the 
contrary, Burton et al. (2012) showed that low concentrations of rotenone not only induced the 
accumulation of autophagic vacuoles, as evidenced by the increase in LC3-II levels, but also 
caused both p62 and α-synuclein levels to rise and this is indicative of an impairment in 
lysosomal degradation. These results were assessed and confirmed in a rotenone-treated rat 
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model (Wu et al., 2015). Recently, autophagic flux was determined by western blot (WB) 
analysis in PC12 cells exposed to PQ, which displayed increase levels of both LC3-II and p62 
proteins compared to control cells (Zhou et al., 2017).  
The role of dysfunctional autophagy in neurodegenerative disorders has been studied in depth 
in the last decade, however, little is known about the effects of Mn on autophagy and how these 
effects can promote PD pathogenesis. SH-SY5Y cells, expressing mRFP-GFP tandem 
fluorescence-tagged LC3, displayed an induction of autophagy in response to 6 h exposure of 
500 µM MnCl2. This was evidenced by an increased amount of red LC3 puncta when 
compared to untreated cells (Tai et al., 2016). Furthermore, C6 astrocytoma cells, treated with 
750 µM MnCl2 for up to 24 h, exhibited increased LC3-II and Beclin 1 levels and autophagic 
vesicles labelled with monodansylcadaverine (marker for autophagic vacuoles) or LC3, 
compared to control cells (Gorojod et al., 2015). In a time course study carried out by Ma et al. 
(2017), in SH-SY5Y cells, it was discovered that autophagy was activated in cells exposed to 
400 µM MnCl2 for 0–12 h; whilst the autophagy-lysosome pathway was impaired following 
24 h treatment. Zhou et al. (2018) conducted a study to assess the effect of Mn exposure on 
autophagy, and whether and how modulation of the autophagy pathway could affect Mn 
toxicity in PC12 cells. Their results revealed that exposure to 300 μM MnCl2 for 12 h caused 
an increased expression of autophagic marker LC3-II protein, as well as accumulation of p62, 
indicative of autophagy dysfunction. In addition to this, other studies have reported autophagy 
impairment caused by Mn (Wang et al., 2017, Chen et al., 2018a). Interestingly, pre-incubation 
of cells with chloroquine (CQ) inhibited autophagy flux and exacerbated Mn-induced 
cytotoxicity, whilst rapamycin treatment promoted autophagy activation and significantly 
reduced cell death caused by Mn treatment (Zhou et al., 2018). The effects of Mn on autophagy 





Chronic neuroinflammation is another hallmark of PD pathophysiology. Although 
inflammation may not typically represent an initiating factor in neurodegenerative disorders, 
emerging evidence implicates microglia and astrocytes in the disease progression.  
Microglia are the principal innate immune cells in the brain involved in inflammatory 
responses and have fundamental roles in CNS homeostasis. The first evidence implicating 
microglia in PD pathology derives from post-mortem analysis of PD brain samples that 
exhibited human leukocyte antigen D-related- (HLA-DR) positive reactive microglia (McGeer 
et al., 1988). In addition, biochemical analysis revealed high levels of pro-inflammatory 
mediators including tumour necrosis factor-α (TNF-α), interleukins (IL-2,  IL-4, IL-6, IL-1), 
and interferon γ (IFNγ), in the serum of PD patients (Mogi et al., 1996, Brodacki et al., 
2008). Post-mortem studies also uncovered upregulated levels of cytokines in the CSF and 
nigrostriatal regions of PD patients compared to age-matched healthy controls (Mogi et al., 
1994, Blum-Degen et al., 1995, Mogi et al., 1995, Mount et al., 2007). Activation of microglia 
can be triggered by bacterial and viral molecules, disease-related proteins (amyloid β and α-
synuclein) and soluble toxic mediators released by dying neurons (von Bernhardi et al., 2015). 
Despite the appearance of microglia being evenly distributed within the nervous parenchyma, 
more in-depth studies have revealed that neither the morphology nor the distribution are equal 
in all brain locations, providing evidence that microglial cells are sensitive to the surrounding 
microenvironment (Lawson et al., 1990). According to their shape, microglial cells can be 
classified into three broadly distinct subtypes: compact, longitudinally branched and radially 
branched (Lawson et al., 1990). In addition, these morphologies are closely related to their 
functional state (Davis et al., 1994). Under physiological conditions, microglia appear ramified. 
During neuroinflammation or after injury, ramified microglia can transform into an “activated 
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state”, characterised by swollen ramified cells with a larger cell body and shorter, thick 
processes. Alternatively, microglia can adopt a “reactive state”, characterised by small, 
spherical cells, that can also exhibit rod-shape or amoeboid-like morphologies (Davis et al., 
1994). Additionally, microglia can be classified according to two distinct phenotypes: the ‘pro-
inflammatory’ and the ‘anti-inflammatory’ phenotype. Depending on the activated phenotype, 
microglia can produce either cytotoxic or neuroprotective effects. The classical ‘pro-
inflammatory’ microglial phenotype is characterised by the production of pro-inflammatory 
cytokines, such as TNF-α, IL-1β, IL-6, IL-12, and other cytotoxic molecules including 
superoxide, nitric oxide (NO) and ROS. They are involved in the amplification of pro-
inflammatory responses during injuries and infections. Whereas ‘anti-inflammatory or ‘pro-
resolution’ microglia can produce neuroprotective effects through a variety of cytokines with 
anti-inflammatory properties, such as IL-4, IL-13, IL-10, and TGF-β (Tang and Le, 2016).  
Besides microglia, astrocytes have also been implicated in the neuropathology of PD 
(Venkateshappa et al., 2012). Under physiological conditions, astrocytes are implicated in the 
development and plasticity of the CNS, providing energy to neurons and maintaining brain 
homeostasis (Rothstein et al., 1996, Anderson and Swanson, 2000, Olsen et al., 2006, Stobart 
and Anderson, 2013). Studies performed in post-mortem brain tissue of PD patients, displayed 
an increase in astroglial cells (Damier et al., 1993), along with an incremented number of 
dystrophic astrocytes compared to healthy neurons (Braak et al., 2007). Furthermore, there is 
evidence that suggests an upregulation of calcium-binding protein S100b, highly expressed in 
astrocytes (Donato, 2001), in the SNpc of post-mortem PD patients (Bianchi et al., 2007). By 
exposing microglia to increasing concentrations of S100b, Bianchi et al. (2007) showed an 
upregulation of the inducible nitric oxide synthase (iNOS) which, in turn, stimulated the 
expression of the pro-inflammatory enzyme cyclo-oxygenase-2 (COX-2) in microglia. These 
results suggest that S100b could act as a cytokine involved in the inflammatory response in the 
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course of brain insults. It has been shown that astrocytes response to in vitro stimulation is 
relatively slower than microglial activation. Microglia are the primary responders to 
LPS treatment, and they respond to inflammation by releasing mediators such as TNF-α and 
IL-1β that activate astrocytes (Saijo et al., 2009).  
Along with activated microglia and astrocytes, the infiltration of the adaptive immune system 
has also been shown to promote PD pathophysiology. The BBB is a key mediator between the 
peripheral circulation and the CNS. It regulates ion balance, facilitates nutrient transport and 
restricts the passage of pathogens and harmful substances  (Desai et al., 2007). A deterioration 
and dysregulation of the BBB has been proposed to represent a relevant factor contributing to 
PD progression (Kortekaas et al., 2005, Pisani et al., 2012). There is evidence of severe 
morphological changes of endothelial cells in the SNpc of PD brains (Faucheux et al., 1999, 
Kortekaas et al., 2005, Guan et al., 2013) and a strong correlation between disruption of BBB 
and loss of DAergic neurons in mice injected with vascular endothelial growth factor (VEGF) 
(a potent inducer of BBB damages) (Rite et al., 2007, Yasuda et al., 2007). Interestingly, VEGF 
expression levels were found dramatically increased in both PD patients and the MPTP-
induced mice (Yasuda et al., 2007). Further studies revealed the presence of both CD4+ and 
CD8+ T lymphocytes in close proximity of blood vessels and degenerating neurons in post-
mortem PD brains (Brochard et al., 2009).  
Overall, results from both animal and clinical studies have supported the evidence of an 
involvement of inflammation in the progression of PD, however a better understanding of the 
relationship between the CNS and immune system and the molecular mechanisms that underlie 





1.5 Gene-environment interactions in Parkinson’s disease 
Within the last few decades, the genetics associated with PD has dominated the research field 
although, currently, only a small fraction of PD cases can be directly linked to monogenic 
mutations. The remaining cases are attributed to other risk associated genes and environmental 
exposures making PD a multifactorial disorder with a complex aetiology. Given the fact that 
independently genetic and environmental factors cannot account for all sporadic PD cases, the 
view of gene-environment factors (combination of environmental exposures and individual 
genetic susceptibility) has increasingly been appreciated and is now thought to play a central 
role in the development and progression of PD.  
A major topic of debate is the role of heterozygous Parkin and PINK1 mutations that contribute 
to the development of parkinsonism in several patients (Klein et al., 2007), by increasing the 
susceptibility of an individual to environmental toxicants. Equally interesting is a study that 
implicated common single Mendelian mutation of LRKK2 in sporadic PD (Gilks et al., 2005). 
In addition, a large-scale meta-analysis study discovered additional familial PD genes among 
the risk loci identified for idiopathic PD (Nalls et al., 2014). Whilst evidence from multiple 
epidemiological studies have identified specific gene-environment interactions relevant to PD 
(Cannon and Greenamyre, 2013), a significant amount of data derives from genetically 
modified experimental models that assessed the sensitivity of neurons to toxicants.  
There is evidence implicating rotenone in increasing the likelihood of PD onset/progression 
when associated with several PD related genes. Casarejos et al. (2006) assessed the effects of 
rotenone on both midbrain neuronal cultures from Parkin-knockout and WT mice. Results 
showed an increased sensitivity to the neurotoxin in Parkin-knockout culture, with increased 
apoptosis and cell loss compared to the WT cultures. As Parkin is known for its role in the 
mitophagy pathway, it is possible that the effects of Parkin defective cells exposed to rotenone 
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may be related to the reduced clearance of damaged mitochondria. In addition, increased 
neuronal vulnerability to rotenone and VPS35 mutations have also been described (Tsika et al., 
2014, Liu et al., 2017), indicating that PD susceptibility, due to combinatory effects of rotenone 
and genetic modifications, is not limited to a single gene. Furthermore, rotenone was shown 
to induce α-synuclein aggregation in PC12 cells (Yuan et al., 2015) and enhance α-synuclein 
phosphorylation at Ser129 (Wang et al., 2016a, Arawaka et al., 2017). 
 
The association of PQ with multiple PD related genes has further implicated pesticides in 
exacerbating the risk of developing PD. Mitochondrial membrane potential, morphology 
and ATP synthesis were assessed in PINK1-silenced SH-SY5Y cells treated with PQ. 
Results revealed that PQ not only caused a reduction in cell viability, but also reduced ATP 
levels and promoted oxidative stress (Gegg et al., 2009). In addition, 2 mM PQ caused an 
increased sensitivity to oxidative stress in adult flies that carried Coiled-Coil-Helix-Coiled-
Coil-Helix Domain Containing 2 (CHCHD2) mutations (Meng et al., 2017). Manning-Bog et 
al. (2002a) reported interactions between α-synuclein and PQ in vivo. Following PQ serial 
injections, α-synuclein levels were significantly up-regulated in neurons exposed to the 
herbicide. Further, thioflavin S staining revealed that α-synuclein-PQ interactions promoted 
protein aggregation (Manning-Bog et al., 2002a). An additional study showed that oral 
exposure to PQ triggered the earlier expression of phosphorylated α-synuclein (pSer129) in 
the enteric nervous system of A53T mutant human α-synuclein transgenic mice (Naudet et 
al., 2017). The effects of PQ (with or without maneb) have also been investigated in A53T 
transgenic α-synuclein mice. Exposure to PQ and maneb reportedly resulted in widespread α-
synuclein pathology and mitochondrial degeneration, not present in littermate controls (Norris 




Throughout the literature there is increasing evidence on interactions between Mn exposure 
and PD-related genes. Mn and α-synuclein interactions were assessed in biophysical studies 
using Nuclear Magnetic Resonance. Results showed that although Mn can bind to α-synuclein 
via three residues in the C-terminal domain: Asp-121, Asn-122 and Glu-123, Mn displayed 
poor affinity for α-synuclein (1 mM range) compared to other metals (Binolfi et al., 2006). As 
for the deleterious effects on cell survival, Mn treatment induced α-synuclein overexpression 
in cultured cells (Cai et al., 2010, Li et al., 2010) and accelerated its fibrillization rate in vitro 
(Uversky et al., 2001). SK-N-MC neuroblastoma cells stably expressing DAT, upon 
transfection with human α-synuclein, showed increased sensitivity to Mn treatment (Pifl et al., 
2004). As Mn and α-synuclein impair mitochondrial function and other cellular processes, their 
combined effect may have a synergistic effect on cell viability. In addition, Dučić et al. (2015) 
further evaluated this interplay in Mn-treated rat primary midbrain neurons overexpressing α-
synuclein, using X-ray fluorescence imaging. Their results indicated that α-synuclein 
overexpression enhanced intracellular Mn levels, leaving other metals levels unaltered. This 
study proposes an indirect mechanism by which α-synuclein could regulate Mn accumulation. 
A recent study examined α-synuclein immunoreactivity in the frontal cortex of Mn-exposed 
Cynomolgus macaques. Their results clearly showed increased α-synuclein-positive cells in 
the gray matter of these non-human primates and some of these neurons also exhibited loss of 
Nissl staining with spherical α-synuclein-positive aggregates (Verina et al., 2013). Another 
study assessed the effects of Mn on transgenic C57BL/6J mice expressing human WT α-
synuclein or A53T/A30P doubly mutated human α-synuclein mice (under TH promoter) and 
non-transgenic littermates. Mice were exposed to MnCl2-enriched (1%) or control food, 
starting at the age of four months. Their results revealed a decreased DA turnover in the 
striatum of transgenic mice expressing human WT α-synuclein, but not in mice expressing 
A53T and A30P mutations, nor in non-transgenic littermates (Peneder et al., 2011).  
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Mn has been reported by several groups to enhance α-synuclein aggregation and induce 
neurotoxicity when combined with α-synuclein, however some laboratories have also showed 
that WT α-synuclein can be protective against Mn-induced neurotoxicity in C. 
elegans (Bornhorst et al., 2014) and rat DAergic neuronal cells (Harischandra et al., 2015). The 
latter study demonstrated that α-synuclein could protect cells only in the early stages of Mn 
exposure, suggesting that, at later time points, Mn accumulation would eventually induce 
protein aggregation and neurotoxicity (Harischandra et al., 2015). 
 
Most of the current evidence on ATP13A2 function derives from studies which focused on its 
interaction with α-synuclein (Lopes da Fonseca and Outeiro, 2014). Given its physiological 
role in lysosomal function it is not surprising that ATP13A2 mutations can induce lysosomal 
dysfunction and accumulation of aggregated α-synuclein (Gitler et al., 2009, Usenovic and 
Krainc, 2012, Lopes da Fonseca et al., 2016). On the contrary, ATP13A2 was shown to be 
protective in Mn mediated α-synuclein toxicity, in both yeast and SH-SY5Y cells (Gitler et al., 
2009). However, mutations in the ATP13A2 gene were unable to rescue Mn-induced toxicity 
in mammalian cell culture (Tan et al., 2011). Further, two ATP13A2 polymorphisms were 
shown to enhance the neurotoxic effects of Mn in humans (Rentschler et al., 2012).  
To further investigate the effects of Mn and PD-linked genes, Sriram et al. (2010) assessed the 
association of PARK genes and mitochondrial function in causing DAergic abnormality. 
Results showed that Mn accumulation caused mitochondrial impairment and loss of TH 
protein. Interestingly, they discovered an altered expression of Parkin and DJ-1 proteins in 
DAergic neurons (Sriram et al., 2010). In addition, Parkin has been reported to alter Mn 
transport (Roth et al., 2010). DMT1 represents one of the transporters involved in Mn uptake 
and is comprised of four isoforms (Garrick et al., 2006). There is supporting evidence that 
implicate PINK1 and Parkin in the ubiquitination and subsequent proteasomal degradation of 
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one of these isoforms (Roth et al., 2010). Therefore, PINK1 and Parkin mutations could 
facilitate Mn transport, leading to its accumulation in the basal ganglia and facilitating its 
toxicity. Further association between Mn and DJ-1 was assessed by Lee et al. (2012) who 
demonstrated that Mn could reduce both protein and RNA levels of DJ-1 and impair 
mitochondrial function. The effects produced by Mn resemble those induced by mutant forms 
of DJ-1. The fact that both factors can individually promote oxidative stress, increase the 
opening of the mitochondrial permeability transition pore, disrupt membrane potential and 
impair ATP production, suggest possible exacerbating effects of both Mn and DJ-1 on 
mitochondrial function. Moreover, Mn can also affect both the kinase and ATP activity of 
LRRK2 G2019S mutant (Lovitt et al., 2010). While Mn suppresses the kinase activity of WT 
LRRK2, the G2019S mutation abolishes this inhibition and remains highly active. Covy and 
Giasson (2011) suggested that LRRK2 could act as a sensor for cytoplasmic Mn levels, whilst 
the G2019S mutation could abrogate this function. This hypothesis will need in vivo validation, 
however it is possible that the relative low levels of LRRK2 in DAergic neurons (Galter et al., 
2006, West et al., 2014) render these cells more vulnerable to the effects associated with the 
G2019S mutation. Additionally, when LRRK2 was silenced using shRNA, Mn promoted 
oxidative stress and mitochondrial dysfunction (Roth and Eichhorn, 2013). A recent study 
assessed the effects of LRRK2 on Mn-triggered neuroinflammation and its possible 
mechanism. It was discovered that Mn exposure could not only promote damage in DAergic 
neurons and promote microglia inflammation in the SN of treated mice and in microglial 
cultures, but also that LRRK2 was highly upregulated. Interestingly, inhibition of 
LRRK2 reduced the expression of inflammatory cytokines and reduced autophagy impairment 
caused by Mn (Chen et al., 2018a).   
Overall, these findings bring additional support to the theory that neurotoxic agents such as 
rotenone, PQ or Mn, when combined with PD-related genes can be potential triggers for PD 
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pathology (Figure 1.8). Therefore, genetically complex diseases, such as PD, are likely the 
result of an intricate interplay between an individual's genetic make-up and environmental 
or lifestyle influences that an individual is exposed to. 
   
  
Figure 1.8 Gene-environment interactions in PD. The majority of PD cases are most likely 
influenced by both genetic predisposition and environmental exposures. The number and diversity 
of gene-environment interactions that could bear pathogenic relevance to PD is very large, but the 
current figure displays only those interactions discussed in the text.  
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1.6 Hypothesis and aims 
PD is defined as a multifactorial disease, which is not only ascribed to genetic factors 
(representing less than 10% of cases) and normal ageing, but also to a range of environmental 
influences. Mn represents one such example and although the precise mechanism of Mn-
inducing parkinsonism is not yet known, prior studies have implicated multiple PD-associated 
mechanisms, namely mitochondrial and autophagy dysfunction in models of Mn toxicity 
(Gavin et al., 1992, Gavin et al., 1999, Milatovic et al., 2007, Zhang et al., 2013). Mn has also 
been shown to interact with a-synuclein and promote its aggregation (Uversky et al., 2001, 
Bates et al., 2015). It is not fully understood however, how these pathways interact to produce 
a neurodegenerative phenotype. Increasing evidence show that there is a critical interplay 
between mitochondria and autophagy. A reduced autophagic activity and impaired 
mitochondrial function have been described in many neurodegenerative diseases, including 
PD, as many of the PARK genes implicated in familial PD, have functions related to autophagy 
and mitochondrial function. Mitochondrial dysfunction could inhibit the autophagy pathway, 
perhaps by reducing ATP availability and increasing ROS. Equally, impaired autophagy could 
cause mitochondrial dysfunction by reducing the clearance of damaged or dysfunctional 
organelles. The complex relationship between these two cellular pathways still remains to be 
determined, in particular the question regarding whether mitochondrial impairment precedes 
dysfunctional autophagy or vice versa following Mn exposure. The inhibition of the 
mitochondrial fission protein Drp1 represents a therapeutic strategy that has been demonstrated 
to be beneficial in multiple models of neurodegeneration (Cui et al., 2010, Qi et al., 2013, 
Rappold et al., 2014, Kandimalla et al., 2016, Manczak et al., 2016, Bido et al., 2017, Fan et 
al., 2019). Previous data from our group demonstrated that mice injected with recombinant 
adeno-associated virus (rAAV2) encoding the Drp1 dominant negative form (Drp1-K38A) 
displayed a significant reduction in neuronal loss, synaptic dysfunction and α-synuclein 
69 
 
aggregates in brain regions affected in PD (Rappold et al., 2014, Bido et al., 2017). I postulate 
that, in addition to its well-established role in mitochondrial fission, Drp1 has also a direct 
effect on autophagy. Blocking Drp1 will confer protection against α-synuclein and Mn-induced 
protein aggregation and neurotoxicity. To test this hypothesis, I propose to accomplish the 
following aims: 
1)  Investigate the effects of Mn exposure on autophagy flux, mitochondrial function and α-
synuclein aggregation in multiple cell lines. Evaluate the neuroprotective effects of Drp1 
inhibition on Mn-induced toxicity. 
2) Determine the effects of acute subcutaneous Mn exposure on autophagy flux and 
mitochondrial morphology in TH- and GAD67-positive neurons from multiple mouse strains. 
Explore the effect of manipulating Drp1 in TH-positive neurons to restore Mn-induced 
changes. 
3) Assess changes in the autophagy pathway and mitochondrial morphology in SLC39A14 








Materials and Methods 
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2.1 Cell culture 
HeLa cells, stably expressing mRFP-GFP-LC3 (kindly provided by Dr. Shouqing Luo, ptfLC3 
plasmid, Addgene #21074), were grown in Dulbecco's Modified Eagle's Medium (DMEM, 
Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 100 U/mL penicillin/ 100 
µg/mL streptomycin and 100 µg/mL G418 (Gibco) at 37 °C in 5% CO2. BE(2)-M17 (human 
neuroblastoma cells, kindly provided by Dr Oleg Anichtchik) were grown in DMEM, 
supplemented with 10% FBS and 100 U/mL penicillin/streptomycin at 37 °C in 5% CO2. 
Inducible rat dopaminergic neuronal N27 cells (original WT cells provided by Dr. Anumantha 
Kanthasamy) expressing human WT α-synuclein were generated by our laboratory using the 
ecdysone inducible system (provides a tight regulation of the transgene expression) as 
previously described (Cui et al., 2010). N27 cells were grown in Roswell Park Memorial 
Institute (RPMI, Gibco) 1640 medium, supplemented with 10% FBS, 500 µg/mL G418 and 
200 µg/mL Hygromycin (Gibco) at 37 °C in 5% CO2. The inducible overexpression of human 
WT α-synuclein was induced by the introduction of 20 µM PonA (an ecdysone homolog 
compound) for 24 or 48 h. All cell lines were grown to 70-80% confluency and then 
seeded/transfected in either 6, 24 or 96-well plates. The following day, cells were exposed to 
compounds at the indicated concentrations (Table 2.1). 
All cell lines used in the current study were available in the lab. The HeLa reporter cell line 
(stably expressing mRFP-GFP-LC3) was chosen because these cells were genetically 
engineered for direct monitoring of autophagy flux. mRFP-GFP-LC3 vesicle analysis allows 
us to monitor autophagosome synthesis and autophagosome-lysosome fusion by labelling 
autophagosomes (green and red) and autolysosomes (red), since the low lysosomal pH 
quenches the GFP signal. Human M17 neuroblastoma cells were used as a model for human 
DAergic neuron-like cells because they express dopamine synthesis enzymes (Baptista et al., 
2003). N27 cells were used because these are rat DAergic neuronal cells that our lab has 
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genetically modified to express inducible human WT α-synuclein (Fan et al., 2019). As 
missense mutations in SNCA are rare and responsible for a small fraction of PD cases, a WT 
human α-synuclein overexpressing cell line was chosen to study sporadic PD and its potential 
relationship with Mn toxicity. 
 
2.2 Cell viability assay 
Cells were seeded at various densities dependent on the cell line, in 96-well plates. M17 cells 
were plated at 1.2×104 cells/well (for 24 h treatments) and 1×104 cells/well (for 48 h treatments) 
respectively. N27 were plated at 1×104 cells/well (for 24 h treatments) and 8×103 cells/well 
(for 48 h treatments) respectively. HeLa cells were respectively plated at a density of 6×103 
cells/well (for 24 h treatments) or 4×103 cells/well (for 48 h treatments) in 96-well plates. Cells 
were treated with different concentrations of Mn for 24 or 48 h (M17 cells were seeded on 
poly-D-lysine precoated wells).  
Cell viability was assessed using the Calcein AM assay (Thermo Fisher) in accordance with 
the manufacture's protocol. Briefly, cells were washed three times with 0.1 M PBS, then 
incubated in 100 µL Calcein AM (2 μM in 0.1 M PBS) at room temperature for 1 h, protected 
from light. Six replicate wells were included for each condition. Four wells of assay media 
were included as blanks. The fluorescent signal from the Calcein AM dye was measured using 
a plate reader (Synergy H1, Biotek). The parameters measured were 495 nm and 520 nm for 
excitation/emission wavelengths, respectfully. For analysis, an average blank value was 
subtracted from all wells and then normalised to control values. Healthy cells will retain the 
Calcein AM dye and fluoresce whereas dead cells will not. Therefore, a decrease in fluorescent 




Table 2.1 Chemical Compounds used in cell culture experiments. 
Chemical Supplier Catalogue # Diluent Working concentration 
MnCl2 Fisher M87-100 Water or Media 
62.5, 125, 25, 500, 1000, 
2000 µM 
CQ Sigma C6628 Sterile PBS 10 µM 
PonA Enzo ALX-370-014 Ethanol 20 µM 
Mdivi-1 Bionet Customer made DMSO 10 μM 
PQ Sigma 856177 Sterile PBS 




2.3 Reverse transfection 
The following ‘reverse transfection’ procedure was used to increase transfection 
efficiency. Cells were transfected with DNA plasmid (LC3-cherry 0.3 μg/well, mCherry-
hLC3B-pcDNA3.1 plasmid) and/or either 10 nM siRNA (siGenome smartpool DNM1L, 
Dharmacon, against both human or rat Drp1) or with a scrambled control siRNA using 
LipofectamineTM 3000 according to the manufacturer’s instructions (Table 2.2). Briefly, the 
Lipofectamine™ 3000 Reagent was diluted with Opti-MEM™ Medium and mixed by 
pipetting. Then, a master mix of DNA and/or siRNA was prepared by diluting DNA and/or 
siRNA, to concentrations described above, in OptiMEM™ Medium. When transfecting cells 
with a DNA plasmid, P3000™ Reagent was also added and mixed by pipetting. When 
transfecting cells with siRNA the P3000 reagent was not added. Then, the tube containing 
DNA/siRNA master mix was combined with the diluted Lipofectamine™ 3000 Reagent (1:1 
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ratio). The new mixture, mixed by pipetting, was then incubated for 10–15 min at room 
temperature. During this time cells were detached by incubated with 0.05% Trypsin-EDTA, 
quenched with media, spun down (2.5 x g for 3 min) to collect the cell pellet, resuspended with 
OptiMEM™ Medium and counted using a hematocytometer. Subsequently, M17 (1x105 
cells/well), N27 (8x104 cells/well) and HeLa (1.5x105) cells were added to the preformed 
DNA/siRNA-lipid complex solution and plated in appropriate wells (M17 and N27 cells were 
always transfected in 24-well plates, while HeLa cells were transfected in 6-well plates). For 
immunofluorescence experiments, cells were plated directly on poly-D-lysine coated glass 
coverslips. After 8-10 h, Opti-MEM was replaced with complete growth media. 24 h post-
transfection cells were treated with compounds at the indicated concentrations and incubated 
for another 24 or 48 h. 
 
Table 2.2 Lipofectamine™ 3000 Reagent Protocol conditions. Each volume is indicated for one well. 
Component 96-well 24-well 6-well 
P3000™ Reagent 
per well 
0.2 μL 1 μL 5 μL 
Lipofectamine™ 
3000 Reagent per 
well 
0.15 μL 0.75 μL 3.75 μL 
Opti-MEM™ 
Medium per well 
10 µL 50 µL 250 µL 
 
 
2.4 Immunocytochemistry (ICC) 
Cells, grown on poly-D-lysine-coated coverslips (0.1 mg/mL poly-D-lysine), were treated and 
then fixed by incubating with 4% paraformaldehyde (PFA) in cell culture media for 20 min at 
37 °C. The following steps were performed with gentle agitation on a platform shaker. 
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Following washing with 0.1 M PBS, non-specific binding sites were blocked by incubating 
coverslips in 0.1 M PBS 4% normal goat serum (NGS), 0.1% TritonX-100 for 1 h at room 
temperature. Coverslips were then incubated in primary antibody solution, made in 0.1 M PBS, 
2% NGS, 0.1% TritonX-100, overnight at 4 °C. Table 2.3 contains information on the primary 
antibodies used in this study. For co-localisation experiments, primary antibodies were pooled 
together before being applied. Coverslips were then washed with 0.1 M PBS and incubated in 
secondary antibody solution, made in 0.1 M PBS, 2% NGS, for 1 h at room temperature 
protected from light. Table 2.4 contains information on the secondary antibodies used. For co-
localisation experiments, secondary antibodies were pooled together before being applied. 
Coverslips were again washed in 0.1 M PBS before being inverted and mounted onto glass 
microscope slides using ProLong gold antifade mounting reagent. Slides were air dried 
overnight, protected from light, before being sealed with nail polish and stored at 4 °C until 
ready for imaging. For experiments with HeLa cells that did not require antibody staining, 
coverslips were fixed and washed as described above before being directly mounted on 
microscope slides. Images were captured using an Olympus Fluoview FV10i confocal 
microscope. All images were taken using a 60X objective with variable optic zoom (2X and 
3X zoom). 
Specificity of primary and secondary antibody was not tested in this thesis. All the antibodies 
used in this thesis have been previously validated and published either by our lab (Cui et al., 
2010, Rappold et al., 2014, Fan et al., 2019) or other groups. For example, to validate the 
specificity of the Drp1 antibodies, our lab used cells from Drp1-knockdown, knockout or 
overexpressing samples. For all the experiments, optimisation of suitable concentrations to use 




Table 2.3 Primary antibodies used for ICC. 
Target Specificity Host Supplier Catalogue # Dilution 
α-Synuclein Human, Rat 
Rabbit 
Polyclonal 
































Table 2.4 Secondary antibodies used for ICC/IF/DAB. 
Target Conjugate Host Supplier Catalogue # Dilution 
Rabbit IgG AlexaFluor-488 Goat Invitrogen A-11034 1:1,000 
Rabbit IgG AlexaFluor-568 Goat Invitrogen A-11011 1:1,000 
Mouse IgG AlexaFluor-350 Goat Invitrogen A-21049 1:1,000 
Mouse IgG AlexaFluor-488 Goat Invitrogen A-11029 1:1,000 
Mouse IgG AlexaFluor-568 Goat Invitrogen A-11004 1:1,000 
Chicken IgY AlexaFluor-568 Goat Invitrogen A-11041 1:1,000 
















2.5 Detection of proteinase K insoluble α-synuclein species 
Inducible N27 cells were transfected with rat Drp1 siRNA and plated (8x104 cells/well) onto 
poly-D-lysine coated glass coverslips and treated with 20 µM PonA or vehicle (100% ethanol), 
with or without the addition of 125 µM Mn for 24 or 48 h; 10 µM CQ was included as a positive 
control. Cells were processed for ICC as described above however, prior to blocking, coverslips 
were either treated with 0.34 U/mL proteinase K (Sigma) or vehicle (0.1 M PBS) for 15-20 
min at room temperature, protected from light with shaking. Cells were subsequently stained 
for α-synuclein using the AB5038 α-synuclein antibody (Table 2.3), which is particularly 
effective at identifying higher order structures of the protein. Following imaging the number 
of insoluble aggregates was quantified using ImageJ. The image was first converted to 8-bit 
greyscale, background was removed by choosing the appropriate threshold value, and particles 
were analysed. DAPI staining was used to identify the number of cells in each image. The 
number of puncta per cell was determined by counting at least 30 cells per condition, for 
triplicate experiments, followed by One Way Anova with Tukey’s post-hoc analysis. 
 
2.6 Autophagy flux assessment using the tandem mRFP-GFP-LC3 
fluorescent probe 
HeLa (1.5×105 cells/well) cells were transfected with human Drp-1 siRNA and/or treated with 
compounds as described previously in a 6-well plate. 24 h post treatment, cells were fixed and 
ICC was performed, if necessary, as previously described. Following imaging, ImageJ was 
used to score the amount of green and red vesicles and DAPI staining was used to identify the 
number of cells in each image. Following conversion to 8-bit greyscale, background was 
removed by choosing the appropriate threshold value, and particles were analysed. Control 
cells were used to set the appropriate threshold value for each experiment. Green vesicles 
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represent autophagosomes and red vesicles symbolise both autophagosomes and 
autolysosomes (as the low pH inside the lysosome quenches the fluorescent signal of GFP). 
The number of autolysosomes was calculated by subtracting the number of green puncta from 
that of the red puncta as described by Button et al. (2014). The average number of puncta per 
cell in GFP or RFP-positive cells was determined by counting at least 30 cells per treatment 
group per experiment, for triplicate experiments (for a total of approximately 90 cells per 
treatment group). The average number of GFP and RFP puncta was first calculated for each 
experiment by dividing the total number of puncta for each treatment group by the total number 
of cells within that group. This was then averaged between each experimental repeat. No cell 
marker was used to identify cell borders, the total number of puncta within an image was 
divided by the number of cells within that image. This reduced biased as all cells were included 
in the count. This analysis method was utilised by Fan et al. (2019). This same method was 
used to analyse CAG-RFP-EGFP-LC3 transgenic mice. For these experiments 20 marker-
positive (either TH or GAD67) neurons per animal were counted. One Way Anova with 
Tukey’s post-hoc analysis was performed for statistical analysis. 
 
2.7 Quantification of p62 and LC3 puncta 
M17 (1.5×105 cells/well) and N27 (8×104 cells/well) cells were transfected with LC3-cherry 
and/or Drp1 siRNA (human or rat accordingly) in 24-well plates and then treated with 
compounds as described previously. 24 h post treatment, cells were fixed and ICC was 
performed as previously described. Following imaging, ImageJ was used to score the number 
of LC3 and p62 puncta. Following conversion to 8-bit greyscale, a convolve filter (normalize 
Kernel) and 3 x 3 median filter to reduce noise (“despeckle”) were applied. A threshold was 
then determined, and particles were analysed. The number of puncta per cell was determined 
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by counting at least 20 cells per condition, for triplicate experiments. This method was also 
used to analyse LC3 and p62 puncta in mouse brain sections. For these experiments 20 marker-
positive (either TH of GAD67) neurons per animal were counted. One Way Anova with 
Tukey’s post-hoc analysis was performed for statistical analysis. 
 
2.8  Mitochondrial morphology assessment in vitro 
M17 (8x104 cells/well) and N27 (6x104 cells/well) cells were grown on poly-D-lysine-coated 
glass coverslips in 24-well plates. 24 h post treatment cells were fixed and ICC performed as 
previously described. Measurements of mitochondrial size were quantified using ImageJ. After 
opening the image as an 8-bit grayscale, a convolve filter (normalize Kernel) and 3 x 3 median 
filter to reduce noise (“despeckle”) were applied to the image. Quantitative measurement of 
mitochondrial perimeter was calculated as previously described by Cui et al. (2010). The 
appropriate threshold value was then applied, and particles were analysed. More than 2000 
mitochondria from 50 cells per experiment were measured in 3 independent experiments. The 
length and average number of mitochondria per cell was categorised and graphed into eight 
groups (bins) according to their sizes (0.5, 1, 2, 4, 6, 8, 10 and more). Unpaired two-tailed 
Student's t test was performed to assess statistical difference between control and Mn-treated 
cells. 
 
2.9 Gel electrophoresis and western blotting 
M17 (3x105 cells/well), N27 (3x105 cells/well) and mRFP-GFP-LC3 HeLa (2.5x105 cells/well) 
cells were grown in 6-well plates, transfected and treated for 24 h. Cells were then washed with 
0.1 M PBS and detached using 0.05% Trypsin-EDTA for 30 sec, quenched with media and cell 
pellets were collected by pipetting. Cell suspensions were centrifuged at 1 x g for 5 min and 
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the supernatant disposed. Pellets were washed with 0.1 M PBS, centrifuged at 1.5 x g for 5 min 
and the supernatant disposed. Pellets were either used immediately or stored at -20 °C until 
required. For experiments assessing LC3 and p62 levels the BCA method was not used as the 
cell pellet (from each 6-well plate) was directly lysed in sample loading buffer and immediately 
used for experimentation. Cell pellets were resuspended in 20 μL 0.1 M PBS, then lysed by 
adding equal volume of 2x Laemmli sample buffer (Bio-Rad) and mixed by pipetting. For all 
remaining experiments, 30 μg of protein were diluted 1:1 in 2X Laemmli sample buffer and 
loaded to each well following BCA determination (see section 2.10). Proteins were denatured 
by boiling at 95 °C for 5-10 min. 30-40 μL or 30 μg of each sample were loaded per well 
alongside 5 μL of a pre-stained Protein ladder (Chameleon Duo) on 10% or 12% 
polyacrylamide gels. Tanks were filled with running buffer (0.1% SDS, 20 mM Tris-HCl and 
192 mM glycine) and gel electrophoresis was performed at 120 V for 90 min using the Bio-
Rad Mini PROTEAN Handcast system. Next, proteins were transferred to 0.2 μm pore PVDF 
membrane (immobilon Psq, briefly activated by submersion in methanol) using the Bio-Rad 
Mini Trans-Blot Cell with a wet transfer method. Briefly, a Mini gel holder cassette was placed 
in a tray containing transfer buffer (20 mM Tris-HCl, 192 mM Glycine, 10% methanol) and 
the transfer sandwich was created as follows: a foam blotting pad was added to the black side 
of the cassette followed by a blotting filter pad, the electrophoresis gel, activated membrane, 
blotting filter pad and finally a foam blotting pad. A roller was used to remove air bubbles from 
the sandwich and the gel holder cassette was closed and secured in place. The transfer assembly 
was then inserted into the Trans-Blot Cell within the transfer tank taking care to align the black 
sides of each component to ensure the correct migration of proteins. The tank was filled with 
transfer buffer and the transfer was run at 100 V for 90 min on ice. Membranes were then 
briefly submerged in 100% methanol, rinsed with ultra-pure water and then washed with TBS 
(50 mM Tris-HCl, pH 7.6; 150 mM NaCl) for 2 min prior blocking. Membranes were blocked 
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with Odyssey Blocking Buffer (LI-COR) or TBS + 0.1% Tween + 5% Skim milk for 1 hour at 
room temperature. Membranes were washed 3 times for 5 min with TBS + 0.1% Tween and 
then probed with primary antibodies (Table 2.5) diluted in Odyssey Blocking Buffer or TBS 
+ 0.1% Tween at 4 °C overnight, whilst shaking. Membranes were washed 3 times for 5 min 
with TBS + 0.1% Tween and then incubated with appropriate species matched secondary 
antibodies (Table 2.6) diluted in Odyssey Blocking Buffer or TBS + 0.1% Tween. Prior to 
imaging, membranes were washed again with TBS + 0.1% Tween and finally with TBS to 
remove residual Tween 20. Membranes were then visualized and analysed using the Li-Cor 
Odyssey CLx system. 
 
Table 2.5 Primary antibodies used for WB. 
Target Specificity Host Supplier Catalogue # Dilution 



























Santa Cruz FL-145 1:500 
Β-actin Wide range 
Mouse 
monoclonal 












Millipore 657012 1:500 
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Table 2.6 Secondary antibodies used for WB. 
Target Conjugate Host Supplier Catalogue # Dilution 
Rabbit IgG AlexaFluor-680 Goat Li-Cor 926-68071 1:10,000 
Mouse IgG AlexaFluor-800 Goat Li-Cor 926-32210 
1:10,000/ 
1:30,000 
Rabbit IgG AlexaFluor-800 Goat Li-Cor 926-32211 1:10,000 





2.10  Determining protein concentration (BCA colorimetric method) 
Protein estimation was performed using a Pierce BCA Protein Assay Kit (Thermo Fisher) 
according to manufacturer’s instructions. All Bovine Serum Albumin (BSA) standards and 
protein samples were ran in duplicate. BSA standards were created by serially diluting 2 
mg/mL stock in a 96-well plate at a ratio of 1:1 with RIPA buffer (2000 ng/μL, 1000 ng/μL, 
500 ng/μL, 250 ng/μL, 125 ng/μL, 62.5 ng/μL, 32.5 ng/μL, 0 ng/μL). Samples were then diluted 
1:20 with RIPA buffer and then loaded into the plate. The AB reagent was then prepared by 
mixing Reagent A to Reagent B in a 50:1 ratio. 200 μL of AB reagent was then pipetted to each 
well (both standards and samples), including 2 blank control wells. The plate was then 
incubated at 37 °C for 30 min and the sample absorbance was read at 562 nm to determine the 
optical density (OD). The blank-corrected OD of the samples and standards were averaged and 
plotted in a xy scatter graph (average OD562 (y value) versus protein concentration (x value)). 
Protein concentrations for unknown samples were then calculated using the equation x=(y-c)/m 
where m is the gradient of the standard curve and c is the intercept of the y axis. 30 μg of 
protein were mixed with 2x Laemmli sample buffer (Bio-Rad) and incubated at 95 °C for 5-10 
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min. Samples and ladder were then loaded on 10% or 12% polyacrylamide gels and WB was 
performed as previously described (see section 2.9). 
 
2.11 Seahorse assay (Seahorse XF Cell Mito Stress Test) 
M17 (1.5×104) and N27 (1.5×104) cells were plated in XFe96 cell culture microplates (M17 
cells were grown on poly-D-lysine precoated wells). Cells were then treated for 24 or 48 h as 
previously described.  
On the day prior to performing the assay, a sensor cartridge was hydrated by adding 200 µL of 
Seahorse XF Calibrant to each well and incubated at 37 °C overnight in a non-CO2 incubator. 
The following day, XF Base Media (DMEM, low glucose, pyruvate, Gibco), was prepared by 
adding 0.83 g to 100 mL of sterile cell culture grade H2O. The media was stirred until fully 
dissolved, HEPES was added to a final concentration of 4 mM. pH was adjusted to 7.4 with 
0.1 N NaOH and the media was maintained at 37 °C until ready to use. When ready, the assay 
media was filtered with a syringe. Cells were then washed twice and a final volume of 175 µL 
of assay media was added to each well. The culture plate was placed in a non-CO2 incubator 
for 45-90 min prior the assay, to remove all of the CO2 from the media. The sensor cartridge 
has four ports for chemical compound loading. For the seahorse experiments performed in this 
thesis, oligomycin, FCCP and rotenone/antimycin A were loaded into port A-C, respectively. 
Port D was not used. Prior optimisation experiments were performed within the laboratory to 
determine optimal concentrations of each compound for the specific cell lines used. The 
following optimal concentrations were determined: Oligomycin (1.26 µM), FCCP (0.5 µM), 
rotenone/antimycin A (1 µM each). In order to deliver the correct amount of each compound 
to the wells, a stock concentration was loaded into the appropriate ports of the sensor cartridge: 
Oligomycin (10 µM), FCCP (4.5 µM), rotenone/antimycin A (10 µM each). The hydrated 
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sensor cartridge was then loaded into the machine for calibration (15-30 min). Once calibration 
was completed, the calibration plate was replaced with the cell culture microplate and the 
experiment began. Upon completion of an XF assay, cells were fixed in 4% PFA for 20 min at 
37 °C, washed 3 times with 0.1 M PBS and incubated with DAPI (5 µg/mL) for 20 min at room 
temperature, protected from light. After a final series of washing steps, DAPI signal was 
measured using a plate reader (Synergy H1, Biotek). The parameters measured were 
respectfully 358 nm and 461 nm for excitation/emission wavelengths. 
For analysis and interpretation of data, the Wave software was used. It automatically calculates 
and reports the assay parameters of the Seahorse XF Cell Mito Stress Test as absolute Oxygen 
Consumption Rate (OCR) in pmol O2/min (Table 2.7). The seahorse assay and analysis of data 




Table 2.7 Seahorse XF Cell Mito Stress Test Parameter Equations. 
Parameter value Equation 
Non-mitochondrial oxygen consumption 
Minimum rate measurement after 
Rotenone/antimycin A injection 
Basal Respiration 
(Last rate measurement before first 
injection) – (Non-Mitochondrial Respiration 
Rate) 
Maximal Respiration 
(Maximum rate measurement after FCCP 
injection) – (Non-Mitochondrial 
Respiration) 
H+ (Proton) Leak 
(Minimum rate measurement after 




(Last rate measurement before Oligomycin 
injection) – (Minimum rate measurement 
after Oligomycin injection) 
Spare Respiratory Capacity 
(Maximal Respiration) – (Basal 
Respiration) 
Spare Respiratory Capacity as a % 
(Maximal Respiration) / (Basal Respiration) 
× 100 
Coupling Efficiency as a % 
ATP Production Rate) / (Basal Respiration 





2.12 TMRM measurement of membrane potential in flow cytometry  
M17 and N27 cells were plated (1x105 cells/well) into 24-well plates (duplicates for each 
group) and treated with the appropriate compounds for 24 h. Cells were then washed with 0.1 
M PBS and 0.05% Trypsin-EDTA was added to each well (just enough to cover the whole 
surface of the well) for 30 s. Trypsin was quenched by directly adding 500 µL of flow fluid 
(0.1 M PBS + 1% FBS) to each well. Cells were then transferred to 1.5 mL Eppendorf tubes 
and centrifuged at 1000 x g for 3 min. The supernatant was removed and the cell pellet was re-
suspended with 750 µL of HBSS (Gibco) solution (containing 50 nM TMRM for treatment 
groups and 50 nM TMRM + 20 µM FCCP as positive control). Cells were incubated at 37 °C 
for 20 min, centrifuged at 1 x g for 5 min and pellets re-suspended in 400 – 500 µL of flow 
fluid, depending on pellet size (For M17 cells, 100 nM TMRM and 40 μM of FCCP were used 
followed by a 15 min incubation at 37 °C). Cells were then analysed by flow cytometry (BD 
Melody FACS machine). Non-cellular debris and dead cells were gated out and 10,000 events 
from live cells were collected for each analysis. TMRM fluorescence was used to set the 
threshold and results are expressed as percentage of all cells with threshold value above the 
one set by FCCP. The assay and analysis of the data was performed by my colleague Dr 
Rebecca Z Fan.  
 
2.13 Animals and treatment 
Animal care and procedures were approved and conducted in accordance with Home Office 
Animals for Scientific Procedures Act (ASPA) 1986 guidelines and Institutional Animal Care 
and Use Committee (IACUC) regulations. All animals were group housed and maintained on 
a 12 h light/dark cycle, with access to food (PicoLab Irradiated 5V75 diet) and water ad libitum. 
Three different mice strains were used for experiments. The Drp1 heterozygous global 
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knockout (Drp1+/−) mice and control, WT Drp1+/+ mice were acquired from Institut Clinique 
de la Souris (ICS), Mouse Clinical Institute, France. Heterozygous mice were crossed with 
C57BL/6 mice to establish and maintain the colony. Figure 2.1 describes the generation of the 
mouse line as well as the position of the primers used for genotyping for each possible allele. 
No changes during development were visible in these mice compared to littermate controls 
apart from mild coat changes in aged mice, which, however, were not used in this study.  
Figure 2.1 Generation of the Drp1 mouse line and position of the primers used for genotyping. 
This figure depicts the creation of the Drp1 heterozygous global knockout (Drp1+/−) mice using the 
KOMP repository system of transgenic creation. Both conditional and global knockout mice can 
be created from a common ancestor by flipase or cre deletion, respectively. For this study, global 
heterozygous Drp1 knockout mice (highlighted in red) were purchased directly from ICS. The 
lettering underneath the genetic diagram represents a flexible primer system for genotyping these 




The C57BL/6-Tg (CAG-RFP/EGFP/Map1lc3b) 1Hill/J (CAG-RFP-EGFP-LC3 transgenic 
mice), were acquired from the Jackson Laboratory (# 027139). These mice have been designed 
with a human cytomegalovirus (CMV) immediate early promoter enhancer that drives the 
expression of a red fluorescent protein (RFP), an enhanced green fluorescent protein (EGFP), 
and a microtubule-associated protein 1 light chain 3 alpha (Map1lc3a) or LC3 gene. Mice were 
received as heterozygotes and crossed with C57BL/6 mice to establish and maintain the colony. 
Heterozygous mice showed no developmental defects or phenotypic abnormalities compared 
to littermate controls. 
Both WT (SLC39A14+/+) and KO (SLC39A14−/−) mice were kindly provided by Dr Thomas R 
Guilarte. ZIP14 (SLC39A14) is a zinc transporter that has been shown to also transport Mn. 
Heterozygous mice were crossed to yield homozygous, heterozygous and WT at a Mendelian 
ratio of 1:2:1. Mice were bred and genotyped by the Guilarte research group. The mice received 
were all approximately 6 month old (mixture of males and females). 



















2.14  Genotyping 
All mice were genotyped using DNA prepared from ear biopsies of two–three week old mice. 
Genomic DNA was extracted by a rapid alkaline procedure: a skin biopsy was placed in 75 µL 
alkaline solution (25 mM NaOH, 0.2 mM EDTA) and heated to 96 °C for 45 min. After cooling, 
75 µL of cold neutralization solution (40 mM Tris-HCl pH 7.6) was added. The residual tissue 
was pulsed down by brief centrifugation (30 s at 15,000 x g) and 1 µL of DNA was added to 
the PCR reaction (1.5 mM MgCl2, 0.2 mM dNTP mix, 0.4 µM Primers, 0.02 U/µL Taq 
polymerase in PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl)) (Invitrogen) of 25 µL total 
volume. The PCR was then performed using a thermal cycler (Veriti, Applied Biosystems) 
according to PCR cycle instruction listed in Table 2.9. 
Experiment Mouse strain Animals used 
Effects of Mn on autophagy 
and mitochondrial 
morphology 
Drp1+/− and littermate 
control Drp1+/+ mice 
24 





Blocking Drp1 as a 
protective strategy against 














Following PCR, DNA was separated by gel electrophoresis on a 1% agarose gel. Agarose was 
dissolved in TBE buffer (89 mM Tris base, 89 mM Boric acid, 2 mM EDTA pH 8.3) and 
microwaved until completely dissolved. The agarose was then allowed to cool slightly and 3.75 
µL Gel Red (Biotium) was added to the mix. The molten agarose was immediately poured into 
the gel mould with the comb already in place and left to set for 20-30 min. Once set, the gel 
was transferred to a tank ensuring that all the wells were fully immersed in TBE buffer. 1 µL 
ladder (Gene Ruler Mix Ladder, ThermoScientific) with 1 µL loading dye (6x DNA Loading 
Dye, Thermoscientific) and 4 µL H2O was loaded into the first well. For each sample, 2 µL 
loading dye was mixed with 10 µL PCR product and then loaded into the appropriate wells. 
The gel was run at 120V/200mA for 90-120 min. Once completed, the gel was visualised under 
UV light (ChemiDoc XRS system, Biorad). 
 
2.15  Manganese administration in vivo 
For treatments, mice were subcutaneously injected over the shoulders, into the loose skin over 
the neck (26-gauge needles) with 50 mg/kg MnCl2 or vehicle (ddH2O) once every 3 days (0, 3, 
6) and sacrificed 24 h after each injection, unless stated otherwise as previously described 
(Dodd et al., 2005). Mice were checked and weighed every day. No changes in body weight or 
behaviour were noticed and no mortality was associated with the treatment. All mice (mixture 











Table 2.9 PCR conditions used for each animal strain. 
Mouse 
strain 







Control Forward (10 µM) 
(5’ CTAGGCCACAGAATTGAAAGATCT 3’) 
Control Reverse (10 µM) 
(5’ GTAGGTGGAAATTCTAGCATCATCC 3’) 
Mutant Forward (10 µM) 
(5’ CATGGACGAGCTGTACAAGT 3’) 
Mutant Reverse (10 µM) 
(5’ CACCGTGATCAGGTACAAGGA 3’) 
95 °C, 3 min 
94 °C, 30 s 
58 °C, 30 s 
72 °C, 1 min 






Primer Ef (10 µM) 
(5’ GATTGGGCAGGAGCAAGATTCTC 3’) 
Primer Er (10 µM) 
(5’ GTGAGCTGACTGATGTAGGTGCTG 3’) 
Primer Kr (10 µM) 
(5’ GGGCAAGAACATAAAGTGACCCTCC 3’) 
95 °C, 4 min 
94 °C, 30 s 
61 °C, 30 s 
72 °C, 1 min 





Control Forward (10 µM) 
 (5’TCATGGACCGCTATGGAAAG 3’) 
Control Reverse (10 µM) 
(5’ GTGTCCAGCGGTATCAACAGAGAG 3’) 
Mutant Forward (10 µM) 
5’ TGCCTGGCACATAGAATGC 3’ 
Mutant Reverse (10 µM) 
5’ GCAGCGCATCGCCTTCTATC 3’ 
95 °C, 5 min 
95 °C, 30 s 
53 °C, 30 s 
72 °C, 1 min 







2.16  Stereotactic surgery 
In order to assess the effects of blocking mitochondrial fission in Mn-treated mice, rAAV2/9 
vectors encoding human Drp1-K38A (GTPase deficient dominant negative form of Drp1) were 
stereotactically delivered unilaterally to the SNpc using a set of pre-defined coordinates (AP: -
3.1, ML: ± 1.3, DV: -4.2, relative to the Bregma) (Rappold et al., 2014). Viral vector production 
generation was performed by Université de Bordeaux (Dr Erwan Bezard’s Lab) as previously 
described (Bido et al., 2017). Briefly, mRFP-GFP-LC3 mice (six week old) were anaesthetised 
using gaseous delivery of isoflurane (5%), until a loss of the pedal reflex was observed, and 
transferred to a stereotactic frame. Anaesthesia was maintained throughout the surgery with 1-
3% isoflurane, titrated to effect, and body temperature was maintained at 37 °C using a heated 
platform and rectal temperature probe. An incision was made along the midline from between 
the eyes to just before the middle of the ears to expose the bregma landmark (junction of sagittal 
and coronal suture lines) on the skull. The desired injection sites were identified and a small 
hole was drilled in the skull. The injection set up consisted of a frame-mounted 
micromanipulator, holding an UltraMicro pump (WPI Instruments) with a Hamilton syringe 
and a 33-gauge needle (Hamilton). The needle was lowered into the parenchyma at a rate of 
0.8 mm/min, and then held in place for 2 min before injection. 1 µL of rAAV2/9 containing 
Drp1-K38A (1 x 109 U/µL) was delivered to the right hemisphere whereas a sham surgery 
using 1 µL of sterile H2O was performed on the left hemisphere as a control. As LC3 mice 
already express GFP, AAV-GFP could not be used as a control and thus the sham surgery on 
the left hemisphere was performed. All injections were performed at a rate of 0.2 µL/min. After 
injection, the needle was left in place for 2 min, then withdrawn at a rate of 0.4 mm/min. The 
wound was closed using a discontinuous suturing technique using absorbable Vicryl sutures 
and mice were left to recover at 37 °C before being returned to their original cage. Stereotactic 
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surgery was performed by my colleague Dr Rebecca Z Fan. Mice were monitored daily for the 
first two weeks post-surgery and once weekly thereafter. 
Six weeks post-surgery, mice were subcutaneously injected with 50 mg/kg MnCl2 once every 
3 days (0, 3, 6) and all mice were sacrificed on day 7. Quantification of autolysosomes and 
autophagosomes in DAergic neurons within the SNpc was assessed using immunofluorescent 
staining and analysis as described in sections 2.6 and 2.19 respectively. 
 
2.17  Protein isolation from brain samples 
Prior to brain dissection, empty 1.5 mL Eppendorf tubes were labelled and weighed for each 
sample to be collected. Following gross brain dissection, discrete brain regions were dissected, 
cut into small pieces and placed in tubes on ice. Tubes were weighed again and the net wet 
weight of the tissue was calculated. A ratio of 1:10 of RIPA buffer (25 mM Tris-HCl pH 7.6, 
150 mM NaCl, 5mM EDTA, 1% Triton X-1000, 0.1% sodium dodecyl sulfate (SDS), 1% 
sodium deoxycholate, ddH2O) supplemented with 1% protease inhibitor cocktail (Sigma) was 
added to each brain sample, on ice. Samples were then homogenised with a plastic homogeniser 
twisting completely 10-12 times. The whole sample was then transferred to a 26-gauge needle 
and passed through 5-6 times. Samples were then centrifuged at 12,000 rpm for 25 min at 4 
°C. Supernatant was collected and stored in the -80 °C freezer until ready for use. Following 
protein concentration determination (section 2.10), 30 μg of protein were mixed with 2x 
Laemmli sample buffer (Bio-Rad) and incubated at 95 °C for 5-10 min. Samples and ladder 





2.18  Tissue preparation for IF and IHC  
Animals were euthanised by intra-peritoneal injection of a lethal dose of sodium pentobarbital 
(for an average size mouse this is 0.06 cc). A subxiphoid incision was made with a pair of 
microdissection scissors to expose the heart. A haemostat was then applied to the abdominal 
aorta and vein. Using a pair of microdissection scissors an incision was made in the right atrium 
and then the perfusion needle was inserted into the left ventricle near the apex (from interior to 
superior). Perfusion, with a peristaltic pump calibrated to 10 mL/min, was performed with 3 
min of 0.9 % saline followed by 8 min of 4% PFA in 0.1 M phosphate buffer. Whole brains 
were immediately dissected and post-fixed in the same fixative overnight at 4 °C before 
sequential overnight incubations in 15% and 30% sucrose in 0.1 M phosphate buffer. Brains 
were then snap frozen in methyl-butane at -55 °C and stored at -80 °C until sectioned. After 
mounting in OCT medium, brains were cryo-sectioned at 30 µm (Leica CM3050 S cryostat) 
and sections containing SN and striatum regions were collected for staining. All staining 
techniques were performed on free floating sections with gentle agitation throughout. 
 
2.19  Immunofluorescent (IF) staining  
For immunofluorescent staining, tissue sections were washed in 0.1 M TBS before non-specific 
binding sites were blocked in 0.1 M TBS 4% NGS, 0.1% TritonX-100 for 1 h at room 
temperature. Primary antibodies (Table 2.10), diluted in 0.1 M TBS 2% NGS, 0.1% TritonX-
100, were then added and incubated overnight at 4 °C. Following washing, sections were 
incubated with secondary antibodies, diluted in 0.1 M TBS, 2% NGS, for 1 h at room 
temperature protected from light (Table 2.4). Sections were again washed and then incubated 
with DAPI (2 µg/mL) for 10 min at room temperature, protected from light. After a final series 
of washing steps, sections were mounted and coverslipped using ProLong gold antifade 
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mounting media. Slides were air-dried overnight, protected from light, sealed with nail polish 
and stored at 4 °C until being imaged. Images were captured using an Olympus Fluoview 
FV10i confocal microscope. All images were taken, blinded, using a 60X objective with 
variable optic zoom (3X zoom). 
 
Table 2.10 Primary antibodies used for IF/DAB. 







MBL Intl. PM045 1:250 
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Millipore MAB5406 1:500 
 
 
2.20 Immunohistochemistry (DAB) 
All DAB immunostaining was performed using the Vector Laboratories VECTASTAIN ABC 
Kit (PK-4001) according to manufacturer’s instructions. Following perfusion and sectioning, 
tissue sections were washed in 0.1 M TBS prior to 10 min incubation in 10% methanol/3% 
H2O2. Tissues were again washed with 0.1 M TBS before non-specific binding sites were 
blocked in 0.1 M TBS, 5% NGS for 1 h. Sections were then incubated overnight at 4 °C in 
primary antibody (Table 2.10) in 0.1 M TBS, 2% NGS. The following day, sections were 
washed with 0.1 M TBS and then incubated in biotinylated secondary antibodies (Table 2.4) 
for 1 h in 0.1 M TBS, 2% NGS. Sections were again washed with 0.1 M TBS and then 
incubated in Avidin–Biotin Complex (ABC) solution for 1 h at room temperature. The ABC 
solution was made at least 30 min before use by adding 2 drops of Solution A to 10 mL 0.1 M 
TBS, mixing and then adding 2 drops of Solution B with further mixing. Following washes 
with 0.1 M TBS, the peroxidase was developed by incubating the sections with 20 mg (2 
tablets) 3,3’-diaminobenzidine-tetrahydrochloride (DAB) (Sigma D-5905), 200 mg/ml NH4Cl, 
3 mg/mL glucose oxidase, 250 mg/ml D-glucose in 50 mL 0.1 M Tris-HCl pH 7.6, filtered 
before use, for 10-15 min at room temperature, protected from light. Sections were washed 
with 0.1 M TBS and then mounted on SuperFrost slides and air-dried overnight. The following 
day, slides were dehydrated (5 min in distilled water, 10 min in 70% Ethanol, 10 min in 95 % 
Ethanol, 2x 10 min in 100% Ethanol, 2x 10 min in Xylene). Finally, sections were coverslipped 
with Permount mounting medium while still wet and left to dry in a fume hood. Images were 
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captured using an Olympus BX43 brightfield microscope. All images were taken using 20X 
and 100X objectives. 
Of note, for DAB staining, H2O2 was not added but rather I used the generation system with 




Total RNA was isolated from mouse brain samples by phase separation using Trizol Reagent 
(Invitrogen). Total wet weight of brain tissue was calculated and 1 mL of Trizol Reagent was 
added. Tissue was homogenised with 10-15 strokes of a plastic homogeniser and incubated on 
ice for 5 min. 200 µL of chloroform was added and samples were mixed by inversion, incubated 
for 3 min at room temperature and phase separated by centrifugation for 15 min at 12,000 x g 
at 4 °C. The mixture separates into a lower red phenol-chloroform phase, an interphase and a 
colourless upper RNA-containing phase. This upper phase was collected and 500 µL of 
isopropanol added to precipitate the RNA. This mixture was mixed by pipetting, incubated at 
room temperature for 10 min then centrifuged for 10 min at 12,000 x g at 4 °C. The supernatant 
was discarded and the RNA pellet was washed with 1 mL of 75% ethanol, vortexed and 
centrifuged for 5 min at 7,500 x g at 4 °C. The supernatant was discarded and RNA pellet air 
dried for 10 min before being resuspended in 50 µL RNase-free water and heated at 55 °C for 
10 min to aid solubilisation. RNA was quantified using a NanoDrop One (Thermo) and reverse 
transcription performed using SuperScript VILO cDNA synthesis kit (25 °C for 10 min, 42 °C 
for 60 min, 85 °C for 5 min). cDNA was stored at -20 °C until used. 10 ng of cDNA was loaded 
into each well of a 96-well plate and qPCR was performed on a QuantStudio 12K flex (Thermo) 
using TaqMan Fast Advanced Master Mix (Thermo) and TaqMan assays for Drp1 (FAM-
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MGB, Mm01342903_m1) and GAPDH (FAM-MGB, Mm99999915_g1) as an endogenous 
control gene. The reaction conditions were as follows: 50 °C for 2 min, 95 °C for 2 min and 40 
cycles of 95 °C for 3 s and 60 °C for 30 s. Relative quantification was performed in Microsoft 
Excel using the 2-ΔΔCT method. Statistical analysis was then performed using an Unpaired two-
tailed Student's t test analysis. Each reaction was run in triplicate, for three independent 
experiments, and analysed by my colleague Dr. Martin Helley. 
 
2.22 Mitochondrial morphology assessment in vivo 
Following imaging, mitochondrial length was quantified using ImageJ, using a method 
previously described (Chen et al., 2015a). First a region of interest (ROI) was drawn around 
the TH or GAD67 positive neurons. Each image was converted to an 8-bit grayscale image. A 
threshold filter was applied, followed by the application of a 3 x 3 median filter (“Despeckle”). 
Using the skeleton plugin, the mitochondrial network of each cell was skeletonized to one-
pixel-wide lines (skeletons). The length of all skeletons was measured using the analyse 
particles tool (settings were adjusted as required) and the area reported represented the total 
length of skeletons. To calculate the average length of mitochondria per neuron, the total length 
of skeletons was divided by the total number of skeletons (referred in ImageJ as ‘count’). 
Unpaired two-tailed Student's t test was used to reveal the statistic difference of the average 
mitochondria length between vehicle and Mn-exposed groups. 
 
2.23 Striatal optical density measurement 
Striatal optical density (OD) of TH fibres was determined via ImageJ analysis. Following DAB 
immunostaining, all sections were scanned (Epson Perfection V800 Photo Scanner) and saved 
as 8-bit grayscale images. The ImageJ software was then set to record uncalibrated OD 
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(Analyse > Calibrate > select ‘uncalibrated OD’ from the dropdown menu) for each individual 
image. The program was set to provide relevant measurements (Analyse > Set measures > 
uncheck all boxes > check mean gray value and integrated density). The striatum and a small 
region of cortex for each striatal section were then outlined (with the freehand tool) and 
measured (by clicking CTRL + M on the keyboard) to record the data. For each measurement 
the software will provide the following data: 
• Mean gray value: Average gray value within the section. This represents the sum of the 
gray values of all the pixels in the section, divided by the number pixels. 
• Integrated density: the product of area and mean gray value. 
• Raw Integrated density: sum of values of the pixels in the image. 
The data was measured for all sections on the slide/for one animal. For the current analysis 
both mean gray area and integrated density were used. The specific OD of TH-staining was 
then obtained by subtracting the cortex OD from the striatal OD, to adjust for background 
staining in each section. 
  
2.24 Sholl analysis of microglial morphology  
Sholl analysis was used to assess microglial morphology, following Iba1 immunostaining 
(DAB). At least 20 microglia within the SNpc were imaged per animal. Following imaging, 
using the 100X objective, on the bright field microscope, the image was opened in ImageJ and 
converted to 8-bit grayscale. A threshold filter was applied to a level that was representative of 
the original. The binary command was then applied and the freehand selection tool was used 
to draw around each cell of interest, excluding the outside area around the cell (Edit > Clear 
outside). Using the straight-line tool, a line was drawn from the cell soma to the most distal 
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branch of each microglia. Neurons were then analysed by choosing the Sholl analysis 
parameter with a 5-radius increment setting (Figure 2.2).  
 
The number of intersections at each radial increment was averaged for each mouse; the empty 
cells were filled with 0 (important for averaging). After unblinding, the animals were grouped 
and averaged according to their treatment. The graph represents the average number of 
intersections per cell. The area under the curve (AUC) was also calculated for each replicate 
and plotted with a graph. Statistical analysis was then performed on the AUC data using 
Unpaired two-tailed Student's t test analysis. The Sholl analysis was performed by my 
colleague Dr. Martin Helley. 
A B 
Figure 2.2 Representative visualisation of Sholl analysis performed on Iba1-stained microglia 
using ImageJ. (A) Image showing the distribution of radii from the cell soma. Points at which 
microglia processes intersect these radii are denoted by yellow dots. (B) Coloured heat-map of 
branch density. The red colour is representative of an increased number of intersects at the indicated 
radius, whilst blue colours show reduced intersections. The number of intersects is then plotted  




2.25 Immunohistochemistry of glial cell markers in the SNpc  
The quantification of % area of positive staining was used for the assessment of astrocyte and 
microglia activation, following GFAP and Iba1 DAB staining, respectively. The SNpc was 
captured across at least 4 sections per animal using the 20X objective. Using ImageJ, images 
were first converted into 8-bit grayscale images, then a threshold filter was applied (on a black 
background). Area fraction was then obtained using the ‘Analyse particles’ tool (the value is 
represented in %). Following unblinding, results were averaged depending on treatment group.  
 
2.26 Statistical analysis 
All values are expressed as mean ± standard error mean (SEM). Differences between means 
were analysed using a One-way analysis of variance followed by Tukey post-hoc test or 
unpaired two-tailed Student's t test, as appropriate. All analyses were performed using Sigma 
Stat v4.0. Differences were considered statistically significant when P < 0.05. All graphs were 









Cellular mechanisms of Manganese 






The precise pathological mechanism of Mn toxicity is still not fully understood, however 
evidence indicates that mitochondria actively sequester Mn and this accumulation can promote 
mitochondrial damage (Gavin et al., 1992), by modulating oxidative phosphorylation (Malecki, 
2001, Zhang et al., 2004) and/or mitochondrial dynamics (Alaimo et al., 2013, Alaimo et al., 
2014). Mn can additionally trigger α-synuclein misfolding and accumulation at certain 
concentrations (Peres et al., 2016a). The dysregulation of proteostasis pathways, including 
autophagy, are considered to be central in the progression of neurodegenerative disorders 
including PD. There is, however, limited evidence to suggest that Mn can alter the autophagy 
pathway, as most results are controversial (Gorojod et al., 2015, Tai et al., 2016, Ma et al., 
2017, Chen et al., 2018a, Zhou et al., 2018).   
Whilst it has been shown that Mn exposure can promote mitochondrial dysfunction, there is no 
evidence on whether any other cellular processes are altered at that same concentration and 
time point. Mn is accumulated to a greater extent in lysosomes than in mitochondria (Suzuki 
et al., 1983, Okamoto et al., 1997, Gorojod et al., 2017), which, as mentioned above, have been 
classically considered as the main target of Mn toxicity. This raises the question of whether 
mitochondria are the primary target of Mn and provides evidence to suggest autophagy as an 
additional affected pathway. Addressing this issue may have a significant impact on 
understanding the neurotoxic mechanisms of Mn. To this end, I decided to explore this in vitro 
using multiple cell lines. Inhibition of Drp1 has been shown to be protective in several models 
of neurodegeneration (Rappold et al., 2014, Bido et al., 2017, Fan et al., 2019). I, therefore, 
postulate that Drp1 inhibition will confer protection against Mn-induced neurotoxicity. To test 
these hypotheses, I proposed to assess changes in autophagy, α-synuclein aggregation, 
mitochondrial morphology and function concurrently in cells exposed to MnCl2. In addition, I 




3.2.1 Effects of Mn on cell viability 
At relatively high concentrations (350 -750 µM), Mn has been reported to induce mitochondrial 
dysfunction, increase mitochondrial fission and promote autophagy impairment (Alaimo et al., 
2013, Alaimo et al., 2014, Gorojod et al., 2015). Given the complex relationship between 
mitochondria and autophagy and the unanswered question whether mitochondrial dysfunction 
precedes autophagy impairment or vice versa, it is imperative to comprehend whether these 
impairments are the cause or consequence of cytotoxicity. To this end, time course and dose-
response cytotoxicity studies were performed by exposing HeLa, M17 and N27 cells to 
increasing concentrations (62.5 – 2000 µM) of MnCl2. Cell viability was measured after 24 
and 48 h of MnCl2 treatment, using Calcein AM, and the Lethal Dose-50 (LD50), a 
concentration at which 50% of cells are killed, was calculated. Mn caused a decrease in cell 
viability in a time-dependent manner in all cell lines (Figure 3.1). Whilst the higher 
concentrations (500 – 2000 µM) of MnCl2 were toxic to all cell types (over 60% cell death), 
HeLa cells were less sensitive to Mn-induced toxicity when compared to M17 and N27 






Figure 3.1 Mn reduces cell viability in a dose-dependent fashion. HeLa, M17 and N27 cells were 
cultured in 96-well plates and exposed to varying concentrations of MnCl2 (62.5 – 2000 μM) for 
(A) 24 and (B) 48 h. Values are relative to 100% for the vehicle-treated group and they are 
represented as mean ± SEM (n=3 independent experiments, with 6 wells per group, per experiment). 
(C) Summary table of LD50 values generated using GraphPad Prism. One Way Anova with Tukey’s 







Cell lines LD50 ± SEM (µM) 
  24h 48h 
HeLa 323.7 ± 8.7 314.5 ± 15.84 
M17 217.6 ± 4.8 *** 168.8 ± 5.6 *** 
N27 260.6 ± 7.5 **,# 186.9 ± 2.5 *** 
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3.2.2 Effects of Mn on the autophagy pathway 
Defects in the autophagy pathway and the resulting accumulation of protein aggregates 
represent one of the common pathobiological features of PD pathology (Antony et al., 2013). 
As the effects of Mn on this process are not fully understood, it was crucial to investigate the 
effects of Mn on autophagy. To do so, the HeLa mRFP-GFP-LC3 stably expressing cells were 
used. These cells were designed to rapidly assess changes in autophagy flux based on different 
pH stability of GFP and mRFP fluorescent proteins (Figure 3.2). They express the mRFP-
GFP-LC3 fusion protein in which the autophagosome marker protein LC3 (microtubule-
associated protein 1 light chain 3) is fused to two fluorescent reporter proteins: monomeric 
RFP (acid-stable) and GFP (acid-sensitive). Autophagosomes appear yellow (green and red 
signal) whilst autolysosomes are red, since the acidic lysosomal pH quenches the GFP signal 
more rapidly than the mRFP (Kimura et al., 2007). The number of fluorescent puncta structures 




Figure 3.2 Monitoring autophagic flux in HeLa mRFP-GFP-LC3 expressing cells. During the 
early stage of autophagosomes biogenesis, puncta will accumulate and display both green and red 
fluorescent signals (GFP+RFP+). During the late stage of the autophagic process (autolysosomes 
formation), the green signals are quenched in the acidic autolysosomes, while the red signals are 
retained (GFP-RFP+). If autophagy flux is blocked the green signal will not be quenched by the 
lysosomes and both the green and the red signal (yellow) will be expressed. 
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HeLa mRFP-GFP-LC3 cells were exposed to different concentrations of MnCl2 (62.5 – 500 
µM) for 24 h. Following Mn treatment, the number of autophagosomes increased, in a dose 
dependent fashion, whilst autolysosomes markedly decreased compared to control cells 
(Figure 3.3). These results are indicative of a blockade in autophagy flux. As all Mn 
concentrations caused a statistically significant blockade in the autophagy flux, and considering 
the cell viability data, the lowest concentration of MnCl2 (62.5 µM, which caused 8.13 % cell 
death), was chosen as the preferred concentration for future experiments using HeLa cells. 
To further validate these results in a more relevant model to PD, ICC was performed in M17 
human DAergic-like neuroblastoma cells following MnCl2 treatment. M17 cells were 
transiently transfected with LC3-cherry plasmid and then treated with increasing 
concentrations of MnCl2 (62.5 – 500 µM) for 24 h. Chloroquine (CQ), a well-known 
lysosomotropic compound (de Duve et al., 1974), was used a positive control for autophagy 
inhibition. Staining with p62 was performed and the number of LC3- and p62-positive puncta 
were quantified. In control cells, the staining pattern of LC3 and p62 was largely diffuse, with 
a small number of visible puncta. Following Mn treatment, the diffuse staining pattern of LC3 
and p62 visibly changed to a more punctate pattern, which is representative of a recruitment, 
and subsequent accumulation, of LC3 and p62 to the autophagosome. Following quantification, 
results clearly demonstrate accumulation of LC3 and p62 positive puncta, in a dose-dependent 
manner, in Mn-exposed cells (Figure 3.4).  
Again, as a result of statistical analysis, 125 µM MnCl2 (which caused 18.9 % cell death) was 
the lowest concentration of Mn treatment that induced a significant detectable blockade in 
autophagy by increasing both LC3 (39.58 ± 2.99) and p62 (28.31 ± 2.07) levels in comparison 
to control (LC3,19.47 ± 1.90; p62 9.06 ± 0.24) levels and was therefore chosen as the preferred 




Figure 3.3 Mn inhibits autophagy flux in HeLa cells. mRFP-GFP-LC3 stably expressing HeLa 
cells were treated with MnCl2 at different concentrations (62.5 – 500 μM) for 24 h. The number of 
autophagosomes (green vesicles) and autolysosomes (red vesicles minus green vesicles) per cell 
were quantified in at least 30 cells per condition, for triplicate experiments. Data are shown as mean 
± SEM (n=3 independent experiments). One Way Anova with Tukey’s post-hoc analysis ***: P < 








Figure 3.4 Mn treatment blocks autophagy in neuroblastoma cells. M17 cells were transfected 
with LC3-cherry plasmid (0.3 μg). 24 h post-transfection cells were treated with MnCl2 (62.5 – 500 
μM) or CQ (10 μM) for another 24 h. Images show LC3 fluorescence (red) and p62 staining (green). 
The number of LC3 and p62 puncta per cell was quantified in at least 20 LC3-cherry-positive cells 
per condition, for triplicate experiments. Data are shown as mean ± SEM (n=3 independent 
experiments). One Way Anova with Tukey’s post-hoc analysis *: P < 0.05; ***: P < 0.001 compared 
to control. Scale bar 20 μm. 
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3.2.3 Effects of Drp1 inhibition on Mn-induced changes 
Pharmacologically or genetically targeting the function of Drp1 has previously been shown to 
be protective in several models of PD (Cui et al., 2010, Rappold et al., 2014). Furthermore, 
results from our laboratory demonstrated that inhibition of Drp1 could restore the impaired 
autophagy flux of cells exposed to α-synuclein (Fan et al., 2019). Therefore, I investigated 
whether the deficit in the autophagy pathway, caused by Mn exposure, could be rectified by 
blocking mitochondrial fission (via gene silencing and small molecule). HeLa and M17 cells 
were transiently transfected with the appropriate Drp1 small interfering RNA (siRNA, human) 
and siRNA scramble, to assess the efficiency of Drp1 knock-down after 48 h (Figure 3.5). The 
efficiency of knocking down Drp1 was verified using WB and results clearly showed reduced 
Drp1 levels of over 70% in both cell lines compared to control and scramble cells. Scramble 
siRNA did not affect Drp1 protein expression compared to control cells. 
Figure 3.5 Efficiency of Drp1 knockdown mediated by siRNA. HeLa and M17 cells were 
transfected with 10 nM human siRNA and scramble for 48 h. 30 μg of protein were loaded/well. 
Western blot against Drp1 antibody was used to confirm knockdown efficiency compared to control 
and scramble cells. β-actin was used as loading control. Blots were visualized on an Odysey CLx 
machine and optical density measured using Li-Cor Image Studio software. Data are shown as mean 
± SEM (n=4 independent experiments). One Way Anova with Tukey’s post-hoc analysis ***: P < 
0.001 compared to control and scramble cells. 
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To assess the effects of Drp1 inhibition on autophagy flux following Mn treatment, cells were 
processed for immunostaining. HeLa cells were transfected with either siRNA scramble or 
Drp1 siRNA for 24 h and then treated with 62.5 µM MnCl2 for another 24 h. Results clearly 
indicate that Drp1 knockdown attenuated the autophagy impairment induced by MnCl2 
treatment as evidenced by a significant reduction in the number of autophagosomes (from 
41.35 ± 0.91 to 27.21 ± 2.08) and increased autolysosomes (from 3.73 ± 0.66 to 16.84 ± 0.94), 
respectively. In fact, the number of autophagosomes and autolysosomes per cell were restored 
to a level that were no longer considered statistically different to control cells 
(autophagosomes, 22.74 ± 1.91; autolysosomes, 33.57 ± 4.43) (Figure 3.6). 
Similar results were achieved in M17 cells co-transfected with Drp1 siRNA and LC3-cherry 
plasmid, treated with 125 µM MnCl2 and then stained for p62. Data show that Drp1 inhibition 
reduced the Mn-induced accumulation of LC3 (from 140.98 ± 3.45 to 75.79 ± 1.77) and p62 
(from 154.64 ± 3.42 to 62.14 ± 0.55) puncta to control (LC3, 55.10 ± 5.63; p62, 50.88 ± 3.87) 
and siRNA (LC3, 61.64 ± 1.88; p62, 47.03 ±1.51) levels. CQ was used as a positive control for 
autophagy blockade and induced a potent increase in both LC3 (243.17 ± 17.12) and p62 








Figure 3.6 Drp1 inhibition attenuates autophagy blockade induced by Mn treatment in HeLa 
cells. HeLa mRFP-GFP-LC3 expressing cells were transfected with 10 nM human Drp1 siRNA or 
scramble. 24 h post-transfection cells were treated with MnCl2 (62.5 μM) and stained for Drp1 (blue 
channel). The number of autophagosomes (green puncta) and autolysosomes (red minus green 
puncta) per cell was quantified in at least 30 cells per condition, for triplicate experiments. Data are 
shown as mean ± SEM (n=3 independent experiments). One Way Anova with Tukey’s post-hoc 




Figure 3.7 Inhibition of Drp1 attenuates autophagy blockade induced by Mn in M17 
neuroblastoma cells. M17 cells were transfected with human Drp1 siRNA (10 nM) represented in 
the blue staining and LC3-cherry (red). 24 h post-transfection cells were treated with MnCl2 (125 
μM) for another 24 h, then stained for p62. ImageJ was used to quantify the amount of green and 
red vesicles, representing respectively p62 and LC3 puncta.  The number of puncta per cell was 
determined by counting at least 20 LC3-cherry positive cells for each condition, for triplicate 
experiments. Data are shown as mean ± SEM (n=3 independent experiments). One Way Anova 
with Tukey’s post-hoc analysis **: P < 0.01; ***: P < 0.001. Scale bar 20 μm.Scale bar 20 μm. 
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To fortify this data, LC3-II (the only well-characterised protein specifically localised to 
autophagic structures throughout the process from phagophore to lysosomal degradation) and 
p62 protein levels were assessed via WB in M17 cells (Figure 3.8 A-C). An increment in both 
LC3-II and p62 levels was detected when cells were exposed to 125 µM MnCl2 for 24 h, 
indicative of a late blockade in the autophagy pathway Inhibition of Drp1 promoted a 
significant reduction of LC3-II and p62 levels in Mn-exposed cells that was no longer 
considered significant when compared to control cells. In addition, no changes in LC3-I protein 
levels were detected amongst groups (Figure 3.8 D). The LC3-II/LC3-I ratio was analysed to 
further investigate the relative expression of both proteins. Results showed that both Mn and 
CQ treatment caused an increase in LC3-II/LC3-I ratio, which was reduced by inhibiting Drp1 
in Mn-treated cells (Figure 3.8 E). Overall, these results concur with the immunostaining data 






Figure 3.8 Drp1 inhibition is protective against Mn-induced autophagy. (A) WB of M17 cells 
transfected for 24 h with human Drp1 (10 nM) and/or then treated with either MnCl2 (125 μM) or 
CQ (10 μM) for another 24 h. Cell pellets from one well of a 6-well plate were subjected to SDS-
PAGE and probed with the indicated antibodies. (B) P-62, (C) LC3-II (D) LC3-I and (E) LC3-
II/LC3-I levels were quantified using β-actin as a loading control. Blots were visualized on an 
Odysey CLx machine and optical density measured using Li-Cor Image Studio software. Data are 
shown as mean ± SEM (n=4 independent experiments). One Way Anova with Tukey’s post-hoc 
analysis *: P < 0.05; **: P < 0.01; ***: P < 0.001 Note that the band running just below LC3-I at 








First described by Cassidy et al. (2008), mdivi-1 is a cell permeable quinazolinone that inhibits 
Drp1 function in both yeast and mammalian cells. As many previous studies, including those 
from our research group, have reported that the beneficial effects of mdivi-1 in multiple PD 
models, I tested whether 10 μM mdivi-1, as previously described by Cui et al. (2010) could 
also confer protection against Mn toxicity and rescue the autophagy flux in HeLa cells.  
Efficiency of mdivi-1 on Drp1 inhibition was not directly tested in this thesis, however this 
inhibitor has been widely reported to produce effects consistent with blocking mitochondrial 
fission (Smith and Gallo, 2017) and blocking GTPase function of human Drp1 (Numadate et 
al., 2014, Manczak et al., 2018) with an IC50 of approximately 13 µM (Numadate et al., 2014) 
and my lab has previously shown that mdivi-1 treatment could reduce excessive fission (Cui et 
al., 2010, Rappold et al., 2014, Bido et al., 2017, Fan et al., 2019). 
Co-treatment with MnCl2 and mdivi-1 significantly reduced the numbers of autophagosomes 
(19.10 ± 1.05) compared to Mn treated cells alone (25.60 ± 1.48), however, the number of 
autophagosomes remained significantly higher when compared to control cells (8.61 ± 0.96). 
On the other hand, the number of autolysosomes were significantly increased (16.13 ± 0.75) in 
cells co-treated with mdivi-1 and MnCl2 compared to cells treated with MnCl2 alone (4.80 ± 
0.30) (Figure 3.9) and were no longer significantly different when compared to control cells 
(19.01 ± 0.37). Taken together these results suggest that the blockade in the autophagy flux 
caused by Mn exposure could be rescued by pharmacologically inhibiting Drp1. Of note, 
mdivi-1 treatment alone increased the number of autophagosomes (15.40 ± 1.46) as compared 




  Figure 3.9 Mdivi-1 improves autophagy blockade induced by Mn treatment. HeLa mRFP-GFP-
LC3 expressing cells were co-treated with MnCl2 (62.5 μM) and mdivi-1 (10 μM) or control vehicle 
(DMSO) for 24 h. The numbers of autophagosomes (green puncta) and autolysosomes (red minus 
green puncta) per cell were quantified in approximately 30 cells per experiment, for triplicate 
experiments. Data are shown as mean ± SEM (n=3 independent experiments). One Way Anova with 
Tukey’s post-hoc analysis *: P < 0.05; **: P < 0.01; ***: P < 0.001. Scale bar 20 μm. 
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3.2.4 Interplay between Mn and α-synuclein  
In order to further investigate the effect of Mn-induced autophagy dysfunction and to explore 
a potential interaction between Mn and α-synuclein, the inducible human WT α-synuclein 
expressing N27 cell line, previously generated in our lab (Cui et al., 2010), was used. In the 
presence of Ponastrone A (PonA), an ecdysone analogue inducer, the expression of human WT 
α-synuclein was induced (Figure 3.10). 
 
Previous WB results from our lab, using a human α-synuclein antibody, showed that α-
synuclein overexpression in N27 cells was time and dose dependent after induction with PonA 
alone (Fan et al. data not yet published). The optimal induction conditions were determined to 
be 48 h treatment of 20 µM of PonA. A representative image of α-synuclein expression, 
following 48 h of PonA treatment, is described in Figure 3.11 A. To assess the effects of Mn 
on α-synuclein aggregation, N27 cells were exposed to Mn with PonA for 48 h; chloroquine 
(CQ), an inhibitor of lysosomal degradation, was used as a positive control.   
Figure 3.10 Inducible overexpression of human α-synuclein in rat DAergic N27 neuronal cells. 
Stable cells containing a vector that constitutively expresses the ecdysone receptor (VgEcR) and the 
retinoid X receptor (RXR) were generated. These cells were subsequently stably transfected with a 
second vector that contains the ecdysone-responsive element (E/GRE) and a multiple cloning site 
for the insertion of the human WT α-synuclein (SNCA) gene. The VgEcR-retinoid X receptor 
heterodimer binds to the E/GRE. In the presence of PonA, an ecdysone analogue inducer, the co-
repressors are released from VgEcR, and the co-activators are recruited, resulting in SNCA gene 
activation via the minimal heat shock promoter (mHSP). IRES, internal ribosome entry site.   
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Proteinase K treatment was then used to measure the number of insoluble α-synuclein positive 
aggregates as proteinase K resistance is a property of mature aggregated proteins. A significant 
increase in the number of α-synuclein insoluble aggregates in PonA induced cells (9.35 ± 0.40) 
was detected when compared to the non-induced (vehicle) cells (0.78 ± 0.31) (Figure 3.11 D-
E). This observation demonstrates the ability of our model to produce more mature α-synuclein 
containing aggregates. Treatment of cells with 125 μM MnCl2 for 48 h (during PonA induction) 
induced a further increase in the number of α-synuclein aggregates per cell (19.46 ± 3.00) 
(Figure 3.11 D-E). Inhibition of Drp1, via siRNA, reduced the number of α-synuclein 
insoluble aggregates in PonA induced cells alone (1.02 ± 0.36) or in combination with Mn 
treatment (6.98 ± 0.75), no longer statistically different to vehicle cells. Drp1 knockdown 
efficiency was verified via WB (Figure 3.11 B).To determine the time-dependent nature of 
this effect, N27 cells were exposed to Mn and/or PonA for 24 h. As evidenced by the graph 
(Figure 3.11 C), 24 h incubation had no significant effect on α-synuclein in cells treated with 
either PonA alone (2.25 ±0.19) or with MnCl2 and PonA together (2.34 ± 0.20), images not 
shown. In addition, exposure to MnCl2 alone (1.80 ± 0.12), without PonA treatment, did not 
alter/induce α-synuclein expression (images not shown). On the contrary to Mn effects on α-
synuclein expression after 24 and 48 h treatment, CQ treatment induced an increase in α-
synuclein aggregates that was always stronger than Mn and statistically different compared to 
vehicle cells at 48 (24.86 ± 2.34) and 24 h (4.90 ± 0.52).  
These findings indicate that there is a clear increase in number of proteinase K-resistant α-
synuclein aggregates following 48 h exposure to Mn when compared to vehicle and α-
synuclein overexpressing cells alone. Drp1inhibition reduced the amount of protein aggregates 
to normal levels. Given the time point and the effects of an autophagy inhibitor on α-synuclein 




  Figure continues on next page 
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Figure 3.11 Drp1 inhibition attenuates α-synuclein aggregation, induced by Mn in N27 cells. 
(A) Representative image of α-synuclein induction (soluble aggregates), following 48 h of PonA 
treatment. Scale bar 20 μm. (B) Efficiency of Drp1 knock-down mediated by siRNA in N27 cells. 
Cells were transfected with 10 nM human siRNA and scramble for 48 h. 30 μg of protein were 
loaded/well. WB against Drp1 antibody was used to confirm knock-down efficiency compared to 
control and scramble. β-actin was used as loading control. Blots were visualized on an Odysey CLx 
machine and optical density measured using Li-Cor Image Studio software. **: P < 0.01 compared 
to control and scramble cells. Data are shown as mean ± SEM (n=3 independent experiments). (C) 
The graph represents insoluble α-synuclein puncta post Proteinase K treatment. α-synuclein 
overexpression was induced (20 μM PonA) alone or in combination with Mn (125 μM) or CQ (10 
μM) for 24 h, along with Mn treatment alone. Data are shown as mean ± SEM (n=3 independent 
experiments). One Way Anova with Tukey’s post-hoc analysis. No statistical difference was found 
between vehicle and Mn treated groups. ***: P < 0.001. (D) N27 cells were transfected with rat 
Drp1 siRNA (10 nM) or scramble control. 24 h post-transfection α-synuclein overexpression was 
induced (20 μM PonA) alone or in combination with Mn (125 μM) or CQ (10 μM) for 48 h. Post 
fixation, cells were incubated with either PBS (data not shown) or Proteinase K and then processed 
for ICC using an antibody particularly effective at identifying higher order structures of the protein 
(Millipore, AB5038). Images show insoluble α-synuclein aggregates. Scale bar 20 μm. (E) ImageJ 
was used to quantify the α-synuclein-positive puncta per cell in at least 30 cells for each condition, 
for triplicate experiments. Data are shown as mean ± SEM (n=3 independent experiments). One 












To investigate this further, N27 cells were transfected with LC3-cherry plasmid and Drp1 
siRNA (as previously done in M17 cells), treated with MnCl2 and/or PonA for 24 h and then 
processed for p62, Drp1 and α-synuclein staining (Figure 3.12). CQ was used as a positive 
control for autophagy blockade. Mn alone caused an increase in both LC3 (39.72 ± 0.76) and 
p62 (54.30 ± 4.73) puncta compared to vehicle cells (LC3, 18.06 ± 1.12; p62, 27.46 ± 0.99), 
indicating a blockade in the autophagy pathway. Again, inhibition of Drp1 improved Mn-
induced accumulation of LC3 (25.02 ± 2.06) and p62 (33.55 ± 2.36) puncta (Figure 3.12 A 
and C). These results are consistent with both HeLa (Figure 3.6) and M17 (Figure 3.7) cells. 
Upon co-treatment of PonA and Mn, the number of LC3 (48.83 ± 3.54) and p62 (71.16 ± 8.33) 
puncta increased to levels that were statistically different to cells exposed to PonA (LC3, 33.23 
± 1.31; p62, 46 ± 2.20) and Mn alone (LC3, 39.72 ± 0.76; p62 54.30 ± 4.73). These results 
indicate that α-synuclein alone blocked autophagy, as did Mn, however had a greater effect 
when combined (PonA + Mn). Consistently, CQ treatment had a stronger effect and induced a 
greater accumulation of both LC3 (87.36 ± 8.41) and p62 (114.48 ± 11.55) puncta compared 
to any other treatment. Drp1 knockdown significantly reduced LC3 and p62 puncta in both 
PonA induced cells (LC3, 21.43 ± 1.73; p62, 29.69 ± 1.78) and cells co-treated with PonA and 
Mn (LC3, 26.75 ± 0.5; p62, 33.16 ± 1.35), to a level that was not statistically different to vehicle 
cells (LC3, 17.35 ± 0.71; p62, 25.57 ± 0.57) (Figure 3.12 B and D).  
Overall this data suggest that autophagy dysfunction induced by Mn-exposure occurs prior to 




















Figure 3.12 Inhibition of Drp1 attenuates autophagy blockade induced by Mn in N27 DAergic 
cells. N27 cells were transfected with human Drp1 siRNA (10 nM) represented in the blue staining 
and LC3-cherry (red). 24 h post-transfection cells were treated for another 24 h with (A) MnCl2 
(125 μM) and (B) MnCl2 (125 μM) and/or PonA (20 μM). CQ (10 μM) was used as a positive 
control. Following imaging, ImageJ was used to count the amount of green and red vesicles, 
representing respectively p62 and LC3 puncta. The number of puncta per cell in (C) Mn-treated 
alone and (D) co-treated with Mn and/or PonA was determined by counting at least 20 LC3-cherry 
positive cells for each condition, for triplicate experiments. Data are shown as mean ± SEM (n=3 
independent experiments). One Way Anova with Tukey’s post-hoc analysis *: P < 0.05; **: P < 
0.01; ***: P < 0.001 Scale bar 20 μm. 
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3.2.5 Effects of Mn on mitochondrial function and morphology 
As previously stated, Mn toxicity has been widely associated with mitochondrial dysfunction. 
There is no evidence, however on whether mitochondrial dysfunction precedes autophagy 
dysfunction or vice versa and whether these impairments are the cause or the consequence of 
neurotoxicity. To address this issue, both M17 and N27 cells were treated with the same 
concentration of MnCl2 (125 µM) that induced autophagy blockade and α-synuclein 
aggregation and evaluated for multiple measures of mitochondrial function and morphology.  
Mitochondrial respiration was assessed in both cell lines by measuring the oxygen consumption 
rate (OCR), using the seahorse XFe96 Extracellular Flux Analyser, following 24 h of MnCl2 
treatment (Figure 3.13). The herbicide PQ was used as a positive control to induce 
mitochondrial dysfunction (Cocheme and Murphy, 2008). The assay reported multiple key 
parameters, including basal respiration, ATP-linked respiration and spare respiratory capacity 
(SRC, ability of cells to meet an energetic demand, indicative of cell fitness). Results clearly 
showed that Mn exposure led to no changes in any measured paraments at this concentration 










Figure 3.13 Mn does not impair mitochondrial function at a concentration that blocks 
autophagy. (A) Agilent Seahorse XF Cell Mito Stress Test profile of the key parameters of 
mitochondrial respiration. (B) Representative example of the kinetics OCR response in N27 and 
M17 cells exposed to Mn and PQ treatment. M17 and N27 cells were plated in XFe96 tissue culture 
plate and treated with MnCl2 (125 µM) for 24 h. Mitochondrial respiration was assessed by 
measuring OCR using the XFe96 Extracellular Flux Analyzer. Sequential injections of oligomycin 
(to inhibit oxygen consumption mediated by ATP synthase), FCCP (an uncoupler to induce maximal 
OCR), Rotenone/Antimycin (to inhibit complex I and III, respectively). Effects of Mn on (C) Basal 
respiration, (D) ATP Production, (E) Spare Respiratory Capacity (SRC). Data are shown as mean ± 
SEM (n=3 to 4 independent experiments, with 6 wells per group, per experiment). Unpaired two-
tailed Student's t test found no statistic significant difference when comparing control to Mn-











To further corroborate these results, flow cytometry was used to measure membrane potential 
(Δψm) in live cells using TMRM, following Mn treatment in both M17 and N27 cells. The 
uncoupler carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) was used as a 
positive control to collapse membrane potential. As expected, FCCP significantly collapsed 
Δψm, as shown by a curve shift to the left (Figure 3.14 A), however, when cells were exposed 
to Mn, no changes were detected in either cell type (Figure 3.14 B).    
M17 
N27 
Figure 3.14 Mn does not affect mitochondrial membrane potential at a concentration that 
blocks autophagy. (A) Representative example of the fluorometric response of N27 and M17 cells 
exposed to Mn and FCCP. M17 and N27 cells were treated with Mn (125 μM) for 24 h. TMRM (50 
nM) was applied for measuring mitochondrial membrane potential. Cells were incubated with 
TMRM for 20 min in dark and fluorescence signal was quantified using BD FACS Melody™ Cell 
Sorter. Uncoupler FCCP (20 µM) was used as a positive control to collapse membrane potential. 
(B) Δψm in M17 and N27 cells. Data are shown as mean ± SEM (n=3 independent experiments). 
Unpaired two-tailed Student's t test showed no statistic significant difference between control and 







Alaimo et al. (2014) previously suggested that high concentrations of MnCl2 (750 µM)  caused 
an imbalance in the equilibrium of fusion/fission proteins, which resulted in mitochondrial 
fragmentation. To verify these results, N27 cells were exposed to MnCl2 for 24 h and 
mitochondrial morphology was determined following TOM20 immunostaining. Results clearly 
showed no changes in mitochondrial morphology in Mn-exposed cells (Figure 3.15). 
Mitochondrial perimeter measurements were binned to produce a histogram with a normal 
distribution. Mn treatment did not produce a change in any of the perimeter bins nor did it 
produce a shift in the normal distribution. Mitochondrial fragmentation would shift the 
distribution to the left, with more mitochondria in the smaller bins as shown by Cui et al. 
(2010). 
As no changes in either mitochondrial function or morphology were detected using the same 
timepoint and concentration of MnCl2 (125 µM) that impaired autophagy, a higher 
concentration of MnCl2 (250 µM) was used to assess changes in mitochondrial function in N27 
cells. The seahorse XFe96 Extracellular Flux Analyser was used again following 24 h of MnCl2 
(250 µM) treatment. Results clearly indicated that this higher concentration of Mn could indeed 
affect mitochondrial respiration as evidenced by reductions in basal respiration, ATP-linked 











Figure 3.15 No evident changes in mitochondrial morphology in Mn-exposed cells. (A) 
Mitochondrial morphology of N27 cells treated with 125 μM MnCl2 for 24 h. TOM20 was used to 
stain mitochondria (red). (B) Mitochondrial length and number was measured using ImageJ. Data 
represent the mean ± SEM (n=3 independent experiments), grouped into different size bins and 
analysed by Unpaired two-tailed Student's t test. No statistic significant difference was found 










Figure 3.16 A higher concentration of Mn impairs mitochondrial function. N27 cells were 
plated in XFe96 tissue culture plate and treated with MnCl2 (250 µM) for 24 h. Mitochondrial 
respiration was assessed by measuring OCR using the XFe96 Extracellular Flux Analyzer. 
Sequential injections of oligomycin (to inhibit oxygen consumption mediated by ATP synthase), 
FCCP (an uncoupler to induce maximal OCR), Rotenone/Antimycin (to inhibit complex I and III, 
respectively). Effects of Mn on (A) Basal respiration, (B) ATP Production, (C) Spare Respiratory 
Capacity (SRC). Data represent mean ± SEM, n=3 independent experiments. Unpaired two-tailed 
Student's t test *: P < 0.05; **: P < 0.01 compared to control. The seahorse assay was performed 
and analysed by Dr Rebecca Z Fan. 
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3.2.6 Protective effect of Drp1 knockdown against Mn-induced neurotoxicity  
As inhibition of Drp1 had a protective role in alleviating impaired autophagy and protein 
aggregation caused by Mn, I sought to assess the effects of Drp1 knockdown on cell viability 
in cells exposed to Mn for 24 h. As previously described in Figure 3.1, increasing 
concentrations of Mn produced a gradual decline in cell viability, reaching significance at 250 
µM (~ 50 % death). At this concentration Drp1 knockdown significantly increased cell 
viability. At lower concentrations, although no significant difference was established, a trend 
is visible and clearly indicates that Drp1 inhibition increases cell viability (Figure 3.17).  
  
Figure 3.17 Inhibition of Drp1 via siRNA reduces cell death induced by Mn in DAergic cells. 
N27 cells were transfected with 10 nM rat Drp1 siRNA. 24 h post-transfection, cells were exposed 
to different concentrations of MnCl2 (62.5, 125 and 250 µM) for another 24 h. Cell viability was 
performed using the Calcein assay. Values are relative to the untreated control group and they are 
represented as mean ± SEM (n=4 independent experiments, with 6 wells per group, per experiment). 






Mn toxicity has been studied since it was first described by Couper in 1837 (Couper, 1837) and 
despite being recognised for impairing homeostasis and mitochondrial function (Sriram et al., 
2010), the primary mechanism of Mn toxicity still remains to be fully elucidated.  
Using sub-lethal doses of MnCl2 I demonstrate that Mn is able to acutely impair autophagy 
flux in multiple cell lines. Results in Figure 3.1 indicate that all the cell lines were affected by 
Mn exposure in a dose-dependent fashion and that high concentrations of Mn are detrimental 
and toxic for cells. Autophagic flux refers to the dynamic process of autophagy, which involves 
the inclusion of cargo within the autophagosome, the delivery of cargo to lysosomes and its 
subsequent degradation and release of the resulting macromolecules back into the cytosol 
(Klionsky et al., 2016). Results shown in Figure 3.3 and Figure 3.4 indicate that Mn exposure 
blocks autophagic flux in multiple cellular models. Mn impairs autophagy by promoting the 
accumulation of autophagosomes and reducing the number of autolysosomes in HeLa mRFP-
GFP-LC3 expressing cells. The dual colour analysis using HeLa mRFP-GFP-LC3 expressing 
cells enables a direct estimation of both autophagy induction and flux. Further, both LC3 and 
p62 levels were elevated in M17 cells following MnCl2 treatment.  
An observed increase in LC3 levels, following Mn exposure, has previously been attributed to 
an increase in autophagy (Gorojod et al., 2015, Tai et al., 2016) however, this discrepancy 
highlights a common experimental flaw when assessing autophagy. Many past studies have 
solely used LC3 expression as an indication of autophagy levels, however this alone is not 
sufficient to make an accurate conclusion regarding autophagic capacity. Whilst it is true that 
an increased level of LC3 correlates to an increased number of autophagosomes, this could be 
caused by a blockage in autophagic clearance downstream from autophagosome formation. It 
is therefore imperative to measure other aspects of the autophagy pathway in addition to LC3. 
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P62 is an adapter protein that binds to cargo within the autophagosome (Komatsu et al., 2007, 
Pankiv et al., 2007, Bjorkoy et al., 2009) and enables their clearance in the lysosome. Since 
p62 itself is removed during autophagy, its amount inversely correlates with autophagic 
activity. If the autophagy flux is normal then no changes in p62 levels should be observed, 
however if lysosomal fusion is inhibited p62 will accumulate in addition to LC3. By measuring 
both LC3 and p62 expression patterns, in addition to the use of the HeLa cell model as a further 
measure of autophagy, I can confidently state that autophagy flux is impaired following 
exposure to Mn. It has previously been stated that when autophagy is suppressed at any step 
after complete closure of the autophagosome, only autophagosomes accumulate, while 
autolysosomes decrease (Mizushima et al., 2010). Although it is not clear where in the 
autophagy pathway Mn exposure causes a blockade, it appears to suppress the downstream 
steps of the autophagy pathway (e.g. autophagosome – lysosome fusion) or organelle 
trafficking as shown in Figure 3.3 where Mn causes the accumulation of non-fused 
autophagosomes and reduces autolysosome formation. Of note, all figures with the HeLa 
mRFP-GFP-LC3 expressing cells display a GFP nuclear staining signal, which may be caused 
by an artefact of the stable cell line. This seems to correlate with the expression level of the 
reporter signal within each cell. 
Although the results obtained in HeLa and M17 are similar, as they both indicate an impairment 
in the late stage of the autophagy pathway induced by Mn treatment, the concentrations at 
which Mn cause a blockade are different. Given the viability data, in which HeLa cells exhibit 
less sensitivity to Mn compared to M17 cells, the lowest concentration of MnCl2 (62.5 µM) 
significantly impairs autophagy in HeLa but not in M17 cells, in which autophagy is blocked 
following 125 µM MnCl2 treatment. The discrepancies given by these results could be related 
to the following reasons: 1) The mRFP-GFP-LC3 tandem fluorescent probe is stably over-
expressed in HeLa cells and these cells may exhibit an exaggerated autophagy response to 
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stress. 2) The mRFP-GFP-LC3 assay is highly sensitive, as it is dependent on pH changes, and 
directly measures the number of autophagosome and autolysosomes, without any staining 
needed. 3) M17 cells were transiently transfected and then stained, providing less transfection 
efficiency and variable protein expression compared to HeLa cells and therefore display 
increased variability across experiments. 
Autophagy is a fundamental process for the cell as it recycles cellular constituents, eliminates 
damaged organelles and protein aggregates. Neurons rely highly on this process particularly as 
the brain ages (Son et al., 2012). Therefore, it is not surprising that mutations in genes 
regulating autophagy can cause different neurodegenerative diseases. In AD, Huntington's 
disease, amyotrophic lateral sclerosis and PD defects can occur at different stages of the 
autophagy pathway and therefore have diverse implications for pathogenesis and eventually 
therapy (Son et al., 2012). Results from this study support previous studies that show that Mn 
has a detrimental effect on autophagy (Wang et al., 2017, Chen et al., 2018a). It still remains 
elusive, however, whether Mn can directly or indirectly impact autophagy as Mn may affect 
other cellular processes linked to autophagy. Regardless of this it is becoming clear that Mn 
can interact with proteins directly implicated in different neurodegenerative disorders by 
promoting their pathology and possibly accelerating the progression of the disease. 
Previous studies have identified a link between autophagy dysfunction and accelerated α-
synuclein aggregation (Dehay et al., 2012b, Usenovic et al., 2012, Bae et al., 2015), and also 
showed that by promoting autophagy, α-synuclein accumulation could be attenuated (Spencer 
et al., 2009, Decressac et al., 2013, Hoffmann et al., 2019). To further study gene-environment 
interactions in PD pathology, N27 cells overexpressing α-synuclein were exposed to Mn for 
24 and 48 h. Results shown in Figure 3.11 suggest that 48 h of MnCl2 treatment is sufficient 
to exacerbate α-synuclein aggregation in vitro. No effects were exhibited after 24 h of α-
synuclein induction via PonA treatment. Further, when autophagy was assessed in N27 
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overexpressing cells treated with MnCl2 for 24 h (Figure 3.12), an exacerbated effect on the 
autophagy pathway was observed compared to cells overexpressing α-synuclein or exposed to 
Mn alone. These results may indicate that an increase in α-synuclein aggregation is a 
consequence of autophagy blockade induced by Mn exposure, as no significant changes in the 
number of α-synuclein aggregates was observed following 24 h of MnCl2 treatment. In 
addition, the use of an autophagy inhibitor, CQ, supports the idea that interfering with the 
autophagy pathway might regulate α-synuclein aggregation. In fact, the number of α-synuclein 
positive aggregates caused by CQ exposure was higher compared to cells induced by PonA 
treatment alone or in combination with Mn at 24 and 48 h. Of note, the newly developed 
method for the detection of α-synuclein oligomers, through life-time imaging (Roberts et al., 
2015), might have been a valuable tool to monitor the progression and the effect of α-synuclein 
accumulation.  
Prior studies have shown that Mn-treated cells displayed increased α-synuclein aggregation 
(Uversky et al., 2001, Cai et al., 2010, Li et al., 2010). In addition, Harischandra et al. (2019) 
showed that Mn exposure could promote misfolded α-synuclein secretion in exosomal vesicles, 
between neurons and microglia, subsequently inducing proinflammatory and 
neurodegenerative responses, in both cells and mice. These results could indicate a possible 
mechanism that involves the exosome-mediated, cell-to-cell transmission of α-synuclein 
following Mn exposure. To my knowledge, however, this is the first time that the relationship 
between Mn and α-synuclein was studied in relation to autophagy. Results from the current 
study suggest that Mn could be involved in PD pathogenesis not only by exerting its previously 
reported toxic effects, but additionally by promoting α-synuclein aggregation and autophagy 
dysfunction. 
To investigate the possibility that Mn exposure could impair autophagy through mitochondrial 
dysfunction, mitochondrial respiration, membrane potential and morphology were assessed in 
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Mn-treated cells using the same concentration that caused impairment in the autophagy 
pathway and promoted the induction of α-synuclein aggregation. Surprisingly, neither 
mitochondrial function (Figure 3.13 and 3.14) nor mitochondrial morphology (Figure 3.15) 
were altered following MnCl2 treatment, despite a significant inhibitory effect on autophagy 
flux. This possibly indicates that the autophagy pathway is a primary target of Mn 
neurotoxicity, prior to any potential alterations in mitochondrial function. Results from the 
current study are not consistent with prior studies, the majority of which show that Mn can 
induce mitochondrial impairment. Most of the studies conducted on mitochondrial dysfunction 
caused by Mn were performed in primary astrocytes/astrocyte-like cells (Milatovic et al., 2007, 
Gonzalez et al., 2008, Yin et al., 2008, Alaimo et al., 2013, Alaimo et al., 2014). These cells 
are known for having much greater affinity to Mn compared to neurons (Aschner et al., 1992), 
therefore it is not surprising that the effects of Mn displayed in astrocytes are more elevated in 
comparisons to neuronal cells. Additionally, the sub-lethal concentrations of Mn used in the 
current study were chosen following cell viability assay, whilst previous studies used 
concentrations of Mn that caused over 40% cell death (Gonzalez et al., 2008, Yin et al., 2008, 
Yoon et al., 2011, Alaimo et al., 2014, Sarkar et al., 2018). Other studies associated Mn 
neurotoxicity with mitochondrial dysfunction at longer timepoints than the current study 
(Malecki, 2001, Rao and Norenberg, 2004). The methods used to assess mitochondrial function 
and morphology were based on work previously published by our lab (Cui et al., 2010, Rappold 
et al., 2014, Fan et al., 2019) and collaborators (Chen et al., 2015a). Despite this, assessing 
mitochondrial morphology, using fixed samples, has its limitations: 1) Mitochondrial function 
and morphology are not always linked (Knott et al., 2008, Chen et al., 2005). Thus, to directly 
evaluate mitochondrial function, I assessed oxidative phosphorylation (Figure 3.13) and 
membrane potential (Figure 3.14) using live cells. At a non-cytotoxic concentration, I did not 
detect functional alterations in mitochondria. 2) Mitochondrial morphology does not measure 
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other dynamic features such as movement and the equilibrium of fission and fusion. Live cell 
imaging could be performed either by tagging mitochondrial proteins with fluorescent proteins 
or by adding specific mitochondrial targeting sequences to fluorescent proteins (Okamoto et 
al., 2001). Of note, mitochondrial morphology performed in the current study relied on a single 
threshold value to be applied to all images for analysis. This could be limiting as the threshold 
value used not always be accurate for all images and this could potentially cause the loss of 
useful information. Positive controls for in vitro experiments should have been used as well. 
In particular, it would have been important to have N27 cells with PonA (expressed α-
synuclein) to display mitochondrial fragmentation, as previously shown by Fan et al. (2019). 
Additionally, only mitochondrial length was assessed in this thesis, whilst degree of branching 
or form factor could have also apported additional data to support the results. 
Interestingly, when a greater concentration of MnCl2 (250 µM) was used to assess any changes 
in mitochondrial function, at 24 h, a substantial drop in mitochondrial respiration compared to 
untreated cells was observed (Figure 3.16). This concentration of Mn caused approximately 
40% cell death at 24 h. Effects on mitochondrial function at this high concentration are 
therefore likely to be caused by the induction of cell death pathways and are an indirect 
consequence of Mn-induced cell death. This may partly explain conflicting results from prior 
studies which used higher concentrations of Mn to investigate changes in mitochondrial 
dynamics (Alaimo et al., 2013, Alaimo et al., 2014) or in mitochondrial function (Milatovic et 
al., 2007, Sarkar et al., 2018, Gonzalez et al., 2008). The results obtained in the current study, 
however, are limited to a single time-point (24 h). It is possible that 125 µM MnCl2 may induce 
mitochondrial impairment following 48 or 72 h of exposure. In addition, given the ability of α-
synuclein to impair mitochondria (Rocha et al., 2018, Vicario et al., 2018, Mullin and Schapira, 
2013) and interact with Mn (Peres et al., 2016a), it would be interesting to investigate whether 
Mn could add to the pathologic effects of α-synuclein on mitochondria. 
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Despite the lack of mitochondrial dysfunction, pharmacological and genetic inhibition of Drp1 
was found to be protective against Mn-induced changes in autophagy and α-synuclein 
aggregation. Results in the present study show that mdivi-1 alleviated Mn-induced block in 
autophagy flux evidenced by a reduction in autophagosomes and increase in autolysosomes 
(Figure 3.9). Interestingly, mdivi-1 treatment alone was sufficient to improve autophagic 
capacity of the cell. Mdivi-1 alone promoted an increase in the number of autophagosomes 
whilst the number of autolysosomes remained comparable to control cells. When combined 
with Mn treatment, mdivi-1 restored the numbers of autolysosomes to a level that was not 
statistically different to untreated cells, while maintaining a high number of autophagosomes. 
These results suggest that mdivi-1 may target multiple locations of the autophagy pathway as 
it was able to promote autophagosome formation, indicative of autophagy induction, and 
restore autolysosomal impairment caused by Mn. 
Recently, the ability of mdivi-1 to inhibit Drp1 and impact mitochondrial fission was 
challenged by Bordt et al. (2017). Their evidence showed that mdivi-1 did not acutely elongate 
mitochondria (indicative of fission inhibition) in both primary neurons and COS-7 cells. 
Additionally, mdivi-1 impaired complex I through a Drp1-dependent mechanism at high 
concentrations. The use of high doses of mdivi-1 (≥ 25 µM) used in the latter study may have 
had an off-target effect on cells, as these same results have not been verified at lower doses. 
Given the potential concerns raised by this study and the possible off-target effects of mdivi-1, 
I also inhibited Drp1 via siRNA knockdown to corroborate the results obtained with mdivi-1. 
Immunostaining (Figure 3.7) and WB (Figure 3.8) results showed that Drp1 inhibition is 
protective against Mn effects on autophagy as evidenced by the restored number of both 
autophagosomes and autolysosome in HeLa cells and the levels of LC3 and p62 in M17 cells. 
Whilst assessing interactions between Mn and α-synuclein in N27 overexpressing cells, 
inhibition of Drp1 ameliorated the autophagic blockade caused by cells overexpressing α-
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synuclein alone or co-treated with Mn. In addition, Drp1 inhibition significantly reduced the 
number of protein aggregates in cells exposed to α-synuclein and Mn concurrently or 
independently. Taken together, these data suggest a new role for Drp1 in the modulation of 
autophagy, which warrants further study. Additionally, Drp1 knockdown alone did not have an 
effect on the number of autophagosomes unlike mdivi-1. These results suggest an additional 
mechanism of action for mdivi-1. To my knowledge this is the first time that inhibition of Drp1, 
via small molecule and gene silencing, is protective against Mn-induced toxicity as well as 
combined Mn and α-synuclein toxicity in vitro.  
When assessing the effects on cell viability of Drp1 knockdown in Mn-treated cells results 
showed a trend of improvement in cell survival, although no significance was demonstrated 
when comparing to untreated cells (Figure 3.17). The exact mechanisms whereby Drp1 
inhibition may produce these effects is unknown and warrants further study, however it is 
possible that an increase in proteostasis mechanisms (e.g. autophagy, which is shown in this 
study) may influence the cell viability and cell cycle. However, these results support previous 
studies that have suggested that inhibition of Drp1 confers protection against cell death. Using 
a selective peptide inhibitor of Drp1 (P110), Qi et al. (2013) showed increased neuronal cell 
viability, with reduced apoptosis and autophagic cell death in a PD cell culture model, 
suggesting that Drp1 inhibitors might be useful for the treatment of diseases. 
Understanding, specifically, where Mn blocks autophagy, might help us understand why Drp1 
inhibition can rescue the subsequent autophagy blockade. Although mitochondria and 
autophagy are separate pathways that respond differently to changes in the cellular 
environment such as energy, nutrient availability and stress, there is existing evidence on a 
reciprocal crosstalk between them. This interplay seems to be evolutionarily conserved and 
defects in one of these elements could simultaneously impair the other, resulting in increased 
risk of developing various human diseases, including PD. Autophagy is critical for cellular 
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homeostasis, thus it is not surprising that its loss or dysregulation indirectly compromises 
mitochondrial integrity.  
There is increasing evidence that link mitochondrial dynamics to autophagy. Purnell and Fox 
(2013) established that ATG7 knockdown or chemical inhibition of autophagy (using CQ, 
bafilomycin, E64D and pepstatin) increased Drp1 levels, whilst autophagy induction reduced 
Drp1 levels. These results suggest that Drp1 levels are quite sensitive to autophagy induction. 
A very recent study discovered the formation of stable mitochondria–lysosome membrane 
contact sites (Wong et al., 2018). They propose that contact formation is stimulated by the 
active lysosomal GTP-bound Rab7, whilst contact untethering is mediated by the 
mitochondrial TBC1D15 protein (a Rab7 GTPase-activating protein), recruited to the 
mitochondria by FIS1. Lysosomal Rab7 hydrolysis is therefore induced and results in the 
disconnection of GDP-bound Rab7 from the membrane. Wong et al. (2018) also investigated 
whether mitochondria–lysosome contacts could regulate mitochondrial dynamics. Time-lapse 
images displayed lysosomes contacting mitochondria at the site of mitochondrial division 
before fission in cells expressing LAMP1–mGFP (lysosomes) and mApple–TOM20 
(mitochondria). In addition, mitochondrial TBC1D15, recruited by FIS1, promoted Rab7 GTP 
hydrolysis at mitochondria–lysosome contacts regulating both lysosomal morphology and 
mitochondrial fission. Additionally, Itoh et al. (2018) identified a previously uncharacterized 
isoform of Drp1, termed Drp1ABCD (as it contains four alternative exons A, B, C, D), highly 
expressed in the brain. Drp1ABCD appeared to be located, in addition to the mitochondria, at 
lysosomes (co-localisation with LAMP1), late endosomes (co-localisation with Rab7) and the 
plasma membrane (co-localisation with CAAX-mCherry). Interestingly, immunostaining with 
LAMP1, Drp1 and TOM20 antibodies revealed that Drp1ABCD was localised at interfaces 
between mitochondria and lysosomes/late endosomes. Additionally, Drp1ABCD location 
appeared to be dependent on the presence of both exons A and B in the GTPase domain (Itoh 
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et al., 2018). These results further suggest an interaction between Drp1 and the endosomal-
lysosomal system. Although not directly linked to the autophagy pathway, Koseoglu et al. 
(2013) associated Drp1 with exocytosis, further strengthening the idea of Drp1 being able to 
interact with circular vesicle structures. Results from the current and previous studies suggest 
that Drp1 may be having a direct role in autophagy, by affecting lysosomal function or 
trafficking, rather than solely in mitochondrial dynamics; to confirm this, however, further in-
depth studies are required.  
In conclusion, this study provides a detailed description of the effects of Mn on autophagy flux 
in neuronal and non-neuronal cells and begins to explore the synergistic interaction between 
Mn and α-synuclein in the context of PD. In addition, results show that blocking Drp1 function 
may confer protection against the pathological effects caused by Mn, highlighting its 
importance in regulating the autophagy pathway and suggesting a novel mechanism involving 
Drp1 and autophagy. Given these results, it is important to note that Mn and Drp1 might not 
necessarily have the same target but converge at the autophagy pathway, this interaction 
however warrants further investigation. However, this study not only shows that Mn causes 
autophagy impairment in multiple cell lines but also, and more importantly, that this occurs 
without any mitochondrial complications. In fact, no changes in mitochondrial function and 
morphology were displayed at the concentration and time point used to block autophagy. This 
study is the first, to my knowledge, to examine the effects of Mn exposure on mitochondrial 
function, autophagy flux and α-synuclein aggregation concurrently. I demonstrate that the 
autophagy pathway is primarily affected, followed by α-synuclein aggregation, whilst 
mitochondrial function remains unaffected. Despite this, the inhibition of Drp1 improved the 
effects of Mn on these pathways. The discovery that the pathogenic and protective mechanisms 
of Mn and Drp1 inhibition, respectively, intersect at the autophagic pathway is novel and 
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4.1 Introduction  
In vitro studies have been an important resource for the elucidation of Mn mechanisms of 
action: accumulation in the mitochondria, disruption of calcium homeostasis (Gavin et al., 
1999), ROS formation (Zhang et al., 2004) and inhibition of ATP production (Gunter et al., 
2006). More recently, studies performed in rodents have confirmed the above in vitro results 
and have contributed to new discoveries. Cordova et al. (2012) investigated altered cellular 
mechanisms in the striatum of developing rats (postnatal day 8 to 12) intraperitoneally injected 
with Mn. Results showed that acute exposure to Mn causes impairments of complex I and II of 
the ETC, increased ROS and caspase activity. Intracerebral injection of Mn in the striatum 
induces mitochondrial swelling and dilatation of the ER in TH-positive neurons (Mo et al., 
2016). MitoPark mice orally exposed to Mn display an accelerated disease progression and 
worsening of olfactory function compared to littermate controls. Mn treatment additionally 
causes striatal DA depletion, TH neuron loss, mitochondrial dysfunction, inflammatory 
response and protein aggregation (Langley et al., 2018). The above evidence indicates that 
acute Mn exposure induces mitochondrial impairment.  
On the other hand, not much is known about the effects of Mn on autophagy function in vivo 
and what is available still remains controversial. Zhang et al. (2013) examined the short (4–
12 h) and long-term (1–28 days) effects of Mn on DAergic neurons and autophagy following 
a single intrastriatal injection of Mn in rats. Their TEM results revealed an increased number 
of autophagosomes and swollen mitochondria, along with dysfunctional lysosomes containing 
dense particulate materials. WB results exhibited increased levels of Beclin 1 protein 
expression and LC3-II following short exposure to Mn. When assessing the long-term effects 
of Mn injection, results showed a significant and time-dependent (1, 7, 14, and 28 days) 
decrease of both Beclin 1 and LC3-II levels  (Zhang et al., 2013). This group suggested an 
induction of autophagy following acute exposure and inhibition of autophagy after long-term 
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exposure to Mn. Autophagy dysfunction was also observed in the SN of mice injected 
intraperitoneally with MnCl2, for 2 weeks (Chen et al., 2018a). On the contrary, an induction 
in autophagy was detected in mice injected intraperitoneally with MnCl2 5 times a week, for 4 
weeks (Liu et al., 2018). In this study, MnCl2 exposure caused a-synuclein oligomerisation, 
accompanied by increased formation of autophagic vacuoles. Results showed that Mn exposure 
increased Beclin-1 protein expression, increased the ratio of LC3-II to LC3-I, with a significant 
decrease in p62 expression in Mn-treated mice (Liu et al., 2018). 
Results from the previous chapter have elucidated a new potential role for Mn neurotoxicity, 
in which Mn seems to first impair the autophagy pathway and then promote protein 
aggregation. Inhibition of Drp1, using both pharmacological and genetic interventions, 
improved the autophagy blockade and α-synuclein aggregation caused by the metal. The aim 
of this chapter is to investigate both mitochondrial and autophagy changes in vivo following 
acute Mn exposure in CAG-RFP-EGFP-LC3, Drp1+/− and WT mice. As Mn has been 
previously linked to idiopathic PD, the current work mainly focused on DAergic neurons and 
Mn ability to affect them. Inhibition of Drp1 represents a therapeutic strategy that has been 
demonstrated to be effective in multiple models of neurodegeneration. In the current chapter I 
aim to explore the potential effects of manipulating Drp1 in TH neurons in vivo and restore 
autophagy function. To this end, I assess whether global heterozygous Drp1 knock-out mice 
(Wakabayashi et al., 2009) and LC3 mice transduced with Drp1K38A, a mutant of the Drp1 gene 
with dominant negative abilities (Smirnova et al., 2001, Zhu et al., 2004), can attenuate Mn-





4.2.1 Acute effects of Mn on autophagy flux in CAG-RFP-EGFP-LC3 mice 
Many studies have attempted to address the effects of Mn exposure on cellular mechanisms in 
rodents. Despite the absence of a ‘clinically representable’ model for Mn toxicity I investigated 
the effects of MnCl2 treatment on autophagy and mitochondria in both TH- and GAD67- 
positive neurons following acute exposure to Mn as previously described (Dodd et al., 2005, 
Khalid et al., 2011). 
To assess the effects of Mn exposure on autophagy flux, I used a reporter mouse that harboured 
the same characteristics as the stably expressing mRFP-GFP-LC3 HeLa cells (see Figure 3.2). 
These autophagy reporter mice were generated by Li et al. (2014b) to ubiquitously express the 
tandem RFP-EGFP-LC3 under the CAG promoter. They were maintained by breeding with 
C57BL/6 inbred mice to establish a colony of heterozygous mice, which were viable and fertile 
(Figure 4.1 A). Three month old CAG-RFP-EGFP-LC3 transgenic mice (hereby LC3 mice) 
were given to up to three subcutaneous injections of 50 mg/kg of MnCl2 every three days (0, 
3, 6) and were sacrificed 24 h after each injection (day 1, 4 and 7). Prior each injection mice 
were monitored for weight loss, however no changes in bodyweight of either control or treated 
mice were observed (data not shown). 
This study focused on the effects of Mn associated with PD, therefore changes in the autophagy 
pathway were assessed in TH-positive neurons of the SNpc. Assessment of autophagy was 
carried out blindly. Results showed that, only after three subcutaneous injections of MnCl2, 
autophagy flux was significantly impaired in TH-positive neurons. Compared to the vehicle 
group (autophagosomes, 2.72 ± 0.23; autolysosomes, 3.87 ± 0.30), Mn-exposed animals 
exhibited a greater amount of autophagosomes (7.34 ± 0.46) and a reduced number of 
autolysosomes (1.48 ± 0.48) (Figure 4.1 B). Single (autophagosomes, 6.07 ± 0.83; 
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autolysosomes, 2.36 ± 0.14) or two (autophagosomes, 4.99 ± 0.76; autolysosomes, 2.28 ± 0.78) 
injections of Mn had an effect on the autophagy pathway as autophagosomes increased, whilst 
autolysosomes decreased (images not shown), as evidenced by the graph. These results, 
however, were not significantly different to vehicle levels, therefore the regimen of three 
subcutaneous injections of MnCl2 was applied to all subsequent experiments.  
Many studies have confirmed that Mn primarily accumulates in the GP, a region that is rich in 
GABA projections. GABA is synthesised by two glutamic acid decarboxylases: GAD67 and 
GAD65, respectively encoded by the Gad1 and Gad2 genes (Pinal and Tobin, 1998). GAD67 
is responsible for over 90% of basal GABA synthesis (Fenalti et al., 2007) and was therefore 
used as a marker for GABAergic neurons. When autophagy flux was investigated in GAD67-
positive neurons of the GP the results were consistent with those obtained in TH-positive 
neurons. Mn treatment caused an increase in the number and size of autophagosomes (12.45 ± 
0.78) and a reduction in the number of autolysosomes (0.60 ± 0.28), compared to vehicle mice 
autophagosomes, 6.20 ± 0.18; autolysosomes, 1.71 ± 0.09). Again, results were indicative of 






Figure 4.1 Mn blocks autophagy in TH-positive neurons of LC3 mice. (A) Gel electrophoresis 
of PCR products from DNA samples collected from LC3 pups and WT littermates prior to weaning. 
The WT allele produces a 324 bp product whilst the mutant allele also produces a 208 bp product. 
(B) Animals were injected with either MnCl2 or H2O (50mg/kg) every 3 days (0, 3, 6) for 3 doses 
and sacrificed 24 h after each injection (day 1, 4, 7). 30 µm nigral sections were stained with a TH 
antibody (blue). The red puncta (arrows in the upper panel) indicate functional autophagy as the 
green signal is quenched by the low pH of lysosomes, which fuse with autophagosomes and form 
autolysosomes. The yellow puncta (arrows in the Mn X3 panel) represent accumulated 
autophagosomes due to the colocalization of RFP and GFP signals, indicative of impaired 
autophagy. The numbers of autophagosomes (green vesicles) and autolysosomes (red vesicles 
minus green vesicles) were quantified in at least 30 TH-positive neurons, from multiple brain 
sections per condition. Data represent mean ± SEM (n=3 animals per group, 1 female and 2 males). 
One Way Anova with Tukey’s post-hoc analysis * P<0.05 ** P<0.01 compared to the vehicle group. 







Figure 4.2 Mn blocks autophagy in GABAergic neurons of LC3 mice. LC3 mice were injected 
with either MnCl2 or H2O (50mg/kg) every 3 days for 3 doses and sacrificed on day 7. 30 µm striatal 
sections were stained with GAD67 antibody (blue). The numbers of autophagosomes (green 
vesicles) and autolysosomes (red vesicles minus green vesicles) were quantified in at least 25 
GAD67-positive neurons from multiple brain sections, per condition. Data represent mean ± SEM 
(n=3 animals per group, 1 female and 2 males). Unpaired two-tailed Student's t test * P<0.05 ** 




4.2.2 Acute exposure to Mn does not impact mitochondrial morphology  
In vitro results suggested that Mn targeted the autophagy pathways prior to altering 
mitochondrial function and morphology; it was imperative to confirm this in an in vivo model. 
To do so, WT C57BL/6 mice were exposed to Mn and then mitochondrial morphology was 
investigated in both TH- and GAD67-positive neurons. The average length of mitochondria in 
each neuron was automatically determined using ImageJ as previously described (Chen et al., 
2015a). The skeletonised mitochondria are representative of actual mitochondrial images. TH-
positive neurons (Figure 4.3 A) exhibited an intact mitochondrial network with an 
unfragmented morphology in both Mn- and vehicle-treated groups. In addition, no statistical 
difference was observed as evidenced by the similar average mitochondria length in Mn (12.75 
± 0.57) and vehicle (10.85 ± 0.56) groups. GAD67-positve neurons appeared normal, with a 
slight, although not significant, reduction in mitochondrial length in the Mn-exposed (15.60 ± 
1.11) group compared to vehicle (20.07 ± 1.73), however, the mitochondrial network appeared 
intact (Figure 4.3 B). When performing a power analysis on the G*Power Software using 
differences between groups and standard deviations as reported above, results suggest a n=6 
may produce statistical significance. 
Taken together, these results indicate that sub-acute exposure of Mn impairs autophagy flux 










Figure 4.3 Sub-acute Mn expose does not alter mitochondrial morphology in vivo. WT mice 
were injected with either MnCl2 or H2O (50mg/kg) every 3 days for 3 doses and scarified on the 
day 7. 30 µm nigral and striatal sections were stained for TOM20 to assess mitochondrial 
morphology in (A) TH- and (B) GAD67-positive neurons (red), respectively. (C) Mitochondrial 
length was quantified in at least 20 TH- and GAD67-positive neurons from multiple brain sections 
per condition, using ImageJ. Data represent mean ± SEM (n=3 animals per group, 3 males). 
Unpaired two-tailed Student's t test found no statistical difference between vehicle and Mn-treated 




4.2.3 Investigating the effects of inhibiting Drp1 to restore Mn-induced 
changes on autophagy flux in TH-positive  neurons 
Experiments performed in vitro showed that by blocking Drp1 the autophagy impairment 
caused by Mn treatment could be improved. To this end, I utilised a Drp1 knockout mouse 
model to investigate whether changes in mitochondrial dynamics could restore autophagy 
function. Drp1+/− heterozygous mice were bred with WT C57BL/6 mice to establish a colony 
of heterozygous mice (Figure 4.4 A). Drp1+/− mice express a partially reduced level of Drp1 
and are viable, in contrast to Drp1−/− homozygous mice that die during embryonic development 
(Wakabayashi et al., 2009). Similarly to their Drp1+/+ littermates (hereby WT), Drp1+/− mice 
are fertile, normal in size, and did not display any physical or behavioural abnormalities. Prior 
to exposing both WT and Drp1+/− mice to MnCl2, as for previous experiments, Drp1
+/− mice 
were characterised to accurately establish and quantify Drp1 levels via immunostaining, WB 
and qPCR for gene expression. A reduction of ~ 40% Drp1 protein levels was obtained via WB 
(Figure 4.4 B), whilst qPCR results displayed over 60% reduced Drp1 gene expression levels 
(Figure 4.4 D) in Drp1+/− mice compared to littermates. Figure 4.4 C shows a representative 





Figure 4.4 Characterisation of the global Drp1 heterozygous mouse strain (Drp1+/−). (A) Gel 
electrophoresis of PCR products from DNA samples collected from Drp1+/− pups and WT 
littermates prior to weaning. The WT allele produces a 268 bp product, whilst the knock-out allele 
also produces a 312 bp product. (B) Drp1 protein expression in WT and Drp1+/− mice was quantified 
using WB. Whole brains were dissected and one hemisphere was homogenised in RIPA buffer. 15 
µg of protein was loaded on a 10% Bis-Tris gel, transferred onto a PVDF membrane and stained for 
both Drp1 and the loading control -actin; each lane of the gel represents one animal. Blots were 
visualized on an Odysey CLx machine and optical density measured using Li-Cor Image Studio 
software. Unpaired two-tailed Student's t test, **P < 0.01 compared to WT mice. Data are shown as 
mean ± SEM (n=3 separate animals). (C) Representative image of 30 µm SNpc brain sections 
stained with Drp1 (green) and TH (red) antibodies (n=1). Scale bar 10 µm. (D) The other hemisphere 
was homogenised in Trizol reagent and RNA isolated by phase separation. 1 µg of RNA was reverse 
transcribed, and relative gene expression of Drp1 measured by qPCR, using TaqMan based 
detection chemistry, with GAPDH as a reference gene. Comparisons were made using Unpaired 
two-tailed Student's t test, **P < 0.01 compared to WT mice. Data are shown as mean ± SEM (n=3 




Following Drp1+/− mice characterisation, 12 animals in total, 3 per group (Drp1+/− or WT) were 
subcutaneously injected with either 50mg/kg of vehicle (H2O) or MnCl2 every 72 h for 3 doses 
and sacrificed on day 7. Blindly, autophagy was assessed in TH-positive neurons using LC3 
and p62 antibodies and the number of puncta were quantified using ImageJ, as previously 
described. LC3 and p62 staining appeared diffuse in the vehicle groups of both WT (LC3, 
112.32 ± 4.23; p62, 115.95 ± 5.14) and Drp1+/− (LC3 100.51 ± 0.52; p62, 106.90 ± 4.63) mice. 
The punctate pattern of the Mn-exposed group appeared to be more accumulated with clearly 
increased numbers of both LC3 (133.70 ± 5.35) and p62 (211.63 ± 30.17) puncta, suggesting 
a blockade in autophagy, and therefore confirming the results obtained in the LC3 mice.  
In the Drp1+/− Mn-exposed mice, however, no significant changes were identified in the 
autophagy markers (LC3, 144.38 ± 4.79; p62, 212.22 ±18.01) when comparing to the Mn-
treated WT group (Figure 4.5). These results suggest that a reduction of ~ 40% of Drp1 protein 
is not sufficient to clear the accumulated LC3 and p62 vesicles caused by Mn treatment and 












Figure 4.5 Heterozygous KO of Drp1 does not impact Mn-dependent changes in autophagy 
flux. WT and Drp1+/− mice were injected with either MnCl2 or H2O (50mg/kg) every 3 days for 3 
doses and scarified on day 7. Nigral sections (30 µm) were stained for (A) LC3 and (B) p62 to 
assess autophagy flux in TH-positive neurons (red). LC3 and p62 puncta were blindly quantified in 
at least 20 neurons from multiple brain sections per condition, using ImageJ. Data represent mean 
± SEM (n=3 animals per group). One Way Anova with Tukey’s post-hoc analysis: * P<0.05 ** 





The global Drp1+/− mice did not confer protection against the effects of Mn treatment on the 
autophagy pathway. Thus, I sought to assess whether using recombinant adeno-associated virus 
serotype 2/9 (rAAV2/9) vectors, to manipulate Drp1 function in SNpc neurons, could improve 
autophagy blockade caused by Mn treatment in LC3 mice.  
To inhibit Drp1 function, rAAV2/9 was used to deliver Drp1K38A (rAAV2/9-Drp1K38A). K38A 
is a mutant form of the Drp1 gene with well-characterised dominant negative effects (Smirnova 
et al., 2001) and my laboratory has used this mutant successfully in vitro (Cui et al., 2010) and 
in vivo (Rappold et al., 2014) studies. The decision to using rAAV2/9 was based on several 
considerations: 1) AAV9 was proven to have high neuronal transduction rates in TH-
positive neurons of the SNpc under control of the human synapsin (hSYN1) promoter to drive 
GFP expression (McLean et al., 2014, Bido et al., 2017). 2) rAAV2/9 displayed a high 
transduction efficiency in the brain (Chakrabarty et al., 2013). 3) Homozygous germline 
deletion of the Drp1 gene in mice is embryonically lethal, precluding the use of a complete 
knockout mouse. 
The GTP-hydrolysis defective mutant K38A consists of a lysine-to-alanine mutation in one 
GTP-binding element of Drp1. Although K38A is deficient in hydrolysis, it is still capable of 
binding GTP and can stimulate Drp1 to bind and tubulate membranes. In addition, the 
expression of this mutant can induce the formation of large cytoplasmic structures (Pitts et al., 
1999, Yoon et al., 2001). To monitor the expression of the Drp1-K38A protein, the rAAV-
Drp1K38A was engineered to express the HA (Human influenza hemagglutinin) tag, which 
facilitates its detection and to harbour a neuronal promoter (SYN1) for neuronal selectivity. A 
total of 8 mice were stereotactically injected with rAAV2-Drp1K38A or H2O (sham surgery) 
delivered to the SNpc of the right or left hemisphere, respectively (AP: -3.1, ML: ± 1.3, DV: -
4.2, relative to the Bregma).  
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Six weeks after the injection (to allow sufficient time for protein expression in the DAergic 
neurons), 4 mice were subcutaneously injected with H2O (vehicle) and 4 mice with MnCl2 
(Figure 4.6). The number of autophagosomes and autolysosomes was assessed, blindly, in TH-
positive neurons of both hemispheres, to confirm that the delivery of the construct was 
successful. The surgery was successful in most animals as evidenced by clear K38A-positive 
inclusions. However, the expression of rAAV2/9-Drp1K38A in the SNpc of two of the Mn-
exposed mice, was not specific to TH neurons, therefore the ipsilateral sections of these mice 
could not be used. This made statistical analysis impossible when comparing vehicle (n=4) and 
Mn-treated (n=2) animals. Transduction efficiency in nigral DA neurons was calculated by 
quantifying TH-positive neurons transduced with Drp1-K38A (HA-tagged). The transduction 




Figure 4.6 Schematic illustration of stereotactic infusion of rAAV-Drp1K38A and experimental 
design. Six weeks old LC3 mice were unilaterally injected in the SNpc (right hemisphere) with 
rAAV2/9-Drp1K38A (1 x 109 U/µL). A sham surgery using 1 µL of sterile H2O was performed on 
the left hemisphere as a control. Six weeks post-surgery mice were injected with 50 mg/kg MnCl2 
or H2O every 72 h for 3 doses and sacrificed 24 h after the last injection (day 7). 
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Overall, results confirmed a blockade in autophagy in Mn-treated sections, as evidence by an 
increase in the number of autophagosomes (12.96 ± 1.03) and a reduction in the number of 
autolysosomes (0.55 ± 0.21) compared to vehicle-treated (autophagosomes, 7.55 ± 0.79; 
autolysosomes, 2.9 ± 0.3) mice. Inhibition of Drp1 using rAAV2/9-Drp1K38A displayed similar 
numbers of autophagosomes (8.02 ± 0.65) and autolysosomes (3.56 ± 0.73) compared to the 
vehicle. Interestingly, preliminary results show that the addition of the dominant negative 
Drp1K38A might reduce the number of autophagosomes (9.71 ± 0.08) and increase 
autolysosomes (2.99 ± 0.59) in Mn-treated mice. Despite the lack of enough Mn + Drp1K38A 
mice necessary for statistical analysis, a trend is visible and suggests that the use of a dominant 
negative form of Drp1, which blocks Drp1 physiological function more than what is achieved 
with the Drp1+/− mice, might be protective against Mn-induced changes in the autophagy flux 












Figure 4.7 Drp1-K38A might improve autophagy impairment in TH-positive neurons. (A) The 
number of autophagosomes (green vesicles) and autolysosomes (red vesicles minus green vesicles) 
were quantified in 25-30 TH-positive neurons (blue staining) per condition. The expression of 
Drp1K38A was confirmed by staining with a HA antibody (red, 633 channel). Arrows indicate HA-
positive aggregates caused by K38A. The merge image shows autophagy in TH-positive neurons. 
(B) Data represent mean ± SEM (2 males and 2 females in the Mn-treated group; 1 male and 3 
females in the vehicle group). One Way Anova with Tukey’s post-hoc analysis: * P<0.05 ** P<0.01 
compared to the vehicle group (no statistics was performed for the Mn-treated K38A group as only 
n=2 due to lack of expression of Drp1K38A in TH neurons). Scale bar 10 µm. Stereotactic surgery 




Previous in vivo studies have shown controversial results in relation to Mn effects on the 
autophagy pathway. In particular, some have shown autophagy induction (Zhang et al., 2013, 
Liu et al., 2018) whilst others reported autophagy blockade following Mn exposure (Zhang et 
al., 2013, Chen et al., 2018a). These differences could be related to differences in the duration 
of exposure and/or routes of administration and the methods of assessments.  
I used a newly generated strain of autophagy reporter mice that ubiquitously expresses (RFP)-
EGFP-LC3 fusion protein under the CAG promoter (Li et al., 2014b) to assess the effects of 
autophagy changes following Mn exposure. These mice were created to advance the 
understanding of the dynamics of the autophagy pathway under stress conditions. 
Autophagosomes can be distinguished from autolysosomes according to the differential pH 
sensitivity of RFP (pKa 4.5), stable in acidic pH, and EGFP (pKa 5.9), which is quenched in 
the acidic lysosomal environment following fusion of autophagosomes with lysosomes 
(Kimura et al., 2007, Zhou et al., 2012, Lin et al., 2014). These mice have been previously used 
to investigate the dynamics of renal epithelial cell autophagy, by measuring autophagy flux 
under starvation and ischemic injury (Li et al., 2014b). This is, the first attempt, to the best of 
my knowledge, at measuring autophagy changes in neurons, following Mn exposure in this 
mouse model. 
The major concerns for a representative model of acute Mn toxicity were the choice of the 
adequate dose that could promote its accumulation in the basal ganglia, the administration route 
and the reduction of systemic side effects. I opted for multiple subcutaneous injections of 
MnCl2 (50 mg/kg), previously described by Dodd et al. (2005), which caused a significant 
increase in basal ganglia Mn concentration, accompanied by a significant but not severe 
decrease in locomotor behaviour (Dodd et al., 2005).  
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In the current study, three injections of 50 mg/kg MnCl2 over 7 days induced changes in 
autophagy flux, with a reduction in the number of autolysosomes and a substantial 
accumulation of autophagosomes in TH-positive neurons, indicative of dysfunctional 
autophagy. No significant changes in autophagy flux were detected following one or two 
injections of Mn, suggesting that, although Mn can reach the brain and start to accumulate after 
a single or two injections (Dodd et al., 2005), measurable toxic effects on the autophagy 
pathway do not manifest until the third dose. Overall these results suggest that acute exposure 
to MnCl2 causes a late suppression (autophagosome-lysosome fusion) of the autophagy 
pathway as shown in Figure 4.1.  
It is difficult to compare my data to what is available in the literature as the evidence on in vivo 
effects of Mn on autophagy in the SN is scarce and exposure paradigms vary between studies. 
My results, however, are in line with Zhang et al. (2013), who showed that a single intrastriatal 
injection of MnCl2 could disrupt and block the autophagy pathway. TEM data displayed 
increased autophagosome numbers and dysfunctional lysosomes containing dense granules 
compared with control animals. It should be noted that the quantification of relative numbers 
of autophagosomes and autolysosomes observed by TEM can help discriminate between 
activation and blockade of autophagy, however it does not does provide direct insight into 
lysosomal degradation of autophagic substrates and is therefore not classified as an ‘autophagic 
flux’ assay (Mizushima et al., 2010). Chen et al. (2018a) investigated the role of autophagy in 
microglia inflammation following Mn-exposure (intraperitoneal injection of 100 mg/kg 
MnCl2, every third day for two weeks) and detected an increase in both ATG5 and Beclin-1 
protein levels, implying that Mn induced autophagy dysfunction in microglia. Again, although 
consistent with our results, Chen et al. (2018a) assessed the early stages of autophagosome 
formation, without measuring autophagic substrates levels to evaluate autophagic flux. The 
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current study provides a more thorough assessment of autophagy flux in TH-positive 
neurons, following Mn treatment, which has not been fully assessed in the past literature.  
As previously mentioned, Mn is known to preferentially accumulate in the GP, a region rich in 
GABA projections. Many studies have associated Mn exposure to alterations in GABA levels, 
metabolism and motor impairments, however this is the first assessment of autophagic changes 
following Mn exposure in GABAergic neurons. My results, again, indicated that three 
subcutaneous injections of 50 mg/kg MnCl2 over 7 days, in LC3 mice, caused an autophagy 
flux impairment in GAD67-positive neurons (Figure 4.2). This autophagy blockade induced 
by Mn could potentially promote other known features of Mn toxicity, including α-synuclein 
aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation and apoptosis, 
generating a loop of neurotoxicity.  
One of the pitfalls of the CAG-RFP-EGFP-LC3 model is the fact that the EGFP signal is 
dependent on the enzymatic degradation and the speed at which lysosome quenches its 
fluorescence (Mizushima et al., 2010). This may cause the presence of EGFP fluorescence in 
autolysosomes, limiting the use of yellow puncta (red plus green) to identify autophagosomes 
and red puncta to identify autolysosomes. To address this possibility, additional 
immunostaining of LAMP1 with the RFP fluorescence could have helped to distinguish 
autolysosomes (containing LAMP1) from autophagosomes (containing no LAMP1) as 
previously performed by Li et al. (2014b). However, by assessing changes in LC3 and p62 
staining in WT mice, following Mn treatment, I confirmed the results obtained in the LC3 mice. 
As autophagy flux was impaired in TH- and GABA-positive neurons following Mn exposure, 
the next step was to assess whether mitochondria were also affected. Due to the difficulty of 
monitoring mitochondrial function in vivo, only mitochondrial morphology was assessed in 
WT mice exposed to three subcutaneous injections of 50 mg/kg MnCl2 over 7 days. My results 
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did not reveal any changes in mitochondrial morphology following immunostaining with 
TOM20 in both vehicle and Mn-exposed animals. TH- and GAD67-positive neurons exhibited 
normally distributed filamentous mitochondria that did not appear fragmented, following Mn 
treatment, as evidenced by the skeleton image in Figure 4.3. Although these results are 
indicative of an unaltered mitochondrial structure, the effects on mitochondrial function 
following this dose-regimen are not known. Therefore, although Mn seems to induce changes 
in the autophagy flux without causing the destabilisation of the mitochondrial network, it is 
imperative to confirm that mitochondrial function remains unaffected. In fact, the majority of 
the work investigating the effects of Mn on mitochondria in vivo, were all assessed in relation 
to mitochondrial respiratory chain complex activity and ROS production (Zhang et al., 2003b, 
Cordova et al., 2012). Results showed that both acute (Cordova et al., 2012) and prolonged 
(Zhang et al., 2003b) exposure to Mn promoted ROS production and caspase activity, in 
addition to inhibiting the mitochondrial respiratory chain. Particularly, Cordova et al. (2012) 
reported no morphological changes, cellular degeneration or death in mice exposed to Mn. 
Although not specific to mitochondrial morphology, their results suggest that changes in 
mitochondrial function can occur without any morphological alterations. It is thus possible that 
mitochondrial dysfunction is present in mice exposed to Mn in the current study. TEM may 
help to assess the microstructure of mitochondria and provide further insight on the effects of 
Mn on mitochondria. 
Direct inhibition of autophagy has previously been shown to impair mitochondrial oxygen 
consumption and energy production (Guo et al., 2011, Liang et al., 2012). Mutations in the 
GBA gene are well known to cause Gaucher disease (GD), the most common lysosomal storage 
disorder (resulting in reduced enzyme (GCase) activity, accumulation of substrate 
(glucocerebroside) within lysosomes, and impaired lysosomal activity) and to increase the 
susceptibility of developing PD (Brady et al., 1965, Westbroek et al., 2011, Murphy et al., 
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2014). Osellame et al. (2013) discovered that primary neurons and astrocytes from a mouse 
model of neuronopathic GD harboured defective autophagic and proteasomal machineries 
that induced the accumulation of α-synuclein aggregates and promoted mitochondrial 
dysfunction, ultimately leading to neuronal cell death. Similar results were obtained by Jinn et 
al. (2017), who showed that deficiency of the lysosomal K+ channel transmembrane protein 
175 (TMEM175) impaired lysosomal capacity to clear autophagosomes, thus blocking the 
completion of autophagy. TMEM175 deficiency lead to reduced mitochondrial energetic 
capacity. It is possible that MnCl2 is impairing the autophagy pathway prior to inducing 
mitochondrial dysfunction and that continuous exposure to Mn would eventually cause 
mitochondrial impairment. The other possibility is that mitochondrial function is indeed 
impaired, but to a level that is not affecting morphology. This said, further experiments 
assessing mitochondrial function, including the use of the seahorse XF analyser on purified 
mitochondria or synaptosomes, are needed to confirm these hypotheses. 
Although the exact mechanism of action of Mn neurotoxicity is not fully known, results from 
this chapter suggest that Mn is affecting autophagy at the later stage, either by causing a 
disruption in the fusion of the autophagosomes with the lysosomes or at the lysosomal level 
itself. Suzuki et al. (1983) first described an interplay between Mn and lysosomes following a 
single intraperitoneal injection of Mn in mice. Their results indicated that most of the absorbed 
Mn in the brain was found in mitochondria and lysosome-rich fractions separated by density 
gradient centrifugation. In particular, lysosomes took up Mn to a greater extent than 
mitochondria when compared to controls. Similar results were obtained in rats overexposed to 
the metal, which displayed Mn-rich particles in pancreatic lysosomes (Okamoto et al., 1997). 
Recently, Gorojod et al. (2017) provided further insight into the interplay between the Mn and 
lysosomes, following intrastriatal administration of MnCl2 in rats. Results showed that Mn 
exposure caused lysosomal membrane permeabilization and cathepsin upregulation. In 
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particular, cathepsin D levels were increased in striatal and SN neurons, accompanied with a 
marked reduction of immunoreactive cells. This evidence supports results from my study to 
suggest that Mn-exposure could indeed first target the autophagy pathway, as shown by the 
current in vivo data. 
In recent years, targeting mitochondrial dynamics, either by blocking mitochondrial fission or 
promoting mitochondrial fusion, has been reported to be protective in several models of 
neurodegeneration and has been highlighted as a potential therapeutic (Cui et al., 2010, Qi et 
al., 2013, Rappold et al., 2014, Filichia et al., 2016, Kandimalla et al., 2016, Manczak et al., 
2016, Bido et al., 2017). Mitochondrial dynamics, however, requires balance in order to 
maintain optimal mitochondrial function. In vitro results, from the previous chapter, showed 
that inhibiting Drp1 improved autophagy impairment caused by Mn-overexposure despite the 
absence of mitochondrial dysfunction. In the current chapter, Drp1+/− mice and WT littermates 
were exposed to MnCl2, to investigate whether a partial reduction of Drp1 could be protective 
against Mn-induced changes in autophagy in TH-positive neurons. Previous studies have 
revealed that heterozygous knockdown of Drp1 could decrease fission activity and enhance 
fusion machinery compared to WT mice (Manczak et al., 2012). Additionally, Drp1+/− mice 
displayed reduced oxidative stress compare to WT mice and presented no mitochondrial or 
synaptic deficiencies. Based on these observations, it was hypothesised that a partial reduction 
of Drp1 could be beneficial against Mn-induced neurotoxicity. WT mice, again, displayed an 
impaired autophagic pathway, following Mn-exposure, as evidence by the accumulation of 
both LC3 and p62 proteins in TH-positive neurons. LC3 and p62 are degraded during 
autophagy; therefore, their amounts provide an estimate of the autophagic activity. Mn-
exposure caused an incrementation of both proteins, as evidenced by the number of puncta and 
indicative of increased amount of autophagosomes and reduced degradation of autolysosomes. 
Surprisingly, LC3 and p62 levels were unchanged in Drp1+/− mice compared to WT littermates, 
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suggesting that heterozygous inhibition of Drp1 was not able to restore Mn-induced autophagy 
deficits (Figure 4.5). Partial reduction of Drp1 function has previously been shown to be 
protective in two models of neurodegeneration (Kandimalla et al., 2016, Manczak et al., 2016), 
however this was not the case for Mn toxicity. It is important to note that these previous models 
(Kandimalla et al., 2016, Manczak et al., 2016) involved mitochondrial dysfunction, whilst 
data from the previous chapter suggest a novel role for Drp1, separate from mitochondrial 
dynamics. It is possible that these two separate roles have varying sensitivity to Drp1 inhibition.  
One potential explanation for these discrepancies may be related to the amount of reduced Drp1 
required to rescue the autophagic dysfunction induced by Mn. It is possible that the Mn regimen 
used in this study is too acute and high for this partial Drp1 reduction to confer protection. 
Future studies are needed to assess whether protection would be observed in these mutant 
animals when a more chronic and low dose of Mn is used. On the other hand, a partial inhibition 
of Drp1 may not be enough to overcome the blockade in the autophagy pathway induced by 
Mn and that a major reduction in Drp1 function is needed to restore autophagy flux.  
To test the above hypothesis, LC3 mice were stereotactically injected with rAAV HA-tagged-
Drp1K38A (a dominant negative mutant of Drp1) to the SNpc and then exposed to Mn. Although 
preliminary (n=2), these results suggested that a more severe inhibition of Drp1 could reduce 
the number of accumulated autophagosomes, whilst increasing the number of autolysosomes, 
ameliorating autophagy flux in TH-positive neurons of Mn-exposed mice (Figure 4.7). 
Germline deletion of mitochondrial fission/fusion genes has previously been shown to be 
detrimental (Davies et al., 2007, Ishihara et al., 2009, Wakabayashi et al., 2009, Kageyama et 
al., 2012). The use of a dominant negative form of Drp1 did not completely ablate Drp1 
function and the expression of K38A alone did not affect autophagy measurements. Smirnova 
et al. (2001) previously stated that only ~ 3% of total Drp1 is required by the mitochondria to 
maintain its physiological functions. It is possible that by producing a strong inhibitory effect 
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on Drp1 function, K38A is still allowing the mitochondria to perform normally, whilst 
improving Mn-induced changes to autophagy flux.  
In the future, it would be worthwhile to apply other approaches for blocking Drp1 function. A 
possibility would be the packaging of the rAAV with shRNA to knockdown Drp1 expression 
or the administration of P110 peptide. Additionally, the effects of blocking mitochondrial 
fission have only been assessed up to eight weeks in vivo (Rappold et al., 2014) and for Drp1 
blockade to be considered as a potentially viable clinical strategy for PD the long-term impact 
of manipulating mitochondrial dynamics must be evaluated. This assessment will be crucial 
for the evaluation of any possible adverse effects not seen within the time frames of my studies. 
Although novel, the current study has some limitations. For systemic injections targeting the 
brain, MnCl2 can be injected intravenously, intraperitoneally, or subcutaneously. All have been 
widely used, and there is no major evidence in the literature that suggest that one route is 
preferential or causes more toxicity than the others. A considerable drawback of using systemic 
injections, however, is that prior to entering the brain, Mn reaches the liver (Mn 
is absorbed into the mesenteric blood supply and directly carried to the liver), heart, and 
kidneys, increasing the risk of acute toxic effects, such as cardiac, renal, and liver failure. The 
choice of injecting MnCl2 subcutaneously was decided in regard to the slower rate of 
absorption compared to other routes, providing a more sustained effect. Although inhalation or 
ingestion of Mn may be more representative of human exposure compared to subcutaneous 
injections, it should be assessed in a chronic setting. 
When comparing this study to those in the literature it is difficult to make direct comparisons 
as different doses, routes of administration and time frames were used when assessing 
autophagy changes following Mn-exposure. Unfortunately, this is a disadvantage of using an 
acute model of Mn toxicity. Assessment of the acute toxic potential of MnCl2 is required to 
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determine the effects that occur during accidental or deliberate short-term exposure to the metal 
and will serve as a guide in selecting the appropriate dose for long-term toxicity studies. 
However, acute models do not mimic the progression of the disease and therefore do not 
represent a direct model for a continuous, low exposure to the metal, which is seen in the human 
setting. In fact, most of the evidence on Mn intoxication derive from both occupational and 
environmental exposures (O'Neal and Zheng, 2015). Therefore, results from the current study 
might shed more light on the early effects of acute Mn toxicity. However the gradual 
accumulation of Mn in the brain will be addressed in the next chapter. 
In conclusion, the current study indicates that Mn is causing an inhibition of the autophagy 
pathway in both DAergic and GABAergic neurons, without inducing any changes in 
mitochondrial morphology. Preliminary results also indicate that six weeks of gene therapy 
with Drp1K38A directly injected in the SNpc could potentially confer neuroprotection against 
acute Mn toxicity. Collectively these studies provide further insight into the pathogenic 
mechanisms of Mn toxicity in relation to PD and support previously reported in vitro data 
describing a novel regulatory function for Drp1 in the autophagy pathway. These results 








Assessment of cellular mechanisms 
of Manganese toxicity in six month 
old SLC39A14−/− mice 
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5.1 Introduction  
Parkinsonism induced by Mn neurotoxicity can vary between individuals according to their 
disease onset, severity and symptoms and could be caused by a combination of genetic 
susceptibility and/or environmental factors (including occupational exposure); this chapter will 
focus on the neurotoxic insults induced by gradual accumulation of physiological Mn.  
Whilst Mn neurotoxicity was first recognised in 1837 (Couper, 1837), the first genetic disorder 
of Mn metabolism, SLC30A10, was reported in 2012 (Quadri et al., 2012, Tuschl et al., 2012). 
Recently, two new genetic mutations have been described - mutations in SLC39A14 (increased 
Mn accumulation and toxicity), SLC39A8 (Mn and Zn deficiency). Current evidence on these 
three inherited disorders of Mn metabolism have helped to increase the understanding of Mn 
homeostasis and consequent neurotoxicity. Despite this, little is known about changes in 
intracellular mechanisms caused by chronic accumulation of Mn.  
The aim of this chapter is to better understand the impacts of chronic Mn accumulation on the 
autophagy pathway and mitochondrial morphology using six month old SLC39A14−/− mice as 
a model. These mice have previously been shown to have elevated Mn levels in the brain. As 
evidence from rodents, non-human primates and patients show that both the GP (Yamada et 
al., 1986, Lucchini et al., 2000, Dorman et al., 2006b) and the SNpc (Hauser et al., 1994, 
Cersosimo and Koller, 2006, Park et al., 2007, Stanwood et al., 2009, Robison et al., 2012) are 
targeted by Mn, I addressed Mn-induced cellular changes in TH- and GAD67-positive neurons 





5.2.1 Effects of chronic Mn accumulation on striatal density and TH levels 
SLC39A14−/− mice are viable and do not present any morphological abnormalities at birth 
(Hojyo et al., 2011, Aydemir et al., 2012). Young (eight weeks) SLC39A14−/− mice display high 
brain Mn levels of approximately 10-fold higher than age-matched WT control mice (Xin et 
al., 2017, Jenkitkasemwong et al., 2018) and, by six months of age, start to show signs of 
dystonia, accompanied by a reduced ability to coordinate their movements compared to 
littermates. These symptoms are similar to the PD-like motor deficits observed in patients that 
harbour a SLC39A14 mutation (Tuschl et al., 2016). Based on these results, it was decided to 
assess changes in autophagy and mitochondrial morphology in six month old SLC39A14−/−. 
When kept on a normal (10 ppm) or high (2400 ppm) Mn diet for 30 and 7 days, respectively, 
SLC39A14−/− mice exhibited elevated Mn concentrations in several tissues, including brain 
(Jenkitkasemwong et al., 2018). For the following experiments, all mice were fed with a 
standard chow diet, containing 130 ppm Mn, throughout the whole six months. Both 
homozygous (SLC39A14−/−; KO) and litter-matched control (SLC39A14+/+; WT) mice were 
used and genotyped a described in Figure 5.1 A. For most of the following experiments 6 WT 
(4 males and 2 females) and 5 KO (3 males and 2 females) were used. 
As previously described by Xin et al. (2017), PD-like motor impairments were observed in six 
month old KO mice, however these were not explicitly measured in the current study. The first 
aim was to address possible changes in TH levels in the SN and striatum. To this end, WT and 
KO striatal sections were stained for TH using DAB based detection to assess any damage or 
loss of striatal terminals. TH staining revealed widespread transduction of DAergic fibres 
throughout the striatum of both groups. No difference in TH optical density was detected in 
striatal DAergic innervation of both WT and KO mice (Figure 5.1 B–D). To further 
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corroborate these results, TH protein levels, were assessed in the ventral midbrain of WT and 
KO mice by WB (Figure 5.1 E). No statistical difference was identified between KO and WT, 
suggesting that DAergic neurons and terminals are not affected in mice lacking the SLC39A14 
transporter.  
Figure 5.1 Six month old SLC39A14−/− mice do not exhibit detectable changes in striatal 
density and TH protein levels. (A) Gel electrophoresis of PCR products from DNA samples 
collected from WT (SLC39A14+/+), KO (SLC39A14−/−) and Het (SLC39A14+/−) mice. The WT allele 
produces a 164 bp product, the mutant allele produces a 469 bp product, whilst the Het allele 
produces both. (B) 30 µm striatal sections from WT and KO mice were immunostained with a TH 
antibody (brown, diaminobenzidine chromogen). Scale bar 3500 µm. ImageJ was used to calculate 
(C) the mean gray value and (D) the integrated density of both groups. Unpaired two-tailed 
Student's t test displayed no statistical difference between groups. (E) From ventral midbrain 
regions, 30 µg of protein from 4 WT and 5 KO mice were loaded on a 12% polyacrylamide gels 
and WB was performed using a TH antibody. TH levels were quantified using β-actin as a loading 
control. Blots were visualized on an Odysey CLx machine and optical density measured using Li-
Cor Image Studio software. Data represent mean ± SEM (WT n=4; KO n=5 animals per group). 
Unpaired two-tailed Student's t test displayed no statistical difference between WT and KO animals. 
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5.2.2 Autophagic changes in DAergic and GABAergic neurons of 
SLC39A14−/− mice 
Next, changes in the autophagy pathway were assessed in nigral sections of TH-positive 
neurons using LC3 and p62 antibodies, following immunostaining. An increased number of 
LC3 and p62 puncta was observed in TH-positive neurons of KO mice compared to WT. In 
WT animals, the staining pattern of LC3 and p62 was largely diffuse, with a reduced number 
of visible puncta. Following Mn treatment, the diffuse staining pattern of LC3 and p62 visibly 
changed to a more punctate pattern (Figure 5.2 A-D). The number of LC3 (179.37 ± 12.59) 
and p62 (350.07 ± 10.41) puncta per cell in KO mice was statistically different from LC3 (52.69 
± 12.09) and p62 (162.89 ± 20.01) puncta in WT animals, indicating a blockade in autophagy 
flux. Interestingly, the average size of both LC3 (0.041 ± 0.001) and p62 (0.047 ± 0.002) were 
enlarged in KO mice in comparison to WT (LC3, 0.031 ± 0.0008; p62, 0.036 ± 0.0015) (Figure 
5.2 E-F). This could be the result of an increase in accumulated proteins, unable to be degraded 
due to a block in autophagy flux. 
The GP has been shown to be one of the earliest brain regions in which MRI imaging exhibit 
a hyperintensive signal caused by Mn intoxication (Guilarte et al., 2006b). To this end, 
autophagy changes were also investigated in GAD67-positive neurons located in the GP. 
Results were similar as those obtained in TH-positive neurons. LC3 (88.65 ± 4.43) and p62 
(68.63 ± 10.36) staining appeared diffuse with fewer puncta in WT mice, whilst an 
accumulation in both LC3 (112.85 ± 5.77) and p62 (180.46 ± 13.21) puncta was observed in 
KO mice (Figure 5.3 A-D). Again, these results showed an impairment in autophagy caused 
by lack of SLC39A14 and therefore Mn overload. When assessing changes in LC3 and p62 
puncta size between WT and KO mice, LC3 (WT and KO, 0.38 ± 0.001) puncta displayed no 
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significant changes between the two groups, whilst p62 staining in KO (0.37 ± 0.002) mice 
exhibited evident larger puncta compared to WT (0.31 ± 0.0008) mice (Figure 5.3 E-F). 
B 
Figure 5.2 The autophagy pathway is impaired in TH-positive neurons of six month old 
SLC39A14−/− mice. Following perfusion and sectioning, 30 µm nigral sections were stained for (A) 
LC3 and (B) p62 to assess autophagy changes in TH-positive neurons (blue). (C) LC3 and (D) p62 
puncta/cell were counted in at least 20 neurons from multiple brain sections per condition, using 
ImageJ. Average size of (E) LC3 and (F) p62 puncta per TH-positive cells. Data represent mean ± 








   
Figure 5.3 The autophagy pathway is impaired in GABAergic neurons of six month old 
SLC39A14−/− mice. Striatal sections (30 µm) were co-immunostained for GAD67 plus (A) LC3 and 
(B) p62 to assess autophagy flux in GABA neurons (blue) in the GP. (C) LC3 and (D) p62 
puncta/cell were quantified in at least 20 neurons from multiple brain sections per condition, using 
ImageJ. Average size of (E) LC3 and (F) p62 puncta per GAD67-positive cells. Data represent 
mean ± SEM (WT n=6; KO n=5). Unpaired two-tailed Student's t test: ** P<0.01 *** P<0.001. 







5.2.3 Assessment of morphological changes in the mitochondria of DAergic 
and GABAergic neurons of SLC39A14−/− mice 
Having found an impairment in autophagy flux in a genetic model of Mn accumulation, it was 
imperative to assess changes in mitochondrial function and morphology. However, due to lack 
of samples and difficulty in assessing mitochondrial function, WT and KO mice nigral and 
striatal sections were immunostained with TOM20 to investigate potential morphological 
changes caused by brain Mn accumulation. In both TH- (Figure 5.4 A) and GAD67-positive 
(Figure 5.4 B) neurons from the SN and GP regions, respectively, the mitochondrial network 
of WT (TH, 22.44 ± 2.09; GAD67, 21.21 ± 2.44) and KO (TH, 26.90 ± 2.07; GAD67, 20.65 ± 
1.09) groups appeared integral, with no evident fragmentation or changes in mitochondrial 
length (Figure 5.4 C). Additionally an unpaired two-tailed Student's t test revealed no 
statistical difference of average mitochondria length between the two groups.  
Taken together, these results indicate that chronic accumulation of Mn in SLC39A14−/− mice 
induces autophagy impairment in both TH- and GAD67-positive neurons, without causing 











Figure 5.4 No evident alterations in mitochondrial morphology in SLC39A14−/− mice. Nigral 
and striatal sections (30 µm) were stained for TOM20 to assess mitochondrial morphology in (A) 
TH- and (B) GAD67-positive neurons (red). (C) Mitochondrial length was quantified in at least 20 
TH- and GAD67-positive neurons per condition, using ImageJ. Data represent mean ± SEM (WT 
n=6; KO n=5 animals per group). Unpaired two-tailed Student's t test displayed no statistical 







In the current chapter, I report that chronic accumulation of Mn, caused by a homozygous 
deletion of the ZIP14 transporter, impairs the autophagy pathway in the SNpc of six month old 
SLC39A14−/− mice. 
PD and Mn-induced parkinsonism share some similarities in their pathophysiological 
mechanisms and motor symptoms, however many clinical and pathologic manifestations differ 
between these two disorders (Kwakye et al., 2015). Degeneration of DAergic neurons of the 
SNpc represent the major feature of PD, whereas, a loss of DAergic neurons has not been a 
consistent feature in autopsy samples from humans or non-human primates exposed to Mn 
(Perl and Olanow, 2007, Burton and Guilarte, 2009, Guilarte, 2010). Neuroimaging data from 
some occupational Mn exposed cases have shown reduced levels of DAT (Kim et al., 2002, 
Huang et al., 2003), however other studies have revealed no effects of Mn exposure on DAT 
levels in the caudate and putamen (Guilarte et al., 2008, Sikk et al., 2010). Discrepancies in 
these results could be related to the unique genetic and environmental makeup of a patient, 
causing the disease to present as a spectrum.  
The discovery of the ZIP14 Mn-specific transporter (Tuschl et al., 2016), has provided insight 
into Mn transport and elucidated further mechanisms underlying Mn-related diseases (Aydemir 
et al., 2017, Jenkitkasemwong et al., 2018). Despite this, the effects of Mn accumulation in 
basal ganglia circuitry have not been fully elucidated. To this end, I first investigated alterations 
in TH levels in both the SN and the striatum in six month old mice. Data shown in Figure 5.1 
indicate no apparent change in TH levels in the SN or the striatum of KO mice compared to 
WT. Of note, striatal OD measures TH protein expression but it does not distinguish between 
alterations in TH protein expression and the number of TH-positive fibres. However, this is a 
standard and well-established technique that our lab has published on extensively (Cui et al., 
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2009, Rappold et al., 2011, Rappold et al., 2014). This method does allow distinction of the 
background and specific signal. As shown in Figure 5.1B, the TH immunoreactivity is very 
faint in regions such as the cortex, corpus colosum and septal nucleus when compared to nearby 
regions high in TH protein such as the striatum, nucleus accumbens and olfactory tubercle. The 
background intensity was subtracted from the specific signal when striatal OD was quantified. 
Based on experience in our and other labs, a loss of nigral DAergic neurons does result in a 
reduction in striatal TH immunoreactivity, which is a reflection of TH positive fibres.  
Overall my results could suggest  that the locomotor deficits described by several groups (Xin 
et al., 2017, Jenkitkasemwong et al., 2018) are not associated with the loss of DAergic neurons 
within the nigrostriatal pathway. This evidence is consistent with Guilarte et al. (2008) who 
showed that the nigrostriatal DAergic system is dysfunctional but intact in non-human primates 
chronically exposed to Mn, therefore suggesting that the neuropathology of chronic Mn 
exposure differs from that observed in idiopathic PD.  
As demonstrated in Chapter 4, acute exposure to Mn caused a blockade in the autophagy 
pathway, without affecting mitochondrial morphology. To further investigate possible 
alterations in cellular mechanisms caused by chronic Mn accumulation in SLC39A14−/− mice, 
autophagic and mitochondrial markers were again used. As the GP represents the major site of 
Mn accumulation in the brain, changes in autophagy and mitochondrial morphology were 
assessed in both TH- and GAD67-positive neurons in the SN and GP, respectively. Results in 
Figure 5.2 and 5.3 show an accumulation of both LC3 and p62 in the SNpc and GP of 
SLC39A14−/− mice. This was evidenced by an increased number of LC3 and p62 puncta in both 
TH- and GAD67-positive neurons. Additionally, LC3 and p62 puncta size was enlarged 
compared to WT mice in TH-positive neurons, whilst only p62 puncta size incremented in 
GAD67-positive neurons of KO. Although not clear, these results could indicate that Mn has 
effects on multiple levels of the autophagy pathway. For example, an increase in 
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autophagosome size could suggest a deficit in autophagosome maturation. This result however 
is preliminary and warrants further study, including the ultrastructural examination of 
autophagic vesicles in the presence of Mn.  
Previous studies have additionally shown that autophagy impairment caused formation of p62 
aggregates (Komatsu et al., 2007) and that p62-positive inclusions can contain endogenous α-
synuclein (Sato et al., 2018). However, to demonstrate direct sequestration of aggregates by 
autophagosomes, immuno-TEM is required. In particular, these aggregates could be 
representative of α-synuclein. Verina et al. (2013) previously showed that moderate exposure 
to Mn promoted α-synuclein aggregation in neuronal and glial cells in the frontal cortex of non-
human primates. As previously discussed in section 3.2.4, an increase in α-synuclein 
aggregation occurred consequently to autophagy dysfunction induced by Mn in N27 DAergic 
cells. It would be interesting, in the future, to assess whether these p62-positive aggregates co-
localise with α-synuclein in DAergic and GABAergic neurons of SLC39A14−/− mice and 
perform a time course to investigate whether protein aggregation occurs prior to autophagy 
blockade or vice versa.  
As discussed, prior to the discovery of SLC39A14 being implicated in Mn influx (Tuschl et 
al., 2016), SLC39A14 was known for only transporting Zn (Taylor et al., 2005). Therefore, 
although this is the first time that changes in the autophagy pathway were assessed in 
SLC39A14−/− mice, previous results from Aydemir et al. (2016), whilst assessing the effects of 
Zn on glucose metabolism, showed that liver endosomes of SLC39A14−/− mice displayed 
impaired cathepsin D activity, thus suggesting an indirect link between Mn and lysosomes. 
This study supports results from multiple chapters in which Mn accumulation causes a late 
stage block in the autophagy pathway. 
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Furthermore, Aydemir et al. (2016) examined the association between SLC39A14 and 
mitochondrial function. In addition to localising to mitochondria, SLC39A14 is involved in 
ATP synthesis. Interestingly, by evaluating the amount of ATP in total and mitochondrial 
fractions from SLC39A14−/− mice total liver ATP concentrations were reduced, whereas no 
changes were detected in mitochondrial ATP concentrations (Aydemir et al., 2016). It is of 
important note that the latter study assessed changes in mitochondrial metabolism in the liver, 
therefore it is possible that the brain, being more sensitive to Mn overload, might react 
differently. Results from the current study, however, show no changes in mitochondrial 
morphology in TH- and GAD67-positive neurons SLC39A14−/− mice. TOM20 staining shown 
in Figure 5.4 revealed an intact mitochondrial network between the two groups in both nigral 
and striatal regions. These results support those from the above study, suggesting that a 
deficiency in the SLC39A14 transporter in six month old mice does not affect mitochondrial 
morphology and rather causes an impairment in the autophagy pathway. As previously stated 
in section 4.3, it is important to note that this study has the limitation of not assessing 
mitochondrial function in full. Given the scarce tissue availability for my PhD study, 
mitochondrial respiration and ultrastructure by TEM were not evaluated and therefore it is 
imperative to do so in future studies to fully ascertain that Mn overload does not affect 
mitochondrial function in SLC39A14−/− mice.  
To conclude, this study provides evidence, for the first time, of a role for the autophagy 
pathway in chronic Mn overload in mice lacking the ZIP14 transporter. Results show that 
chronic Mn accumulation causes autophagy impairment without affecting mitochondrial 
morphology nor causing DAergic neuron cell death in six month old SLC39A14−/− mice. These 
preliminary findings expand our understanding of Mn effects on cellular mechanisms in 
SLC39A14−/− mice and highlight its importance in neurodegenerative disease processes. In 
addition, they support findings from previous chapters and suggest that the autophagy pathway 
187 
 
is impaired in a chronic model of Mn neurotoxicity. These results emphasise the importance of 
conducting future experiments to fully understand the mechanisms by which Mn is inducing 
these cellular changes. Some key future investigations include 1) assessing changes in the 
autophagy pathway, mitochondrial function and protein aggregation at multiple timepoints (3 
– 12 month old mice); 2) investigating whether improving autophagy could have a positive 
effect on motor symptoms. This might shed light on understanding how Mn 
dyshomeostasis/toxicity might contribute to PD pathology and provide new paths for drug 
































6.1 General discussion  
Heavy metals are known for causing neurotoxicity and are of major concern due to their long-
lasting and possible irreversible nature; particularly, elevated Mn levels can accumulate in the 
basal ganglia and cause a PD-like syndrome referred to as Manganism. Since genes involved 
in early and late onset of PD and Mn overload potentially disrupt similar cellular processes in 
the basal ganglia, it is possible that PD symptoms may overlap with Mn toxicity. As previously 
discussed by Roth et al. (2014), there are four key themes that correlate PD and Mn 
neurotoxicity: oxidative stress triggered by mitochondrial dysfunction, abnormal vesicular 
trafficking, α-synuclein aggregation and impaired proteostasis. The association of Mn with 
each of these processes further implicates its potential risk of promoting the onset of 
parkinsonism. Prior research has implicated Mn in causing mitochondrial impairment (Gavin 
et al., 1992, Gunter et al., 2010, Gunter et al., 2012, Martinez-Finley et al., 2013) and promoting 
α-synuclein aggregation (Uversky et al., 2001, Bates et al., 2015), whereas evidence on the 
effects of Mn on the autophagy pathway are controversial and not fully understood (Zhang et 
al., 2013, Gorojod et al., 2015, Ma et al., 2017, Zhou et al., 2018). Moreover, none of these 
intracellular processes have been studied concurrently and therefore it is not clear which one 
precedes the other. Unravelling this could pose great value to both our further understanding 
of Mn-induced neurotoxicity and possible benefits to disease therapy. To this end, the present 
study set out to investigate how exposure to Mn affects cellular mechanisms, in both in vitro 
and in vivo models, with the following core aims:  
• To investigate the effects of Mn on autophagy, mitochondria and α-synuclein 
aggregation. 
• To assess whether inhibition of Drp1 may be protective against Mn-induced changes 
on intracellular PD-associated processes. 
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• To explore any autophagic and mitochondrial changes in the newly 
developed SLC39A14 knockout (SLC39A14−/−) mouse model. 
Autophagy is a dynamic process that encompasses autophagosome formation with cargo 
capture and consequent shuttling to the lysosomes, whereupon the two vesicles fuse, yielding 
autolysosomes which will degrade the contents and recycle them. Completion of this process 
is termed ‘autophagy flux’. Two methods were used to accurately assess changes in autophagy 
flux induced by Mn exposure: 1) mRFP-GFP-LC3 expressing cells/neurons, which provide a 
useful system to distinguish between non-degraded autophagosomes and autolysosomes, 2) the 
combination of LC3 (autophagosome marker) and p62 (autophagy substrate) markers in either 
WB or immunostaining studies.  
Results in the current study demonstrate that Mn impairs autophagy flux by promoting 
autophagosomes accumulation and reduction of autolysosomes both in vitro and in vivo. 
Additionally, the effect of Mn on autophagy flux was exacerbated in cells overexpressing WT 
human α-synuclein, indicating an interplay between Mn and α-synuclein and further suggesting 
a link between Mn and PD. A recent study showed that increased autophagosome synthesis, 
which cannot be processed at the lysosomal level, are futile for the cells as responsible for 
depleting energy and nutrition, ultimately contributing to the cell’s demise (Button et al., 2017). 
Although Mn mechanism of action on the autophagy pathway is still not fully understood, I 
suggest Mn could be either directly affecting autolysosome formation, lysosomal function or 
indirectly targeting the autophagy pathways through a different mechanism. 
Consequently to autophagy blockade, Mn exposure increased α-synuclein aggregation in cells 
overexpressing α-synuclein. α-synuclein accumulation has previously been associated with 
impaired functioning of protein degradation mechanisms (Xilouri et al., 2013, Ebrahimi-
Fakhari et al., 2012), autophagy being one of the key pathways. On the other hand, reduced 
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autophagic function was shown to promote intracellular accumulation of proteins and 
neurodegeneration (Hara et al., 2006, Komatsu et al., 2006). The reliance of neurons on a 
functional autophagic pathway is supported by observations that the brain is particularly 
vulnerable to lysosomal disorders, especially during aging (Nixon, 2013).  
Unlike previous studies assessing the effects of Mn on mitochondria, I did not find any 
significant morphologic alterations or functional changes in the mitochondria of cells and 
neurons exposed to Mn, unless the dose of Mn used was increased to a level that caused over 
40% cell death. Given Mn physiological role in mitochondrial homeostasis, the majority of the 
studies focused on Mn toxicity and assessed changes in mitochondrial metabolism, ROS and 
recently mitochondrial morphology (Alaimo et al., 2013, Alaimo et al., 2014, Martinez-Finley 
et al., 2013). Most of the prior evidence has pointed to mitochondria being the major target of 
Mn toxicity. These assessments, however, were not performed in conjunction with changes in 
other cellular pathways, using sub-toxic concentrations. I, therefore, suggest that Mn is 
primarily causing autophagy impairment, resulting in α-synuclein aggregation, whilst 
mitochondrial function and morphology (not affected at the studied timepoint) may cause a 
decline in intracellular ATP or elevation in ROS production at a later time point. This could 
be, in fact, expected since autophagy is responsible for clearing intracellular toxins and 
damaged organelles that generate oxidative stress (Lemasters, 2005). As the autophagy 
machinery helps to clear damaged mitochondria, if autophagy is dysfunctional/impaired there 
will be an increase in dysfunctional mitochondria, unable to be cleared. In addition, as the 
material used to generate the initial membrane of the autophagosomes has been shown to be 
attributed to several organelles, including mitochondria (Hailey et al., 2010), it is possible that 
the accumulated number of autophagosomes, caused by Mn, will potentially induce 
mitochondrial stress and promote ROS production over time. It has been reported that in the 
mitochondria Mn alters oxidative phosphorylation and that Mn3+ is more potent than Mn2+ in 
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producing ROS (Ali et al., 1995, Chen et al., 2001). Since the enhanced ability of trivalent Mn 
to cause oxidative stress has been confirmed in rats injected with either MnCl2 (Mn
2+) or 
Mn(OAc)3 (Mn
3+) (Ali et al., 1995), it is possible that low concentrations of MnCl2, used in the 
current study, were not potent enough to induce oxidative stress and affect mitochondrial 
function. Overall our findings suggest a novel mechanism of action for Mn toxicity (Figure 
6.1). Mn overexposure appears to first promote autophagy impairment and consequently α-
synuclein aggregation. 
  
Figure 6.1 Proposed model of Mn-induced changes on cellular mechanisms. Given results 
obtained from the current study I propose a novel mechanism of action of Mn neurotoxicity. The 
red lines represent the effects of Mn, whereas the black arrows show the effects of each pathway on 
the others. Mn primarily affects the autophagy pathways by causing a late stage block, with 
increased number of autophagosomes and reduced autolysosomes. This impairment induces protein 
aggregation, without affecting mitochondrial morphology nor function, unless Mn concentrations 
are increased to a level that is detrimental for the cell. The question mark represents the possibility 
of future mitochondrial dysfunction that may appear with continuous exposure to the metal.  
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In the current study I used different strategies to inhibit Drp1 and assess its effects on cells 
exposed to Mn alone or combined to α-synuclein. Whilst inhibition of Drp1, via siRNA and 
mdivi-1, ameliorated autophagic impairment induced by Mn, their effects on the autophagy 
pathway appeared different. siRNA mediated knockdown of Drp1 attenuated the accumulation 
of autophagosomes caused by Mn and/or α-synuclein and promoted the increase in the number 
of autolysosomes. Mdivi-1 alone promoted autophagosome formation, indicative of autophagy 
induction (significantly different to control cells), however in combination with Mn it 
maintained a high number of autophagosomes whilst increasing the number of autolysosomes. 
It appears that mdivi-1 is possibly targeting multiple sites of the autophagy pathway or having 
off target effects. These results, however, suggest the inhibition of Drp1 improved autophagy 
flux either by promoting autophagosome-lysosome fusion or restoring lysosomal function.   
The evidence available in the literature suggests that Mn can accumulate in lysosomes (Suzuki 
et al., 1983, Okamoto et al., 1997) and affect the enzymatic capacity of cathepsins (Fan et al., 
2010, Gorojod et al., 2017). Specific Drp1 isoforms, abundant in the brain, have been shown 
to locate to lysosomes and late endosomes (Itoh et al., 2018) as well as mitochondria (Smirnova 
et al., 1998). Additionally, mitochondria can interact dynamically with lysosomes and these 
contacts were proven to be different from those targeting damaged mitochondria into 
lysosomes for degradation (Wong et al., 2018). Given the ability of Mn to impair lysosomes 
and Drp1 to interact with endosomal-lysosomal pathways, it is possible that inhibiting Drp1 is 
restoring autophagy defects in Mn-exposed cells/neurons through lysosomes. Interestingly, 
heterozygous deletion of Drp1 in mice did not confer protection against Mn-induced changes 
in autophagy flux, whilst preliminary results from mice transduced with Drp1K38A displayed 
potential restoration of autophagy flux. These results indicate that heterozygous knockout of 
Drp1 cannot exert protective effects against Mn-induced changes in autophagy, whilst the use 
of a dominant negative form of Drp1, that allows sufficient fission for the maintenance of 
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normal physiological function, could be protective and represents a potential new target against 
Mn-induced neurotoxicity. Based on the current study and those from previous groups, which 
indicate a non-canonical function of Drp1 signalling (possibly within the lysosomes), I suggest 
a novel role for Drp1 in the regulation of the autophagy pathway, which will warrant more in-
depth studies.  
Although the protective mechanism of Drp1 inhibition on the autophagy pathways is novel, the 
interplay between mitochondria and autophagy has been previously shown to be crucial for 
maintaining homeostasis in eukaryotic cells. Komatsu et al. (2005) showed that ATG7 
knockout mice exhibit deformed mitochondria, and accumulated ubiquitin-positive aggregates. 
Similarly, mitochondrial swelling and oxidative stress have been reported in liver-
specific ATG7 knockout and systematically ATG5-deficient mice (Inami et al., 2011, 
Takamura et al., 2011). In addition, independently to their role in autophagosome formation, 
defects in the ATG12-ATG3 complex, cause an increase in mitochondrial mass, affecting 
mitochondrial homeostasis (Radoshevich et al., 2010). Conversely, mitochondria have been 
shown to play key roles in regulating nonselective autophagy. ROS are essential for autophagy 
and specifically regulate the activity of ATG4 (a cysteine protease that regulates autophagy 
through the processing and deconjugating of ATG8 to the autophagosomal membrane) 
(Scherz‐Shouval et al., 2007). Mitochondria were shown to serve as a membrane source for 
autophagosome formation and cells lacking Mfn2 did not form autophagosomes (Hailey et al., 
2010). Recently, Thomas et al. (2018) reported that phenformin (inhibitor of mitochondrial 
complex I)  or genetic defects in complex I (Rodenburg, 2016), impaired autophagy, suggesting 
the requirement of mitochondrial complex I (or perhaps mitochondrial function in general) in 
the autophagy pathway. This evidence not only shows an evolutionarily conserved interplay 
between mitochondria and autophagy, but also indicates that defects in one of these elements 
could simultaneously affect the other. 
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In addition to restoring autophagy flux impaired by Mn both in vitro and in vivo, Drp1 
inhibition was also neuroprotective against Mn-induced cell death and also ameliorated α-
synuclein aggregation. As α-synuclein aggregation was suggested to be the result of autophagy 
dysfunction, I speculate that protein aggregation was rescued by restoring autophagy flux. This 
suggestion has been previously confirmed (Moors et al., 2017, Fowler and Moussa, 2018, 
Arotcarena et al., 2019). In fact, following the discovery of accumulated autophagic vacuoles 
in the SN of post-mortem patients with PD (Anglade et al., 1997), an extensive amount of 
recently identified genetic factors, including α-synuclein, was proven to be involved in or to 
interact with the autophagy pathway (Gan-Or et al., 2015). Given the evidence for a role of 
autophagy deregulation in PD and the identification of autophagy as key player in degrading 
α-synuclein, a decade ago pioneering studies have explored the possibility of autophagy-
enhancing strategies as disease-modifying therapy to reduce α-synuclein aggregation in PD 
(Moors et al., 2017). Indeed, the use of rapamycin or lithium, promoted α-synuclein clearance 
and reduced neurodegeneration both in vitro and in vivo (Webb et al., 2003, Crews et al., 2010, 
Xiong et al., 2011, Hou et al., 2015). Additionally, direct targeting of lysosomes has emerged 
as an attractive strategy for manipulating autophagy in neurodegenerative diseases, as evidence 
suggests that strategies that solely promote autophagosome synthesis may be deleterious for 
the cell (Button et al., 2017). These studies include: the use of acidic nanoparticles to restore 
lysosomal function (Baltazar et al., 2012, Bourdenx et al., 2016), the direct targeting of specific 
lysosomal enzymes, such as GCase, to stimulate α-synuclein clearance (Sardi et al., 2011, 
Rocha et al., 2015) and overexpression of TFEB, a master gene for lysosomal biogenesis, for 
alleviating α-synuclein pathology and rescue midbrain DA neurons (Decressac et al., 2013). 
These examples give precedence and credence to my suggestion: promoting or restoring 
autophagy activity could represent a promising and relevant therapy for protein accumulation-
based neurodegenerative diseases.  
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How is Drp1 inhibition improving Mn-inducted cytotoxicity? Recently, Zhang et al. (2019) 
investigated the role of Mn exposure in autophagy regulation. Their results showed that 24 h 
100 µM MnCl2 suppresses TFEB activity, causing autophagy dysfunction and mitochondrial 
pathology in primary astrocytes. These results were validated in vivo, using the same acute Mn 
treatment regime adopted in the current thesis. Overexpression of TFEB partially restored Mn-
induced autophagy dysfunction (Zhang et al., 2019). These findings suggest an interplay 
between compromised autophagic and mitochondrial function in Mn toxicity and identify 
TFEB as a potential therapeutic target for Mn-induced toxicity. Interestingly, Fan et al. (2019) 
utilised three complementary approaches to investigate the protective role of Drp1 inhibition 
in cells overexpressing human WT α-synuclein. They discovered that reduction of Drp1 
function could inhibit mTOR (mammalian target of rapamycin) activity, to an equivalent extent 
as rapamycin, and attenuate autophagy impairment caused by α-synuclein. mTOR kinase is 
involved in conveying nutrient-sensing signals to lysosomes, thus paring lysosomal functions 
to cellular energy demands (Dunlop and Tee, 2014, Rabanal-Ruiz and Korolchuk, 2018). To 
accomplish this, mTOR phosphorylates TFEB to modulate its localisation, transcriptional 
activity, stability and cellular abundance (Puertollano et al., 2018). Upon mTOR inhibition, 
dephosphorylated TFEB translocates to the nucleus and upregulates the activity of its targets 
genes, many of which are involved in lysosomal biogenesis and function (Palmieri et al., 2011, 
Settembre et al., 2012).  
Given the above information, I propose that Drp1 inhibition reduces mTOR activity and thus 
promotes TFEB expression to a level that improves autophagy dysregulation caused by Mn 
exposure. It is thus possible that Drp1 inhibition confers neuroprotection through the 
autophagy-lysosomal pathway. This proposed effect of Drp1 inhibition on the autophagy 






Lastly, I investigated the effects of chronic accumulation of Mn in a newly developed mouse 
model of Mn neurotoxicity. My results indicated that impaired uptake of Mn in SLC39A14−/− 
mice, which promotes Mn to accumulate in multiple tissues (particularly in the bone and brain) 
(Jenkitkasemwong et al., 2018), causes autophagy flux impairment in DAergic and GABAergic 
neurons of six month old mice without affecting the mitochondrial network. It is possible that 
mitochondrial dysfunction is not associated with any perturbations in mitochondrial 
morphology, thus further studies are needed to assess mitochondrial function. These results are 
in line with those achieved in mice subcutaneously injected with MnCl2, further implicating 
Mn involvement in negatively impacting the autophagy pathway. It would be interesting to 
investigate whether the autophagy-induced changes in neurons are also observed in astrocytes 
and where this proteostasis dysfunction occurs first. However, this is the first time that a more 
in-depth mechanistic study has been performed in this new genetic model of chronic Mn 
deposition. These findings expand our understanding of chronical Mn neurotoxicity, 
particularly given the lack of satisfactory treatment for Mn neurotoxicity. Our results could be 
of further interest in the clinical setting as patients acutely or chronically exposed to Mn will 
probably display autophagy impairment in nigral and striatal neurons, in addition to 
Figure 6.2 Proposed effect of Drp1 inhibition on autophagy dysregulation promoted by Mn 
treatment. Inhibition of Drp1 deregulates mTOR activity, which in turn alters TFEB 
phosphorylation status, thus affecting its levels. Increase in TFEB levels upregulates autophagy-




astrogliosis. This knowledge could potentially help target those neurons and reduce the risk of 
promoting α-synuclein oligomerization and enhance cellular toxicity.  
In summary, the major findings and contributions of the present study to the area of Mn 
research report that: 
• Autophagy is an initial target of Mn neurotoxicity, rather than mitochondria.  
• Consequently to autophagy dysfunction, Mn exposure promotes α-synuclein 
aggregation in vitro. 
• α-synuclein and Mn can independently block autophagy flux but have a greater effect 
when combined. 
• Drp1 inhibition, via small molecule or siRNA, alleviates impaired autophagy, protein 
aggregation and cell death induced by Mn in vitro.  
• Preliminary results show that stereotactic delivery of Drp1K38A in the SNpc of mice, is 
protective against acute Mn-induced changes in autophagy flux.  
• Six month old SLC39A14−/− mice exhibited an impairment in the autophagy pathway 
in both DAergic and GABAergic neurons, caused by a gradual accumulation of 
physiological Mn in the brain. 
Collectively the results included in this thesis provide further insight into the pathogenic 
mechanism of Mn and its potential role in PD pathogenesis.  PD has previously been associated 
with the accumulation of intracytoplasmic aggregates and autophagy impairment. Mn 
accumulation could therefore represent a potential risk for PD by affecting the autophagy 
pathway and promoting α-synuclein aggregation. Inhibition of Drp1 was discovered to be 
restorative against autophagy and protein aggregation changes caused by the metal, suggesting 
a new role for Drp1. Given Drp1’s potential role in the autophagy pathway, I hypothesise that 
targeting Drp1 may represent a novel method to modulate the autophagy pathway with 
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particular relevance for neurodegenerative diseases. Despite several limitations, I believe that 
the results presented in the current study are an important assessment at multiple cellular 
pathways and represent a starting point from which a more comprehensive and detailed analysis 




6.2 Future perspectives  
Across most neurodegenerative disorders, proteostasis has been widely studied given that many 
of these diseases, including PD, display protein aggregation and dysfunctional UPS or 
autophagy as part of their cellular pathology. Given the role of Mn in PD pathogenesis and the 
results obtained in the current study, a more in-depth understanding of Mn’s mechanism of 
action in the autophagy pathway is needed and will enable the identification of possible 
methods for effective therapeutic strategies. Although results from the current study suggest a 
late-stage block caused by Mn overexposure, it is important to investigate multiple sites of the 
autophagy pathway to fully ascertain this. Additionally, as the autophagy pathway represents 
one of the major proteolytic systems that maintain cellular protein homeostasis, it would be 
interesting to assess whether Mn also affects CMA and UPS pathways both in the presence and 
absence of α-synuclein.  
A particularly novel finding in the current study is that the inhibition of Drp1 improved the 
observed autophagic deficits and protein aggregation in multiple cell lines and in mice caused 
by Mn. As the exact function of Drp1 in the autophagy pathway is currently not known it is 
important to understand how and where in the autophagy pathway Drp1 is ameliorating Mn-
induced neurotoxicity. Using different Drp1 isoforms, colocalization studies with various 
autophagy markers could be performed, in addition to deleting ATG proteins and evaluating 
changes in Drp1 levels to better comprehend this mitochondria-autophagy interplay. Whilst 
blocking Drp1 function inhibits mitochondrial fission, would promoting fusion, produce a 
similar effect on autophagy or are these results only specific to Drp1? Xue et al. (2018) 
demonstrated that Mfn2 could promote LC3-II expression and downregulate p62 expression in 
pancreatic cancer cells. It would be interesting to assess whether overexpressing the fusion 
protein Mfn2 could also ameliorate Mn-induced changes. Furthermore, as Drp1 is mainly 
known for being implicated in mitochondrial fission, would prolonged Mn exposure impair 
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mitophagy? A recent study showed that, contrarily to the thought of Drp1 being essential for 
mitophagy (Gomes et al., 2011, Rambold et al., 2011), Drp1 knockout cells could recruit Parkin 
to elongated mitochondrial networks and enhance mitophagy (Burman et al., 2017). 
The current study clearly shows that Mn promotes the aggregation of α-synuclein following 
autophagy impairment. Aggregation and spread of a misfolded α-synuclein represent a 
hallmark of PD pathogenesis. A recent study demonstrated that Mn exposure could promote 
the transfer of α-synuclein between neurons and microglia, causing neuroinflammatory and 
neurodegenerative responses in both cell culture and animal models (Harischandra et al., 2019). 
These results indicate that Mn is contributing to PD-associated propagation of both α-synuclein 
and neuroinflammation involving neuronal and microglial interactions. It would be interesting 
to assess whether inhibiting Drp1 or overexpressing Mfn2 may prevent this α-synuclein release 
and spread. 
Another key finding of the current study was the ability of low concentrations of Mn (at 24 h) 
to primarily block autophagy flux, without affecting mitochondrial function or morphology in 
vitro. Future experiments are needed to investigate Mn effects on PD-processes over a longer 
time frame. In addition, my in vivo studies focused on morphological changes, without 
assessing mitochondrial function following acute and chronic exposure to the metal. It is 
imperative to establish whether Mn indeed impairs mitochondrial function, independently to 
mitochondrial morphology, via EM and seahorse assay.  
Assessment of autophagic function, mitochondrial morphology and neuroinflammation in 
SLC39A14−/− mice has increased our knowledge of the effects of Mn following deletion of the 
newly discovered SLC39A14 influx Mn transporter. Although novel, further research is needed 
to fully characterise this genetic model of Mn neurotoxicity. In particular performing 
stereology both in the GP and the SN would be key to support results obtained in the current 
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study and definitely demonstrate whether Mn can promote neuronal cell death. I performed 
immunostaining using specific markers for microglial activation and astrocytic response, 
however, an assessment of cytokine/chemokine expression, that are upregulated during 
neuroinflammation, would give further insight into the effect of Mn on glial cell functions and 
tissue microenvironment in general.  
Previous studies have shown impaired DA release in animals exposed to Mn (Guilarte et al., 
2006a, Guilarte et al., 2008, Khalid et al., 2011). Particularly, Khalid et al. (2011) used the 
same injection strategy adopted in Chapter 4 to acutely expose mice to MnCl2 and showed 
altered striatal DA release in these mice. It would be interesting to replicate this data in both 
WT and LC3 mice as well as investigate whether SLC39A14−/− mice could display similar 
deficits, performing HPLC or in vivo microdialysis. As previously reported by Rappold et al. 
(2014) inhibition of Drp1 restored pre-existing DA release deficits in PINK1−/− and MPTP 
mice, the same strategy could therefore be used to ameliorate possible DA release deficits in 
SLC39A14−/− and WT/LC3 mice exposed to Mn.  
Finally, the long-term impact of blocking Drp1 should be evaluated in order to assess potential 
detrimental effects of this therapy. To achieve this aim, Drp1 expression could be reduced using 
WT mice stereotactically expressing dominant negative Drp1 forms over 12 to 18 months. 
Neuropathological parameters including cell loss (stereology), DA release (HPLC), and 
synaptic function (immunostaining of synaptic markers, synaptosome isolation) will need 
investigation.  
These proposed experiments, in combination with those detailed in the current study, will allow 
for a more in-depth understanding of Mn mechanisms of action, its interaction with α-synuclein 











7.1 Appendix A - Additional introduction 
7.1.1 Rotenone 
Rotenone, a potent non-competitive mitochondrial complex I inhibitor derived from the 
Leguminosa plant family (Soloway, 1976), is a naturally cytotoxic compound used as a 
pesticide/piscicide and associated with increased risk of developing PD (Tanner et al., 2011, 
Kamel, 2013). Rotenone is highly lipophilic and does not require specific transporters to cross 
the blood-brain barrier (BBB) (Higgins and Greenamyre, 1996). Moreover, due to its relatively 
short half-life (~ 3 days) (Hisata, 2002), the most likely route of exposure is through low 
chronic exposure to the pesticide. Rotenone impairs mitochondrial function by inhibiting the 
ETC, through direct inhibition of complex I (NADH–dehydrogenase). This inhibition leads to 
a reduction in ATP production and electron leakage that can generate ROS such as superoxide, 
subsequently causing a reduction in glutathione levels and ultimately leading to oxidative stress 
(Schuler and Casida, 2001, Sherer et al., 2003). Rotenone has also been shown to induce rapid 
mitochondrial fragmentation in primary cortical neurons, within two hours of treatment (Barsoum 
et al., 2006b). This neurotoxicity was averted by promoting mitochondrial fusion with Mfn1 and 
blocking Drp1 with Drp1-K38A (Barsoum et al., 2006b). Recent studies have demonstrated 
that rotenone can also be involved in altering mitochondrial transport and protein interactions 
within neurons (Choi et al., 2011, Di Maio et al., 2016). Although in vivo models of rotenone 
toxicity display variable neuropathology, rotenone has been shown to cause selective 
nigrostriatal neurodegeneration with the presence of α-synuclein-positive cytoplasmic 
inclusions and a neuroinflammatory component, which resulted in motor impairments 





Paraquat (PQ) is a non-selective herbicide that interferes with photosynthesis and produces 
ROS, resulting in the damage of plant membranes proteins (Breckenridge et al., 2013). It is 
also commonly used to control pests in a variety crop (Bromilow, 2004). PQ is a molecule that 
exists as a divalent cation (PQ2+) and undergoes redox cycling with cellular diaphorases such 
as NADPH oxidase and nitric oxide synthase (NOS) to generate a monovalent cation 
(PQ+).  From this redox cycle, superoxide is produced, which can generate ROS and result in 
cellular toxicity (Day et al., 1999). PQ requires the L-neutral amino acid transporter to enter 
the brain (Shimizu et al., 2001, McCormack and Di Monte, 2003). Once in the brain PQ+ can 
enter cells via the dopamine transporter (DAT) and the organic cation transporter-3 (OCT-3) 
(Rappold et al., 2011), a bidirectional transporter that is highly expressed in astrocytes and in 
γ-aminobutyric acid (GABA) producing neurons in nigrostriatal regions (Cui et al., 2009, 
Gasser et al., 2009). Although PQ is not a complex I inhibitor, this seems to be the preferred 
site in which PQ induces superoxide formation (Richardson et al., 2005, Cochemé and Murphy, 
2008). Consistent with the role of promoting oxidative stress, a recent study showed that PD 
patients, who had been previously exposed to the pesticide, exhibited mitochondria DNA 
damage (Sanders et al., 2017). Along with mitochondrial dysfunction, several other studies 
reported that oxidative stress induced by PQ led to inhibition of basal autophagy in PC12 cells 
and primary astrocytes (Janda et al., 2015, Zhou et al., 2017). 
Systematic injections of PQ in WT mice were reported to induce motor deficits and loss of 
DAergic neurons in the SNpc (~20-25%). The effects of PQ appeared to be specific as 
GABAergic neurons in the SNpc and striatum, DAergic neurons in the VTA and glutamatergic 
neurons in the hippocampus remained unaffected.  Interestingly, although the damage induced 
by PQ affected DAergic cell bodies, no significant depletion of striatal DA was observed 
(Thiruchelvam et al., 2000, McCormack et al., 2002, Tieu, 2011). It has been suggested that, 
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due to an increase in TH activity following PQ administration, the increased DA synthesis may 
counteract the effects of terminal damage and help restore tissue levels of the neurotransmitter. 
When co-administered with manganese ethylenebisdithiocarbamate (Maneb), the loss of 
DAergic SNpc neurons is more severe and a slight reduction of striatal DA was visible, 
although this was not statistically significant (Thiruchelvam et al., 2000). In contrast to WT 
mice, mice lacking the organic cation transporter-3 (Slc22a3), displayed enhanced striatal 
damage when exposed to PQ, likely due to a reduced buffering capacity by non-DAergic cells, 
allowing PQ to damage DAergic terminals (Rappold et al., 2011). Additionally, PQ treatment 
in rodents induced neuroinflammation, α-synuclein up-regulation and aggregation, reminiscent 
of LBs in PD (Manning-Bog et al., 2002a, Wu et al., 2005, Fernagut et al., 2007, Purisai et al., 
2007). Despite inconsistent data from in vivo studies, evidence from epidemiological and 
mechanistic studies corroborate the theory of PQ increasing the risk of developing PD. 
 
7.1.3 The roles of Rabs, SNAREs and tethering factors (Figure 7.1) 
Rab proteins are known to confine to specific membranes and recruit effector proteins. These 
include cargo adaptors, motor proteins and tethering proteins to help SNARE proteins with the 
fusion machinery upon arrival of the vesicular cargo (Stenmark, 2009, Zhen and Stenmark, 
2015). Rab proteins are activated by specific guanine nucleotide exchange factors (GEFs) that 
promote GTP binding. Upon binding GTP, Rabs alter their conformation to interact with their 
effector proteins. In contrast, Rabs are inactivated by specific GTPase-activating proteins 
(GAPs) that hydrolyse GTP to GDP, which cause a disconnection between Rabs and effector 
proteins and extraction from the membranes (Nakamura and Yoshimori, 2017).  
Rab7, localised on late endosomes and lysosomes is essential for endocytic membrane 
trafficking from late endosome to lysosome and has been suggested to be important for 
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autophagosome–lysosome fusion (Rab7 knockdown leads to an accumulation of late 
autophagic vacuoles) and subsequent digestion (Gutierrez et al., 2004, Jäger et al., 2004). 
Interestingly, UV radiation resistance-associated (UVRAG) and Run domain Beclin-1 
interacting and cysteine-rich containing protein (Rubicon), two components of the PI3K-III 
complex, take part in endocytic transport, autophagosome maturation and/or autophagosome–
lysosome fusion via Rab7 (Liang et al., 2008, Matsunaga et al., 2009, Zhong et al., 2009, Tabata 
et al., 2010). These proteins have opposite effects: UVRAG induces autophagosome–lysosome 
fusion by binding to VPS16 (a subunit of the homotypic fusion and protein sorting (HOPS) 
complex), which stimulates Rab7 GTPase activity (Liang et al., 2008), whereas Rubicon 
inhibits it by physically interacting with UVRAG and binding to VPS34, thus suppressing its 
lipid kinase activity and autophagy maturation (Sun et al., 2011).  
More than 60 SNAREs are involved in fusion processes of mammalian cells. Functionally, 
SNAREs are organized into v-SNAREs located on donor vesicles and t-SNAREs on target 
vesicles. Structurally, SNAREs are classified into Q-SNAREs (with a Q amino acid residue) 
and R-SNAREs (with a R amino acid residue) (Nakamura and Yoshimori, 2017). Studies have 
shown that upon starvation, the Q-SNARE syntaxin 17 (STX17) is recruited from the cytosol 
to mature autophagosomes, where it interacts with the Q-SNARE SNAP29 and the lysosomal 
R-SNARE VAMP8 to promote autophagosome–lysosome fusion (Itakura et al., 2012). Further 
evidence has also implicated STX17 to be involved in the formation of the isolation membrane 
at the ER-mitochondria contact site (Hamasaki et al., 2013). The ER-resident STX17 protein, 
upon starvation, binds to and recruits ATG14L to initiate autophagosome formation (Hamasaki 
et al., 2013).  
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Membrane tethers are implicated in docking and fusion by bridging opposing membranes and 
by stimulating the formation of SNARE complexes. The HOPS complex, acting as a tethering 
factor, mediates autophagosome–lysosome fusion by interacting with STX17 (Jiang et al., 
2014). Ectopic P granules protein 5 (EPG5), originally discovered in a C. elegans genetic 
screen, represents another Rab7 effector and tethering factor required for fusion specificity of 
autophagosomes with endosomes/lysosomes (Tian et al., 2010, Wang et al., 2016b). By 
interacting with Rab7 and R-SNARE VAMP7/VAMP8 proteins, EPG5 can be recruited to late 
endosomes/lysosomes. EPG5 also interacts with LC3 through its LC3-interacting region (LIR) 
motif and with Q-SNARE complexes on autophagosomes (Wang et al., 2016b).  
Figure 7.1 Fusion of autophagosome and lysosome – the roles of Rabs, SNAREs and tethering 
factors. Following recruitment to the late endosomes/lysosomes, together with Rab7 and VAMP-8, 
EPG5 tethers late endosomes/lysosomes by binding to LC3 and STX17–SNAP29. This induces the 
assembly of the trans-SNARE complex for fusion. On the other hand, ATG14L binds to STX17 and 
to a binary complex formed between STX17 and SNAP29 (STX17–SNAP29) on autophagosomes, 
facilitating its interaction with VAMP8 to promote autophagosome–lysosome fusion. This suggests 
that ATG14L acts earlier than EPG5. PLEKHM1 is an adaptor protein that interacts with Rab7, 
HOPS–SNARE complexes and LC3 proteins to enable autophagosome–lysosome fusion. EPG5, 
ATG14L and the HOPS complex act as tethering factors, although their exact relationship is not 
fully understood. O-GlcNAcylated SNAP-29, generated by O-linked β-N-acetylglucosamine (O-
GlcNAc) transferase (OGT), does not have a high binding affinity for its partner SNAREs. This 
modification is suppressed by starvation, and a reduction in O-GlcNAcylated SNAP-29 levels 
triggers the assembly of SNAP-29-containing trans-SNARE complexes, thus stimulating autophagy. 
Adopted from Nakamura and Yoshimori (2017) 
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7.2 Appendix B – Supplementary results 
7.2.1 Effects of paraquat on autophagy and α-synuclein aggregation 
In addition to Mn, several studies have suggested that exposure to pesticides, such as paraquat 
(PQ), can increase the risk of developing PD (Liou et al., 1997, Tanner et al., 2011, Wang et 
al., 2011a). Despite extensive research in PQ’s mechanism of action, not much is known of its 
effect on the autophagy pathway. Previous evidence has shown that PQ can block autophagy 
flux by promoting an increase in both LC3 and p62 levels in PC12 cells (Zhou et al., 2017), 
however the concentration of the pesticide used was particularly high (4 mM). I therefore first 
performed a cell viability assay on both HeLa mRFP-GFP-LC3 and inducible N27 cells treated 
for 24 and 48 h with increasing concentrations (25 – 1600 µM) of PQ (Figure 7.2). PQ caused 
a decrease in cell viability in a time-dependent fashion in both cell lines, however contrarily to 








Figure 7.2 PQ reduces cell viability in a dose-dependent fashion. HeLa and N27 cells were 
cultured in 96-well plates and exposed to varying concentrations of PQ (25 – 1600 μM) for (A) 24 
and (B) 48 h. Values are relative to 100% for the untreated group and they are represented as mean 





Following cell viability, HeLa cells were exposed to several concentrations of PQ (all shown 
to have little effect on cell viability at 24 h) to assess changes in autophagy flux, as previously 
described in section 3.2.2. Following PQ treatment, the number of autophagosomes 
significantly increased, whilst autolysosomes decreased compared to control cells (Figure 7.3). 
Similarly to Mn, these results are indicative of autophagy dysfunction. As all PQ concentrations 
caused a statistically significant blockade in autophagy flux, 50 µM PQ was chosen as the 
preferred concentration for future experiments.  
Given the effects of PQ on autophagy flux and the previous results obtained with Mn, I 
evaluated whether Drp1 inhibition could restore autophagy flux blocked caused by PQ in HeLa 
cells. Knockdown of Drp1 (via siRNA) attenuated autophagy impairment by reducing the 
number of autophagosomes and increasing the number of autolysosomes to a level that was no 
longer statistically different to control cells (Figure 7.4).   
In addition, as previous studies described and up-regulation and aggregation of α-synuclein in 
mice exposed to PQ (Manning-Bog et al., 2002b), I assessed whether inhibiting Drp1 could 
reduce α-synuclein aggregation promoted by the pesticide in inducible N27 cells 
overexpressing WT human α-synuclein (Figure 7.5). 48 h induction by PonA alone produced 
a significant increase in the number of proteinase K-positive puncta in comparison to control 
cells. Treatment of cells with 50 µM PQ for 48 h (during PonA induction) promoted a further 
increase in the number of α-synuclein aggregates per cell. As for Mn (Figure 3.11), inhibition 
of Drp1, via siRNA, completely rescued α-synuclein aggregation in cells expressing α-






Figure 7.3 PQ inhibits autophagy flux in HeLa cells. mRFP-GFP-LC3 stably expressing HeLa 
cells were treated with PQ at different concentrations (50 – 200 μM) for 24 h. The numbers of 
autophagosomes (green vesicles) and autolysosomes (red vesicles minus green vesicles) per cell 
were quantified in at least 30 cells per condition, for triplicate experiments. Data are shown as mean 
± SEM (n=3 independent experiments). One Way Anova with Tukey’s post-hoc analysis ***: P < 
0.001 compared to control cells. Scale bar 20 μm. 
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 Figure 7.4 Drp1 inhibition attenuates autophagy blockade induced by PQ treatment in HeLa 
cells. HeLa mRFP-GFP-LC3 expressing cells were transfected with 10 nM human Drp1 siRNA 
(blue channel) or scramble. 24 h post-transfection cells were treated with PQ (50 μM). The numbers 
of autophagosomes (green puncta) and autolysosomes (red minus green puncta) was quantified in 
at least 30 cells per condition, for triplicate experiments. Data are shown as mean ± SEM (n=3 
independent experiments). One Way Anova with Tukey’s post-hoc analysis **: P < 0.05; **: P < 




Figure 7.5 PQ induces α-synuclein aggregation, improved by inhibition of Drp1 in N27 cells. 
N27 cells were transfected with rat Drp1 siRNA (10 nM). 24 h post-transfection α-synuclein 
overexpression was induced (20 μM PonA) in combination with PQ (50 μM) or CQ (10 μM) for 48 
h. Post fixation, cells were incubated with either PBS (data not shown) or Proteinase K and then 
processed for ICC using an antibody (Millipore, AB5038) particularly effective at identifying higher 
order structures of the protein. Images show insoluble α-synuclein aggregates. ImageJ was used to 
quantify the α-synuclein-positive puncta. Data are shown as mean ± SEM (n=3 independent 
experiments). One Way Anova with Tukey’s post-hoc analysis **: P < 0.01; ***: P < 0.001. Scale 




As previously discussed in section 3.2.5, PQ was used as a positive control to induce 
mitochondrial dysfunction when assessing the effects of Mn on mitochondria, however the data 
was not shown. PQ caused a significant reduction in mitochondrial respiratory capacity 
compared to untreated cells (Figure 7.6). These results indicate that PQ exposure reduces the 
cell's ability to respond to energetic demand, therefore promoting mitochondrial dysfunction.  
 
 
Figure 7.6 Effects of PQ treatment on mitochondrial respiration. (A) Representative example 
of kinetic OCR response of N27 and M17 cells to Mn and PQ treatment. M17 and N27 cells were 
plated in XFe96 tissue culture plate and treated with MnCl2 (125 µM) and PQ (100 µM) for 24 h. 
Mitochondrial respiration was assessed by measuring OCR using the XFe96 Extracellular Flux 
Analyzer. Sequential injections of oligomycin (to inhibit oxygen consumption mediated by ATP 
synthase), FCCP (an uncoupler to induce maximal OCR), Rotenone/Antimycin (to inhibit complex 
I and III, respectively). (B) Effects of PQ on Spare Respiratory Capacity (SRC). Data are shown as 
mean ± SEM (n=3/4 independent experiments). Unpaired two-tailed Student's t test *: P < 0.05 
when comparing control to PQ-exposed cells. The seahorse assay was performed and analysed by 





Overall these results indicate that PQ blocks autophagy flux, impairs mitochondrial function 
and promotes α-synuclein aggregation in vitro. Inhibition of Drp1 ameliorated autophagic 
impairment and α-synuclein aggregation induced by PQ.  
Although results from this supplementary chapter suggest that PQ is having an impact on both 
mitochondrial function and autophagy flux, in comparison to Mn, the concentrations used for 
the seahorse assay were higher (100 µM) than the lowest dose (50 µM) used in the autophagy 
flux assay. Whilst my results show that 100 µM PQ does indeed block autophagy flux and also 
induce mitochondrial dysfunction, this cannot be said for the lowest concentration of PQ used 
in this study. In fact, it is possible that 50 µM PQ is altering autophagy flux without affecting 
mitochondrial function (as for Mn) and therefore more studies are needed to address this issue.  
Despite this, the effects of Drp1 inhibition on the autophagy pathway and protein aggregation 
are in line with the results obtained in Chapter 3 and confirm the possibility for a new regulatory 





7.2.2 Evaluation of astrocyte and microglia activation in the SNpc 
of SLC39A14−/− mice 
Moreno et al. (2009) have previously established that Mn exposure can induce 
neuroinflammation in glial cells. Astrocytes and microglia are essential within the CNS and 
can adopt, in response to foreign or endogenous signals, an activated phenotype which leads to 
the release of pro-inflammatory mediators. In particular, glial cells represent an important 
target of Mn in the brain, as they are involved in sequestering the metal and activating 
inflammatory signalling pathways harmful for neurons through overproduction of ROS, NOS 
and inflammatory cytokines (Zhao et al., 2009, Verina et al., 2011, Tjalkens et al., 2017).  
Aschner et al. (1992) showed that Mn preferentially accumulates in astrocytes given their 
expression of high-capacity transporters and that Mn concentrations in astrocytes can be 50-
folds greater compared to neurons. Additionally, given their key role in maintenance of cellular 
homeostasis, astrocytes regulate extracellular glutamate levels that can be disrupted by Mn and 
cause an inflammatory response (Tjalkens et al., 2017).  
The main focus of this chapter was to investigate the effects of chronic accumulation of Mn in 
SLC39A14−/− mice in the SNpc. As astrocytes can be morphologically characterised by the 
expression of the intermediate filament proteins glial fibrillary acidic protein (GFAP), 
immunostaining against GFAP in the SNpc was used to label astrocytes and assess any changes 
between WT and KO mice. The total area of stained astrocytes appeared increased in KO mice 
(10.54 ± 0.68) compared to WT (5.89 ± 0.31) (Figure 7.7 A-B), suggesting that chronic Mn 
accumulation induces inflammatory response in astrocytes. In contrast to WT, KO mice 
displayed a moderate/severe reactive astrogliosis in which most astrocytes display cellular 
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hypertrophy with some overlap of astrocyte processes, which may result in potential disruption 




Figure 7.7 SLC39A14−/− mice display activated astrocytes in the SNpc. Nigral sections (30 µm) 
were immunostained with GFAP to assess changes in astrocytic morphology in (A) WT and KO 
mice. The representative images are 20X and 100X zoom, respectively. (B) Quantification of % 
area of GFAP positive staining in WT and KO mice. Data represent mean ± SEM (WT n=6; KO 





In the current study, Iba1 was used as a microglia marker to investigate microglial activation 
in cells lacking SLC39A14. In both WT and KO animals, Iba1-positive cells were evenly 
distributed throughout the SNpc (Figure 7.8 A). 
Cells appeared small with fine ramified processes typical of resting microglia. Statistical 
analysis revealed that the density of Iba1-positive cells was not altered in KO (10.48 ± 0.83) 
when compared to WT mice (9.81 ± 1.11), suggesting there was no association between 
microglia reactivity and the level of Mn in KO mice (Figure 7.8 B). Sholl analysis (assessment 
of the morphological changes in relation to the radial distance from the soma) of microglial 
cells did not reveal any variations in morphological characteristics and no overall group 
differences were detected (Figure 7.8 C-D). Overall, these results indicate that SLC39A14−/− 
mice display a marked increase in astrocyte activation without impacting microglial 














Figure 7.8 Microglial morphology is not altered in the SNpc of SLC39A14−/− mice. Nigral 
sections (30 µm) were immunostained with Iba1 to assess microglial morphology in (A) WT and 
KO mice. The representative images are 20X and 100X zoom, respectively. (B) Quantification of 
% area of Iba1 positive staining in WT and KO mice. Data represent mean ± SEM (WT n=5; KO 
n=5 animals per group). Unpaired two-tailed Student's t test displayed no statistical difference 
between WT and KO animals. (C) Analysis of microglial morphology using Sholl Analysis. The 
graph represents the average number of intersections per cell at defined radial lengths. Data 
represent mean ± SEM (WT n=5; KO n=5 animals per group). (D) The area under the curve from 
the Sholl analysis was also calculated for each animal. Data represent mean ± SEM (WT n=5; KO 
n=5 animals per group). Unpaired two-tailed Student's t test displayed no statistical difference 




Increasing evidence have associated Mn exposure to neuroinflammation, including both 
microglia and astrocytes (Moreno et al., 2009, Verina et al., 2011, Krishna et al., 2014, Wang 
et al., 2017, Chen et al., 2018a, Langley et al., 2018). When assessing changes in astrocytic 
morphology, results displayed astroglial activation in the SN of KO mice compared to WT, 
evidenced by an increased total astrocytic volume. Although the regions in which astrocyte 
activation was observed may differ, my data agrees with prior studies (Kern et al., 2010, Peres 
et al., 2015, Sarkar et al., 2018), which report increased GFAP expression following Mn 
exposure. One of the hallmarks of Mn toxicity, in addition to the neuronal degeneration in the 
GP and in some cases the SN, is the mild-to-moderate proliferation of astrocytes (Yamada et 
al., 1986). Astrocytes have been suggested to be particularly susceptible to Mn neurotoxicity 
given the propensity of Mn to accumulate within them (Aschner et al., 1992). Within the brain, 
the enzyme glutamine synthetase is known to be exclusively expressed in astrocytes and to be 
responsible for converting glutamate to glutamine (Martinez-Hernandez et al., 1977). One of 
the proposed mechanisms of action of Mn accumulation in astrocytes is the impairment of 
glutamate/glutamine transporters (Erikson and Aschner, 2002, Sidoryk-Wegrzynowicz et al., 
2009), which disrupts synaptic homeostasis and elicit neurotoxicity. Previous studies have also 
reported the ability of astrocytes to release inflammatory cytokines and nitric oxide (NO) 
during Mn exposure (Liu et al., 2006, Moreno et al., 2008, Moreno et al., 2009), indicative of 
an enhanced neuroinflammatory response. Results from the current study suggest that chronic 
Mn induces astrogliosis in conjunction with autophagy impairment in neurons and could 
possibly promote neuroinflammatory cytokines production. It would be interesting, in the 
future, to investigate changes in neuroinflammatory cytokines and autophagic alterations in 
astrocytes caused by chronic Mn accumulation.  
The involvement of microglia-mediated inflammation in PD pathology was first described by 
McGeer et al. (1988) and confirmed by many others (Imamura et al., 2003, Gerhard et al., 2006, 
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Mount et al., 2007, Doorn et al., 2014, Grozdanov et al., 2014). Prior studies have also 
suggested a potential role for microglia in mediating Mn-induced neurodegeneration (Zhao et 
al., 2009, Verina et al., 2011). I therefore sought to investigate the chronic effects of Mn on 
microglial cells of the SN of SLC39A14−/− mice compared to WT. Iba1-labelled microglia 
displayed remarkably consistent morphologies between KO and WT in both the total % of area 
and morphological assessments (Sholl analysis). Progressive neuronal loss can activate and 
recruit microglia or vice versa, therefore it may not be surprising that no microglial response 
was observed in mice that did not display any changes in TH levels. In fact, when Zhao et al. 
(2009) described an increase in the number of activated microglia, up-regulation of iNOS, 
TNFα and IL-1β in the SNpc of rats intrastriatally injected with Mn, they also detected a clear 
reduction in TH-positive cells. In addition, increased levels of inflammatory cytokines were 
reported in mice intraperitoneally injected with 100 mg/kg MnCl2 for two weeks (Chen et al., 
2018a). Previous studies have shown an association between SLC39A14−/− mice and acute 
inflammation (Aydemir et al., 2017). This was evidenced by an upregulation of TNF-α, 
increase in NF-κB protein and TSPO in the brains of these deficient mice (Aydemir et al., 
2017). Results from the current chapter could differ from previous reports for several reasons: 
1) Differences in age of mice and exposure paradigm (slow chronic increase of Mn vs acute 
high dose). 2) The brain region assessed in the current study was the SN, whilst Aydemir et al. 
(2017) used whole brain. 3) I assessed changes in microglial morphology in contrast to specific 
cytokines activated by an inflammatory stimulus. 4) It is possible that this inflammatory 
response was elicited by astrocytes (due to slight and not drastic increase in inflammatory 
cytokines), not microglia and therefore no changes were observed in Iba1 staining performed 
in the current study.  
Overall, these results are preliminary and warrant further study as a stereological quantification 
of both microglia and astrocytes is required.  
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7.3 Appendix C - Publication 
Publication: Helley, M. P., Pinnell, J., Sportelli, C. and Tieu, K. 2017. Mitochondria: A 
Common Target for Genetic Mutations and Environmental Toxicants in Parkinson's Disease. 
Frontiers in genetics, 8, 177. 
 
Parkinson’s disease (PD) is a devastating neurological movement disorder. Since its first 
discovery 200 years ago, genetic and environmental factors have been identified to play a role 
in PD development and progression. Although genetic studies have been the predominant 
driving force in PD research over the last few decades, currently only a small fraction of PD 
cases can be directly linked to monogenic mutations. The remaining cases have been attributed 
to other risk associated genes, environmental exposures and gene–environment interactions, 
making PD a multifactorial disorder with a complex aetiology. However, enormous efforts 
from global research have yielded significant insights into pathogenic mechanisms and 
potential therapeutic targets for PD. This review will highlight mitochondrial dysfunction as a 
common pathway involved in both genetic mutations and environmental toxicants linked to 
PD. 
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